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Abstract	  
	   Current	   abiotic	   synthesis	   is	   very	   effective	   in	   yielding	   enantiomerically	   pure	  
compounds	  with	  high	  yields,	  however	  the	  route	  taken	  may	  not	  be	  very	  efficient	  nor	  
green	   with	   the	   use	   of	   solvents,	   heavy	   metals	   and	   toxic	   chemicals.	   Alcohol	  
dehydrogenases	  (ADHs)	  are	  industrially	  useful	  biocatalysts	  in	  providing	  synthetically	  
useful	   building	   blocks	   or	   chiral	   alcohols	   as	   flavour	   or	   fragrance	   chemicals.	   In	   this	  
thesis,	   the	   X-­‐ray	   crystal	   structures	   have	   been	   determined	   for	   the	   ADHs	   from	  
Ralstonia	   sp.	   (RasADH),	  Sphingobium	  yanoikuyae	   (SyADH),	  Thermus	   sp.	   (TADH)	  and	  
Candida	  parapsilosis	  (CPCR2).	  
	   Datasets	   for	   the	  apo-­‐	   and	   NADPH	   complex	   for	   the	   gene	   encoding	   RasADH,	   an	  
ADH	  from	  the	  short-­‐chain	  family,	  from	  Ralstonia	  sp.	  DSM	  6428	  were	  obtained	  at	  1.5	  
Å	  and	  2.9	  Å	  respectively.	  The	  models	  for	  the	  apo-­‐	  and	  NADPH	  complex	  were	  refined	  
to	  Rcryst/Rfree	  values	  of	  15.8%/18.8%	  and	  26.8%/29.3%	  respectively.	  
	   The	  dataset	  for	  the	  gene	  encoding	  SyADH,	  an	  ADH	  from	  the	  short-­‐chain	  family,	  
from	  Sphingobium	  yanoikuyae	  DSM	  6900	   in	   complex	  with	  NADPH	  was	  obtained	  at	  
2.5	  Å.	  The	  model	  was	  refined	  to	  an	  Rcryst/Rfree	  value	  of	  23.4%/25.1%.	  
	   The	  dataset	  for	  the	  gene	  encoding	  TADH,	  an	  ADH	  from	  the	  medium-­‐chain	  family,	  
from	   Thermus	   sp.	   ATN1	   was	   obtained	   at	   2.7	   Å	   with	   three	   of	   four	   active	   sites	   in	  
complex	  with	  NADH.	  The	  model	  was	  refined	  to	  an	  Rcryst/Rfree	  value	  of	  19.6%/24.6%.	  	  
	   The	   dataset	   for	   the	   gene	   encoding	   CPCR2,	   an	   ADH	   from	   the	   medium-­‐chain	  
family,	  from	  Candida	  parapsilosis	  DSM	  70125	  was	  obtained	  at	  2.0	  Å	  in	  complex	  with	  
NADH.	  The	  model	  was	  refined	  to	  an	  Rcryst/Rfree	  value	  of	  20.5%/24.1%.	  
	   These	   crystal	   structures	   provide	   a	   robust	   platform	   for	   rational	   engineering	   to	  
improve	   the	   enzymes’	   substrate	   specificity,	   enantioselectivity,	   thermostability	   and	  
solvent	   tolerance.	   As	   such,	   ADHs	   as	   biocatalysts	   will	   inevitably	   provide	   a	   greener	  
alternative	  for	  the	  synthesis	  of	  chiral	  alcohols	  over	  abiotic	  synthesis.	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  28	  
Figure	   13	   -­‐	   The	  medium	   chain	   alcohol	   dehydrogenase	  mechanism	  as	   proposed	   by	   Eklund	   (31)	   as	   in	  
HLADH.	   Again,	   regaining	   aromaticity	   of	   the	   nicotinamide	   ring	   facilitates	   the	   carbonyl	   reductase	  
pathway.	  .......................................................................................................................................................................................	  29	  
Figure	  14	  –	  Schematic	  diagram	  of	  water	  mediated	  catalysis	   from	  Baker	  2009	  (33),	  viewed	  down	  the	  
His	  63	  NE2–Zn	  bond,	  of	  the	  zinc	  ligands	  in	  the	  NADP(H)/Zn	  complex	  (Left),	  NADP+/Zn/glucose	  complex	  
(Centre),	   and	   NADP+/Zn/gluconolactone	   complex	   (Right).	   The	   arrows	   give	   the	   direction	   of	   the	  
movement	   of	   the	   zinc	   and	   water	   between	   the	   complexes.	   PDB	   entries:	   2VWP,	   2VWQ,	   2VWH	   and	  
2VWG.	  ............................................................................................................................................................................................	  29	  
Figure	  15	  –	  Modified	   from	  Hollmann	  and	  co-­‐workers	   (35).	  Scheme	  of	  aldehyde	  dismutation	   reaction	  
catalysed	  by	  TADH.	  Acetone	  was	  used	  for	  cofactor	  regeneration.	  ........................................................................	  30	  
Figure	  16	   -­‐	  Modified	   from	   Jakoblinnert	  and	   co-­‐workers	   (37).	  Biocatalytic	   reduction	  of	  acetophenone	  
using	   lyophilised	  E.	  coli	   	  cells	  with	  overexpressed	  CPCR2	   in	  neat	  substrate	  with	   iso-­‐propanol	  as	  a	  co-­‐
substrate.	  ......................................................................................................................................................................................	  31	  
Figure	  17	  -­‐	  Chemical	  structures	  of	  the	  nicotinamide	  cofactors,	  shown	  above	  are:	  NAD+	  (left),	  NADP+	  
(middle)	   and	   an	   expanded	   view	   of	   the	   reduced	   form	   of	   the	   nicotinamide	   group	   with	   the	   prochiral	  
hydrogens	  stereospecifically	  labelled	  (right).	  .................................................................................................................	  32	  
Figure	  18	  –	  Schematic	  of	  a	  generic	  enone	  showing	  the	  CIP	  priority	  resulting	  in	  the	  prochirality	  of	  the	  HR	  
and	  HS	  hydrogens	  (left).	  Schematics	  of	  CIP	  equivalents	  of	  a	  carbonyl	  (middle)	  and	  an	  alkene	  (right).	  ...	  32	  
Figure	  19	  -­‐	  Modified	  from	  Bradshaw	  and	  co-­‐workers	  (42).	  Stereospecificity	  of	  ADHs	  where	  'S'	  is	  a	  small	  
group	  and	  'L'	  is	  a	  large	  group.	  ..............................................................................................................................................	  33	  
Figure	   20	   –	   Residues	   responsible	   for	   cofactor	   preference	   for	   TbADH	   (PDB	   entry:	   1KEV)	   and	   HLADH	  
(PDB	  entry:	  6ADH).	  TbADH	  and	  HLADH	  are	  superposed	  on	  their	  cofactors	  and	  only	  the	  cofactor	  from	  
TbADH	   is	   shown.	  HLADH	  would	  not	  allow	  NADPH	  to	  bind	  due	  to	   repulsion	   from	  Asp223,	  however	   in	  
TbADH	  the	  phosphate	  and	  Arg200	  makes	  a	  favourable	  interaction,	  therefore	  allowing	  binding.	  ...........	  34	  
Figure	  21	  -­‐	  Generic	  cofactor	  regeneration	  strategies	  for	  the	  reductive	  reaction	  of	  a	  gene	  of	  interest.	  .	  34	  
Figure	  22	  –	  Reactions	  of	  the	  two	  typically	  used	  recycling	  systems.	  Formate	  Dehydrogenase	  (top)	  and	  
Glucose-­‐6-­‐phosphate	  Dehydrogenase	  (bottom).	  ........................................................................................................	  35	  
Figure	  23	  –	   The	   schematic	   for	   preparation	  of	   the	  PCR	   fragment	  and	  annealing	   to	   the	  pET-­‐YSBLIC3C	  
vector.	  Adapted	  from	  Fogg	  and	  Wilkinson	  (48).	  ...........................................................................................................	  38	  
Figure	  24	   -­‐	  Schematic	  of	   recirculating	  protein	  onto	  a	  column	   (left)	  and	  schematic	  of	   ‘daisy-­‐chaining’	  
columns	  with	  recirculation	  (right).	  .....................................................................................................................................	  57	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Figure	  25	  -­‐	  12%	  SDS-­‐PAGE	  analysis	  of	  different	  purification	  strategies	  of	  nickel	  purification,	  both	  from	  
180	   mL	   lysate	   of	   the	   same	   construct:	   Single	   column	   recycling	   and	   purification	   (top)	   and	   'Daisy-­‐
chaining'	  two	  columns	  recycling	  and	  purification	  (bottom)	  ....................................................................................	  58	  
Figure	  26	  –	  Schematic	  for	  IMAC	  purification	  strategy	  that	  was	  used	  on	  AKTA’s.	  Two	  initial	  washes	  are	  
performed	  by	  a	  step	  gradient	  to	  wash	  away	  any	  impurities,	  while	  the	  gradient	  purifies	  protein.	  ..........	  59	  
Figure	  27	  –	  Schematic	  of	  a	  generic	  equilibration	  of	  SEC	  columns.	  Typically	  1	  column	  volume	  of	  water	  is	  
required,	  followed	  by	  1	  column	  volume	  of	  a	  buffer	  with	  0	  mM	  imidazole.	  .......................................................	  60	  
Figure	  28	  -­‐	  Strategy	  for	  purifying	  proteins	  after	  cleaving	  the	  his-­‐tag	  ..................................................................	  61	  
Figure	  29	  –	  A	  schematic	  of	  a	  Michaelis-­‐Menten	  kinetics	  curve	  where	  Km	  is	  found	  at	  ½Vmax.	  .....................	  62	  
Figure	  30	  –	  Schematic	  of	  kinetics	  by	  UV-­‐Vis	  analysis,	  where	  the	  depletion	  of	  the	  nicotinamide	  cofactor	  
results	  in	  the	  desired	  change	  in	  absorbance	  and	  change	  in	  time.	  .........................................................................	  63	  
Figure	   31	   –	   Schematic	   of	   GC	   analysis	   for	   alcohols	   and	   ketones.	   Typically	   the	   solvent	   peak	  
(ethylacetate)	   elutes	   early	   on,	   with	   carbonyl	   compounds	   such	   as	   acetone	   eluting	   before	   its	   alcohol	  
counterpart,	   isopropanol,	   due	   to	   alcohols	   exhibiting	   a	   higher	   degree	   of	   polarity	   from	   greater	  
intermolecular	  hydrogen-­‐bonding.	  ....................................................................................................................................	  64	  
Figure	   32	   –	   (Left)	   spherical-­‐atom	   approximation	   at	   1.00	   Å	   resolution	   of	   the	   active	   site	   in	   oxy-­‐
myoglobin	   (PDB	   entry:	   1A6M).	   (Right)	   deformation	   of	   electron	   density	   at	   0.48	   Å	   resolution	   of	   the	  
Arg17	  residue	  in	  crambin	  (PDB	  entry:	  3NIR).	  .................................................................................................................	  66	  
Figure	  33	  –	  Schematic	  of	  2-­‐demensional	  crystal	  packing	  with	  zero	  mosaicity	  (left)	  and	  a	  higher	  degree	  
of	  mosaicity	  (right).	  ..................................................................................................................................................................	  67	  
Figure	  34	  –	  Schematic	  of	  diffraction	  spots.	  Well-­‐defined	  spot	  from	  a	  crystal	  with	  negligible	  mosaicity	  –	  
left.	  Poorly	  defined	  spot	  from	  a	  crystal	  with	  low	  mosaicity	  –	  middle.	  Very	  poorly	  defined	  smeared	  spot	  
from	  a	  crystal	  with	  high	  mosaicity	  –	  right.	  .....................................................................................................................	  67	  
Figure	   35	   –	   Schematic	   of	   grid	   scan	   (left)	   and	   line	   scan	   (right)	   screening	   on	   a	   protein	   crystal.	   The	  
defined	  area	  is	  tested	  for	  best	  diffraction	  quality.	  .......................................................................................................	  69	  
Figure	  36	  –	  Schematic	  of	  the	  refinement	  with	  iterative	  cycles	  of	  model	  building	  and	  model	  refinement.
	  ..........................................................................................................................................................................................................	  71	  
Figure	  37	  –	   Schematic	   for	   ligand	  building	   for	   ligands,	   such	  as	  PPK,	   not	   available	   in	   the	  CCP4	   ligand	  
library.	  ...........................................................................................................................................................................................	  73	  
Figure	  38	  –	  Preparing	  the	  ligand	  PPK	  in	  Autodock	  Tools,	  with	  auto	  detection	  of	  the	  torsional	  root.	  .....	  74	  
Figure	  39	  –	  Defining	  the	  area	   in	  the	  protein	  to	  be	  dock	  with	   ligand	  using	  AutoGrid.	  Either	  the	  whole	  
protein	  or	  just	  the	  active	  site	  can	  be	  defined	  for	  docking.	  ........................................................................................	  74	  
Figure	  40	  –	  Defining	  the	  docking	  algorithm	  to	  be	  used	  with	  the	  relevant	  docking	  parameters.	  ..............	  75	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Figure	   41	   -­‐	   The	   docking	   outcome	   with	   AutoDock	   vina	   showing	   potential	   interacting	   residues	   and	  
cofactor,	  with	  the	  ligand	  PPK	  being	  ranked	  in	  vina	  energy.	  .....................................................................................	  75	  
Figure	  42	  -­‐	  Generic	  benzyl	  alcohol	  derivative	  .................................................................................................................	  76	  
Figure	  43	  -­‐	  Induction	  Test	  for	  RasADH	  to	  optimise	  protein	  production	  analysed	  on	  a	  12%	  SDS-­‐PAGE	  gel	  
as	  described	   in	  section	  2.2.3.	  Lane	  1	   is	   the	  Low	  Molecule	  Weight	  Ladder	  from	  BioRad.	  Lanes	  2-­‐4	  are	  
the	  insoluble	  fractions	  for	  the	  control,	  induction	  at	  0.6	  Abs	  and	  2.0	  Abs	  respectively.	  Lanes	  5-­‐13	  are	  the	  
soluble	  fractions	  for	  the	  absorbance’s	  chosen	  for	  testing.	  .......................................................................................	  77	  
Figure	  44	   -­‐	   SDS-­‐PAGE	  analysis	   for	   the	  nickel	  purifiaction	  of	  RasADH.	  The	  SDS-­‐PAGE	  gel	  and	   samples	  
were	  prepared	  as	  described	  in	  sections	  2.2.3.	  and	  2.2.3.1.	  Lane	  1	  is	  the	  Low	  Molecular	  Weight	  Ladder	  
from	  BioRad	  and	  lanes	  2-­‐25	  are	  the	  samples	  obtained	  from	  the	  elution	  gradient	  of	  the	  purification.	  ..	  77	  
Figure	  45	  -­‐	  Chromatagram	  for	  the	  SEC	  of	  RasADH	  after	  nickel	  affinity	  purification.	  Samples	  from	  40-­‐60	  
ml	  of	  the	  SEC	  were	  taken	  for	  analysis	  on	  SDS-­‐PAGE.	  ..................................................................................................	  78	  
Figure	  46	  –	  Protein	  purity	  analysis	  by	  SDS-­‐PAGE	  after	  SEC.	  Samples	  and	  SDS-­‐PAGE	  gel	  were	  prepared	  
as	   described	   in	   sections	   2.2.3.1.	   and	   2.3.3.	   Lane	   1	   of	   the	   SDS-­‐PAGE	   gel	   is	   a	   Low	  Molecular	  Weight	  
Ladder	  from	  BioRad,	  lanes	  2-­‐10	  were	  samples	  every	  second	  fraction	  of	  the	  peak	  between	  40-­‐60	  ml.	  ..	  78	  
Figure	   47	   -­‐	   RasADH	   crystals	   obtained	   from	   PACT-­‐G4	   additive	   optimisation	   (left)	   with	   its	   diffraction	  
pattern	  in-­‐house	  (right).	  .........................................................................................................................................................	  79	  
Figure	   48	   -­‐	   RasADH	   crystals	   obtained	   from	   well	   PACT-­‐H10	   optimisation	   (left)	   with	   its	   diffraction	  
pattern	  in-­‐house	  (right).	  .........................................................................................................................................................	  80	  
Figure	  49	  -­‐	  RasADH	  holo-­‐asymmetric	  unit	  (left)	  and	  apo-­‐asymmetric	  unit	  (right).	  Holo-­‐subunits	  labelled	  
Rh,	  apo-­‐subunits	  labelled	  Ra.	  .................................................................................................................................................	  82	  
Figure	  50	  -­‐	  RasADH	  Rossman	  fold	  represented	  by	  subunit	  Rh1.	  The	  helicies	  are	  represented	  by	  α1-­‐7	  and	  
the	  β-­‐sheets	  are	  represented	  by	  β1-­‐7.	  ..............................................................................................................................	  83	  
Figure	  51	   -­‐	  RasADH	  overlay	  of	  apo-­‐	  and	  holo-­‐structure,	   residues	  173-­‐229	  shown	  with	  the	  rest	  of	   the	  
protein	  greyed	  out.	  Loops	  are	  denoted	  as	  λ.	  α1	  is	  no	  longer	  present	  in	  the	  apo-­‐structure	  as	  it	  becomes	  
λ2.	  The	  electron	  density	  for	  NADPH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  
which	  was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADPH.	  ..........................................................................	  83	  
Figure	  52	   -­‐	  Hydrophobic	  active	   site	  of	  RasADH	   represented	  by	   residues:	   by	   residues	  Tyr150,	   Ser137,	  
Phe205,	  Leu144,	  Leu142,	  Leu201,	  Val138,	  Ile91,	  His147	  and	  Gln191.	  .................................................................	  84	  
Figure	  53	  -­‐	  The	  structure	  of	  SyADH	  with	  10	  subunits	  in	  the	  asymmetric	  unit,	  each	  subunit	  is	  denoted	  as	  
S.	  SyADH	  asymmetric	  unit	  forms	  a	  quinary	  structure	  resembling	  a	  helix.	  ..........................................................	  87	  
Figure	  54	  -­‐	  A	  monomer	  of	  SyADH,	  represented	  by	  subunit	  S1,	  displaying	  helicies	  α1-­‐8	  and	  β-­‐sheets	  β1-­‐
7.	  ......................................................................................................................................................................................................	  88	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Figure	   55	   –	   Subunits	   5	   and	   6	   representing	   the	   major	   dimer	   interface	   of	   SyADH.	   Dimer	   interfaces	  
denoted	  as	  δ;	  δ1	  are	  the	  interlocking	  N-­‐termini	  helicies	  providing	  the	  predominant	  interaction,	  δ2-­‐δ4	  
illustrate	   weaker	   dimer	   interactions	   between	   helicies	   and	   loops.	   The	   electron	   density	   for	   NADPH	   is	  
generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  refinement	  in	  
the	  absence	  of	  NADPH.	  ...........................................................................................................................................................	  88	  
Figure	   56	   -­‐	   The	   binding	   pocket/groove.	   Catalytic	   triad	   in	   ice	   blue:	   Ser-­‐Try-­‐Lys	   other	   residue	   of	   the	  
monomer	  contributing	  to	  the	  binding	  pocket	  are	  in	  Green.	  Residues	  from	  the	  monomer	  are	  denoted	  as	  
“A”.	  Residues	  from	  the	  adjacent	  subunit	  of	  a	  dimer	  denoted	  as	  “B”	  and	  in	  pink	  are	  gln	  and	  ile,	  which	  
are	  from	  the	  N-­‐terminus	  helix.	  The	  electron	  density	  for	  NADPH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  
contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADPH.	  .....................	  89	  
Figure	   57	   –	   Comparison	   of	   active	   site	   with	   RasADH	   (ice	   blue)	   and	   SyADH	   (coral).	   Majority	   of	   the	  
residues	   share	   significant	   homology,	   however	   residues	   Phe205	   and	   Leu144	   in	   RasADH	   are	   opposite	  
locations	  to	  Phe148	  and	  Leu201	  in	  SyADH.	  ....................................................................................................................	  90	  
Figure	  58	   -­‐	  Steric	  bulk	  differences	   in	   the	  active	  sites	  of	  RasADH	  (ice	  blue)	  and	  SyADH	  (coral).	  Where	  
RasADH	  has	  larger	  steric	  bulk	  with	  residues	  Gln191,	  Ile91	  and	  Leu142	  compared	  to	  Ala194,	  Ala92	  and	  
Ala	  145	  in	  SyADH.	  .....................................................................................................................................................................	  91	  
Figure	  59	  –	  Due	   to	   the	   solubility	   in	  water	   of	   the	   substrate	  n-­‐Phenyl	   pentyl	   ketone	   (PPK),	   it	  was	  not	  
possible	  to	  use	  for	  co-­‐crystallisation	  experiments.	  As	  such,	  PPK	  was	  modelled	  into	  the	  active	  site	  using	  
the	  docking	  suite	  AutoDock	  (Section	  2.7.2.).	  .................................................................................................................	  92	  
Figure	  60	  -­‐	  SyADH	  docking	  with	  PPK.	  Key	  catalytic	  residue	  distances	  are	  shown	  with	  closely	  interacting	  
residues	  as	  calculated	  from	  AutoDockVina.	  Again,	  PPK	  bound	  in	  a	  hydrophobic	  pocket,	  however	  PPK	  is	  
able	  to	  fully	  extend	  its	  alkyl	  chain.	  .....................................................................................................................................	  93	  
Figure	   61	   -­‐	   RasADH	   docking	   with	   PPK.	   Key	   catalytic	   residue	   distances	   are	   shown	   with	   closely	  
interacting	  residues	  as	  calculated	  from	  AutoDockVina.	  Most	  noticeably	  is	  PPK	  bound	  in	  a	  hydrophobic	  
pocket	  also	  unable	  to	  fully	  extend	  the	  alkyl	  chain.	  ......................................................................................................	  94	  
Figure	   62	   –	   RasADH-­‐Gln191	   and	   SyADH-­‐Trp191	   are	   potential	   residues	   for	   differentiating	   substrate	  
specificities.	   Conformational	   differences	   of	   PPK	   result	   from	   residues	   SyADH-­‐Trp191	   and	   RasADH-­‐
Gln191.	  PPK	   is	   able	   to	   slot	   into	   the	  pocket	  due	   to	   Trp191	   in	   SyADH.	  PPK	   is	   forced	   to	   curl-­‐up	  due	   to	  
Gln191	  in	  RasADH.	  ...................................................................................................................................................................	  95	  
Figure	  63	  –	  The	  desired	  reaction	  for	  RasADH.	  The	  reduction	  or	  oxidation	  of	  benzoin	  like	  substrates.	  ..	  96	  
Figure	  64	   	  -­‐	  Manual	  dock	  of	  benzoin	   in	  the	  active	  site	  of	  RasADH	  to	  rationalise	  why	  the	  active	  site	  
could	  not	  accommodate	  substrates	  like	  benzoin.	  ........................................................................................................	  96	  
Figure	  65	  –	  The	  proposed	  mutation	  for	  RasADH	  at	  residue	  position	  187.	  Mutating	  Ile187	  to	  Ala187.	  .	  97	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Figure	   66	   –	   Expression	   test	   of	   RasADH	   I187A	   in	   BL21	   (DE3)	   expression	   strain.	   The	   mutant	   yielded	  
better	  expression	  as	  well	  as	  more	  soluble	  protein.	  ......................................................................................................	  98	  
Figure	  67	  –	  SDS-­‐PAGE	  analysis	  of	  RasADH	  I187A	  after	  nickel	  purification.	  ........................................................	  98	  
Figure	   68	   –	   Chromatagram	   for	   RasADH	   I187A	   purification	   by	   SEC.	   The	   peak	   between	   40-­‐60	   mL	  
represents	  the	  dimeric	  form	  of	  the	  mutant.	  ...................................................................................................................	  99	  
Figure	  69	  –	  SDS-­‐PAGE	  analysis	  of	  RasADH	  I187A	  after	  SEC.	  The	  gel	  suggests	  the	  protein	  is	  sufficiently	  
pure	  for	  further	  characterisation.	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  99	  
Figure	  70	  –	  Schematic	  of	  the	  predicted	  reaction	  for	  the	  RasADH	  187A	  mutant.	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  100	  
Figure	  71	  -­‐	  The	  asymmetric	  unit	  for	  TADH	  is	  a	  tetramer	  with	  NADH	  bound	  in	  3	  of	  4	  active	  sites.	  Each	  
subunit	  for	  TADH	  is	  denoted	  as	  T.	  The	  electron	  density	  for	  NADH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐
Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADH.	  ..............	  102	  
Figure	  72	   -­‐	  A	  monomer	  of	  TADH,	   represented	  by	  T4,	  displaying	  the	  Rossman	  fold	  and	  metal	  binding	  
domains.	  .....................................................................................................................................................................................	  103	  
Figure	  73	  -­‐	  Subunits	  T2	  (apo)	  coral	  and	  T4	  (holo)	  ice	  blue	  displaying	  displacement	  in	  cofactor	  binding.	  
The	  two	  domains	  close	  in	  when	  the	  cofactor	  is	  bound.	  ...........................................................................................	  104	  
Figure	  74	  –	  The	  active	  site	  of	  TADH	  in	  subunit	  T4,	  where	  zinc	   is	  coordinated	  to	  three	  protein	   ligands.	  
The	  electron	  density	  for	  NADH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  
was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADH.	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  105	  
Figure	  75	  –	  The	  major	  dimer	  interface	  for	  TADH	  represented	  by	  subunits	  T4	  (blue)	  and	  T1	  (black).	  The	  
electron	  density	  for	  NADH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  
obtained	  after	  refinement	  in	  the	  absence	  of	  NADH.	  ................................................................................................	  106	  
Figure	  76	  –	  CPCR2	  1%	  agarose	  gel	  of	  PCR	  products	  (left)	  and	  double	  digest	  (right)	  of	  the	  plasmid	  with	  
Nde1	  and	  Nco1.	  The	  gels	  and	  samples	  were	  prepared	  as	  described	  in	  sections	  2.1.2	  and	  2.1.3.	  The	  1	  kb	  
ladder	  was	  obtained	  from	  New	  England	  BioLabs.	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  108	  
Figure	  77	  -­‐	  Expression	  test:	  Rossetta	  2	  (left)	  and	  BL21	  (right)	  performed	  using	  the	  methods	  described	  in	  
section	  2.2.4.1.	  Results	  show	  that	  greater	  soluble	  expression	  is	  achieved	  with	  BL21	  (DE3)	  strain.	  ......	  108	  
Figure	  78	  –	  SDS-­‐PAGE	  analysis	  of	  CPCR2	  purified	  by	  cobalt	   IMAC.	  Lane	  1	   is	  a	  Low	  Molecular	  Weight	  
Ladder	  from	  BioRad.	  Lane	  2	  and	  3	  are	  samples	  from	  20	  mM	  and	  50	  mM	  imidazole	  wash	  steps.	  Lane	  4-­‐
15	  are	  samples	  from	  the	  elution	  gradient.	  Gel	  and	  sample	  preparation	  were	  performed	  as	  described	  in	  
Section	  2.3.3.	  and	  2.3.3.1.	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  109	  
Figure	   79	   -­‐	   Chromatagram	  of	   the	   SEC	   purification	   of	   CPCR2	   from	  a	   6	   L	   culture	   preparation.	   Elution	  
between	   40-­‐60	   mL	   would	   represent	   the	   dimer	   form	   of	   CPCR2,	   elution	   at	   100	   ml	   would	   be	   the	  
monomer.	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  110	  
	  	   13	  
Figure	  80	  –	  Protein	  crystals	  (left)	  of	  CPCR2	  in	  conditions	  containing	  0.1	  M	  Tris-­‐HCl	  pH	  8.0,	  30%	  (w/v)	  
PEG	   3350	   and	   2-­‐methyl-­‐1,4-­‐pentanediol	   (40%	   v/v)	   at	   69	   mg/mL	   protein	   concentration	   with	   its	   in-­‐
house	  diffraction	  pattern	  (right).	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  111	  
Figure	  81	  –	  The	  tetrameric	  model	  of	  NADH-­‐complex	  in	  the	  asymmetric	  unit.	  Each	  subunit	  for	  CPCR2	  is	  
denoted	  as	  C.	  The	  electron	  density	  for	  the	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  
to	  3σ.	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  113	  
Figure	   82	   -­‐	   A	  monomer	   of	   CPCR2	   represented	   by	   subunit	   C1	   displaying	   the	   catalytic	   metal	   binding	  
domain	  and	  the	  nucleotide	  binding	  domain.	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  114	  
Figure	   83	   -­‐	   The	   active	   site	   CPCR2	   as	   in	   subunit	   C1.	   NADH	   is	   bound	   in	   the	   base	   of	   the	   cleft	   with	  
surrounding	  hydrophobic	  residues.	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  115	  
Figure	  84	  –	  Split	  conformation	  of	  zinc	  at	  the	  active	  site	  with	  (left)	  and	  without	  density	  (right),	  depicting	  
activation	   and	   inactivation	   represented	   by	   subunit	   C1.	   The	   electron	   density	   for	   the	   active	   site	   was	  
obtained	  from	  2Fo-­‐Fc	  and	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	  ............	  116	  
Figure	  85	  –	  Accurate	  interpretation	  of	  the	  active	  site	  of	  CPCR2	  at	  the	  higher	  resolution	  NADH	  complex	  
(left)	  represented	  by	  subunit	  C3	  where	  the	  electron	  density	  was	  obtained	  from	  2Fo-­‐Fc	  contoured	  to	  3σ.	  
At	  lower	  resolution,	  the	  active	  site	  of	  the	  apo-­‐CPCR2,	  the	  electron	  density	  was	  obtained	  from	  from	  the	  
omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	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Figure	  86	  -­‐	  The	  major	  dimer	  interface	  for	  CPCR2	  represented	  by	  subunits	  C2	  (yellow)	  and	  C3	  (ice	  blue).	  
The	  electron	  density	  for	  the	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	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Figure	   87	   –	   SSM	   superpose	   of	   the	   homology	   model	   (magenta)	   with	   the	   crystal	   structure	   (cyan).	  
Despite	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  of	  secondary	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  there	  is	  still	  a	  lot	  of	  difference	  with	  the	  crystal	  structure.
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Figure	  88	  -­‐	  Active	  site	  comparison	  between	  CPCR2	  (CCR)	  in	  ice	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  TADH	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1.	  Introduction	  
1.1.	  Alcohol	  Oxidation	  and	  Carbonyl	  Reduction	  
	  
The	  general	  oxidation	  of	  alcohols	  and	  reduction	  of	  carbonyl	  groups	  is	  a	  relatively	  
simple	   reaction	   in	   organic	   chemistry	   and	   the	  mechanism	   is	  well-­‐known.	   There	   are	  
many	   different	   forms	   of	   oxidation	   and	   reduction	   reactions;	   for	   example	   Jones	  
Reagent	   (1)	   or	   acidified	   chromate	   (2),	   can	   be	   used	   to	   oxidise	   an	   alcohol	   to	   its	  
corresponding	   aldehyde	   or	   ketone	   (Figure	   1)	   and	   sodium	   borohydride	   (3),	   can	   be	  
used	  to	  effect	  the	  reverse	  reaction	  (Figure	  2).	  
	  
Figure	  1	  –	  Mechanism	  shown	  for	  potassium	  dichromate	  oxidation	  of	  a	  simple	  generic	  alcohol	  where	  chromate	  
(VI)	  is	  reduced	  to	  chromate	  (III).	  
	  
	  
Figure	   2	   –	  Mechanism	   shown	   for	   sodium	  borohydride	   reduction	   of	   a	   generic	   ketone.	   The	   reaction	   is	   driven	  
forward	  by	  the	  formation	  of	  borane.	  
In	  more	  complex	  cases	  of	  alcohol	  oxidation,	  protecting	  groups	  may	  be	  required	  if	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be	  required.	  The	  reduction	  of	  carbonyl	  groups	  also	  presents	  an	  interesting	  problem	  
from	  the	  perspective	  of	  selectivity.	  The	  carbonyl	  group	  is	  planar,	  which	  means	  it	  can	  
be	  attacked	  from	  either	  the	  re-­‐	  or	  si-­‐face.	  The	  topos-­‐selective,	  asymmetric	  reduction	  
of	  carbonyls	  has	  often	  been	  very	  difficult	   to	  accomplish,	  however	  Ryōji	  Noyori	  and	  
co-­‐workers	   developed	  BINAP	   (4,5)	  which	   utilises	   ruthenium,	   rhenium	  or	   palladium	  
(Figure	   4	   -­‐	   right)	   to	   catalyse	   the	  asymmetric	  hydrogenation	  of	   carbonyls	  with	  high	  
enantiomeric	  excess	  (e.e.).	  For	  example,	  (-­‐)-­‐menthol	  could	  be	  synthesised	  using	  Rh-­‐
BINAP	  and	  hydrogen	  to	  asymmetrically	  hydrogenate	  the	  terpene	  precursor	  (Figure	  3)	  
with	  99%	  yield	  and	  98%	  e.e.	  Chiral	  alcohols	  themselves	  are	  often	  flavour	  or	  fragrance	  
chemicals,	   such	   as	   (-­‐)-­‐menthol,	   and	   they	   can	   also	   be	   used	   as	   synthetically	   useful	  
chiral	  building	  blocks.	  
	  
Figure	   3	   –	   Scheme	   of	   the	   asymmetric	   hydrogenation	   step	   using	   Rh-­‐BINAP	   in	   the	   synthesis	   of	   (-­‐)-­‐menthol.	  
Adapted	  from	  Akutagawa	  (6).	  
BINAP	  is	  chiral,	  as	   it	  has	  no	  plane	  of	  symmetry	  due	  to	  restricted	  rotation	  about	  
the	  biphenyl	  single	  bond.	  As	  seen	  in	  Figure	  4,	  due	  to	  this	  restriction,	  the	  binaphthyl	  
groups	  create	  faces	  where	  potential	  aromatic	  groups,	  alkenes,	  alkynes	  and	  carbonyls	  
will	  potentially	  π-­‐stack	  and	  fix	  in	  place	  for	  attack	  on	  a	  specific	  face.	  This	  potential	  π-­‐
stacking	  effect	  leads	  to	  very	  high	  e.e.s.	  
	   	  
Figure	   4	   -­‐	   The	   chiral	   catalysts	   BINAP	   developed	   by	   Noyori	   and	   co-­‐workers	   shown	   above	   with	   both	  
enantiomers:	   (R)-­‐BINAP	   (left),	   (S)-­‐BINAP	   (middle)	   and	   3D	   representation	   of	   (R)-­‐BINAP,	   CCDC	   entry:	   879636	  
(right).	   The	   carbon	   atoms	   are	   represented	   in	   green,	   hydrogen	   atoms	   in	   white,	   phosphorous	   atoms	   are	   in	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Although	   there	   has	   been	   some	   progress	   with	   abiotic	   asymmetric	   catalysis	   for	  
chiral	  reduction	  utilising	  heavy	  metals,	  the	  ligands	  are	  expensive	  and	  require	  gaseous	  
H2,	   which	   is	   a	   potential	   hazard.	   Greener	   solutions	   are	   required,	   such	   as	   using	  
enzymes	  as	  catalysts.	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1.2.	  Enzymes	  as	  Catalysts	  
	  
Enzymes	   perform	   powerful	   functional	   group	   transformations	   and	   can	   offer	   a	  
cleaner	   and	   greener	   alternative	   to	   traditional	   organic	   chemistry	   as	   biocatalysts,	   as	  
well	   as	   performing	   asymmetric	   synthesis	   with	   incredibly	   high	   enantio-­‐,	   regio-­‐	   and	  
chemoselectivity.	   There	   are	   still	  many	   desirable	   natural	   products	   that	   are	   still	   not	  
available	  by	  the	  means	  of	  abotic	  synthesis.	  Certain	  reagents	  and	  solvents	  required	  in	  
synthesis	   are	   toxic	   and	   carcinogenic,	   for	   example	   the	   use	   of	   pyridinium	  
chlorochromate	   (PCC)	   in	   the	   selective	   oxidation	   of	   alcohols	   (7).	   The	   work-­‐up	  
reactions,	  using	  reagents	  such	  as	  PCC,	  are	  also	  not	  trivial.	  Hence	  product	  recovery	  is	  
still	  an	  issue.	  
When	  using	  biocatalysts,	  solvents	  can	  be	  used	  in	  an	  integrated	  biphasic	  organic-­‐
aqueous	  system	  (8),	  to	  separate	  the	  desired	  product	  from	  the	  enzyme	  or	  whole	  cell	  
reaction.	   Biphasic	   systems	   can	   cause	   less	   stress	   to	   purified	   enzyme	   or	   whole	   cell	  
systems	   as	   the	   desired	   product	   may	   be	   cytotoxic	   (9)	   and	   will	   often	   preferentially	  
diffuse	  into	  the	  organic	  layer.	  
Enzymes	   often	   perform	   reactions	   by	   kinetic	   resolution	   (KR),	   this	   implies	   the	  
differentiation	  of	   two	  enantiomers	   from	  a	  racemic	  mixture	  using	  chiral	  catalysts	  or	  
reagents;	  however	  KRs	  may	  not	  always	   fully	   resolve	  a	   racemate	   to	  >99%	  e.e.	   If	   an	  
enzyme	  is	  not	  able	  to	  perform	  the	  desired	  reaction,	   it	   is	  possible	  to	  reengineer	  the	  
enzyme	   to	   improve	   its	   KR	   properties	   using	   techniques	   such	   as	   site-­‐directed	  
mutagenesis	   (SDM)	   and	   Directed	   Evolution;	   however,	   mutations	   can	   be	   time	  
consuming	   and	   expensive	  with	   chances	   that	   the	  mutant	   will	   still	   not	   perform	   the	  
desired	  reaction.	  An	  alternative	  to	  engineering	  is	  to	  make	  the	  KR	  a	  dynamic	  kinetic	  
resolution	  (DKR)	  or	  a	  dynamic	  kinetic	  asymmetric	  transformation	  (DYKAT)	  (10).	  DKRs	  
and	   DYKATs	   are	   dynamic	   systems	   where	   the	   minor	   product	   or	   by-­‐product	   are	  
transformed	  back	  to	  the	  starting	  material,	   thereby	  forming	  a	  continuous	  system	  to	  
produce	   the	  desired	  product	   in	   the	   theoretical	   yield	   of	   100%	   rather	   than	   the	   50%	  
achieved	  in	  KRs.	  While	  it	  is	  often	  difficult	  to	  find	  a	  stereo-­‐complementary	  enzyme	  or	  
a	  racemase	  with	  the	  desired	  reaction	  and	  substrate	  specificity	  for	  DKRs	  or	  a	  suitable	  
substrate	   for	   DYKAT,	   when	   parameters	   have	   been	   optimised	   the	   results	   are	   very	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promising.	   One	   example	   is	   the	   production	   of	   D-­‐alanine	   (Figure	   5)	   from	   L-­‐alanine	  
amide	  using	  D-­‐Aminopeptidase	  (11).	  
	  
Figure	  5	   -­‐	  Production	  of	  D-­‐Alanine	  from	  L-­‐Alanine	  amide	  employing	  a	  DKR.	  The	  D-­‐Aminopeptidase	  kinetically	  
resolves	   the	  amino	  amide	   to	   the	   L-­‐	  and	  D-­‐amino	  acid,	  however	   l-­‐α-­‐amino-­‐ε-­‐caprolactam	   (ACL)	   racemase	  will	  
transform	   the	  by-­‐product	  back	   to	   the	   starting	  material,	   therefore	  100%	  yield	  of	   the	  desired	  product	   can	  be	  
achieved.	  Modified	  from	  Yamaguchi	  and	  co-­‐workers	  (11).	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1.3.	  Alcohol	  Dehydrogenases	  (ADHs)	  
	  
ADHs	  have	  evolved	  to	  be	  able	  to	  oxidise	  alcohols	  and	  reduce	  aldehyde/ketones	  
(Figure	  6).	  By	  exploiting	  this	  reactivity,	  they	  can	  be	  used	  to	  perform	  these	  desirable	  
reactions	  on	  substrates	  of	   choice.	  ADHs	  utilise	   the	  nicotinamide	  cofactor	   [NAD(P)],	  
which	  are	  donors	  or	  acceptors	  of	  hydride,	  to	  perform	  the	  reduction	  or	  oxidation	  like	  
many	   other	   dehydrogenases.	   ADHs	   are	   able	   to	   perform	   biotransformations	   on	  
substrates	   with	   very	   high	   enantioselectivity,	   selectively	   oxidising	   or	   reducing	   the	  
functional	   group.	   They	   are	   able	   to	   perform	   these	   reactions	   much	   more	   elegantly	  
than	  using	  abiotic	  synthesis,	  however	  work-­‐up	  and	  product	  recovery	  can	  still	  be	  an	  
issue.	  
	  
Figure	  6	  -­‐	  The	  two	  pathways	  that	  alcohol	  dehydrogenases	  can	  perform	  on	  a	  generic	  alcohol	  and	  ketone	  aided	  
by	  the	  nicotinamide	  cofactor	  
There	  are	  three	  classes	  of	  ADHs:	  the	  long-­‐chain	  family	  (LDR),	  the	  medium-­‐chain	  
family	   (MDR)	   and	   the	   short-­‐chain	   family	   (SDR).	   Each	   class	   of	   ADHs	   has	   evolved	   to	  
oxidise	   or	   reduce	   a	   specific	   set	   of	   substrates,	   thus,	   ADHs	   often	   have	   very	   narrow	  
substrate	  specificities.	  
	  
1.3.1.	  Previously	  studied	  ADHs	  
	  
ADHs	   have	   been	   extensively	   studied	   as	   a	   family	   of	   enzymes	   not	   only	   as	  
biocatalysts,	  but	  as	  potential	  targets	  for	  inhibition	  in	  the	  treatment	  of	  diseases	  such	  
as	  Alzheimer’s	   (12),	  Parkinson’s	   (13)	  and	  heart	   (14)	  and	   liver	   (15)	   related	  diseases.	  
Many	  of	  these	  medically-­‐related	  investigations	  are	  inhibition	  studies	  of	  ADHs.	  	  
Due	  to	  the	  usefulness	  of	  ADHs,	  many	  have	  been	  become	  commercially	  available.	  
The	   medium	   chain	   alcohol	   dehydrogenase	   from	   Thermoanaerobium	   brockii’s	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biocatalyst.	  The	  mechanism	  of	  MDRs	  was	  initially	  investigated	  using	  Horse	  Liver	  ADH	  
(HLADH)	  (17)	  and	  this	  has	  since	  been	  the	  model	  for	  the	  medium	  chain	  family.	  	  
Many	   enzymes,	   including	   thermostable	   enzymes,	   are	   not	   able	   to	   tolerate	   high	  
concentrations	  of	  solvent.	  Investigations	  in	  solvent	  tolerant	  ADHs	  were	  conducted	  by	  
Karabec	  and	  co-­‐workers	  in	  2010	  (18)	  with	  ADH-­‐‘A’	  from	  Rhodococcus	  ruber;	  ADH-­‐‘A’	  
is	  tolerant	  up	  to	  80%	  v/v	  isopropanol	  and	  still	  active	  in	  99%	  v/v	  hexane	  (19).	  Solvent	  
tolerance	  is	  very	  useful	  as	  hydrophobic	  substrates	  are	  not	  water-­‐soluble.	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1.3.2.	  Short-­‐Chain	  Alcohol	  Dehydrogenases	  (SDRs)	  
	  
SDRs	   are	   composed	   of	   approximately	   250	   amino	   acids	   with	   a	   Rossmann	   Fold	  
nucleotide	   binding	  motif	   GxGxxG	   (20)	   and	   therefore	   utilise	   nicotinamide	   cofactors	  
assisting	   catalysis.	   SDRs	   have	   a	   highly	   conserved	   catalytic	   triad	   (Figure	   7)	   in	   the	  
active	  site	  (21)	  consisting	  of,	   for	  example,	  Ser138,	  Tyr151	  and	  Lys155	  in	  Drosophila	  
ADH	  (DADH),	  PDB	  entry:	  1B2L.	  	  	  
	  
Figure	  7	  –	  Catalytic	   triad	   (Ser138-­‐Tyr151-­‐Lys155)	  with	  nicotinamide	  cofactor	  shown	  for	  SDRs	  as	  proposed	  by	  
Jörnvall	  (22)	  obtained	  from	  the	  crystal	  structure	  of	  DADH	  (PDB	  entry:	  1B2L).	  	  
The	   mechanism	   of	   SDR	   action	   (Figure	   8)	   was	   proposed	   by	   Jörnvall	   and	   co-­‐
workers	   (22).	   The	   reduction	   mechanism	   is	   driven	   by	   regaining	   aromaticity	   of	   the	  
nicotinamide	   ring,	  which	   is	   followed	   by	   the	   substrate	   receiving	   a	   proton	   from	   the	  
proton	  donor	  Tyr151.	  The	  oxidation	  mechanism	  is	  driven	  by	  Tyr151’s	  reprotonation	  
from	  the	  alcohol.	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Figure	  8	  –	  The	  SDR	  mechanism	  as	  proposed	  by	  Jörnvall	  and	  co-­‐workers	  (22)	  in	  DADH.	  Catalytic	  triad	  Ser-­‐Tyr-­‐Lys	  
with	   NAD(P)H	   showing	   the	   carbonyl	   reductase	   mechanism.	   Regaining	   aromaticity	   of	   the	   nicotinamide	   ring	  
facilitates	   the	   carbonyl	   reductase	   pathway.	   Tyrosine	   regaining	   its	   proton	   will	   facilitate	   the	   alcohol	  
dehydrogenase	  pathway.	  
Members	  of	  the	  SDR	  family	   include	  RasADH	  (from	  Ralstonia	  sp.	  DSM	  6428)	  and	  
SyADH	  (from	  Sphingobium	  yanoikuyae	  DSM	  6900),	  each	  of	  which	  has	  been	  a	  target	  
for	  the	  studies	  in	  this	  thesis.	  
	  
1.3.2.1.	  The	  SDR	  from	  Ralstonia	  sp.	  (RasADH)	  	  
RasADH	   has	   previously	   been	   extensively	   characterised	   by	   Lavendera	   and	   co-­‐
workers	  in	  2008	  (23,24)	  and,	  more	  recently,	  by	  Cuetos	  and	  co-­‐workers	  (25)	  and	  Kulig	  
and	  co-­‐workers	  in	  2012	  (26)	  and	  2013	  (27).	  RasADH	  is	  an	  NADPH	  dependent,	  27	  kDa	  
enzyme	   of	   the	   SDR	   family	   with	   249	   amino	   acids	   from	   Ralstonia	   sp.	   DSM	   6428.	  
RasADH	   was	   found	   to	   be	   capable	   biotransforming	   so-­‐called	   ‘bulky-­‐bulky’	   ketones	  	  
(Figure	  9)	  such	  as	  n-­‐pentyl	  phenyl	  ketone	  (PPK),	  with	  a	  high	  preference	  for	  the	  (S)-­‐
alcohol	  of	  up	  to	  99%	  e.e.	  The	  addition	  of	  calcium	  ions	  was	  observed	  to	  stabilise	  the	  
protein	  in	  solution	  (27).	  
	  
Figure	  9	  -­‐	  Representative	  of	  a	  'bulky-­‐bulky'	  ketone,	  n-­‐pentyl	  phenyl	  ketone	  (PPK),	  reduced	  to	  the	  (S)-­‐alcohol	  by	  
RasADH.	  
The	  crystal	  structure	  for	  RasADH	  was	  recently	  solved	  by	  Lerchner	  and	  co-­‐workers	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substrate	   range	   for	   sterically	   demanding	   ketones	  with	   incredibly	   high	  e.e.s	   (>99%)	  
and	  more	  useful	  diastereomeric	  excess	  (d.e.s	  >	  99%)	  with	  respect	  to	  the	  reduction	  of	  
β-­‐hydroxy	  ketones	   to	  1,2-­‐diols.	   It	  has	   therefore	  been	  shown	  that	  RasADH	   is	  a	  very	  
useful	  biocatalyst	  for	  the	  asymmetric	  reduction	  of	  β-­‐hydroxy	  ketones.	  
	  
1.3.2.2.	  The	  SDR	  from	  Sphingobium	  yanoikuyae	  (SyADH)	  	  
SyADH	  is	  also	  an	  NADPH	  dependent,	  29	  kDa	  enzyme	  of	  the	  SDR	  family	  with	  272	  
amino	  acids	  from	  Sphingobium	  yanoikuyae	  DSM	  6900.	  SyADH	  is	  also	  able	  to	  catalyse	  
the	   formation	   of	   enantiomerically	   pure	   ‘bulky-­‐bulky’	   alcohols	   from	   the	   respective	  
ketone	   as	   with	   RasADH;	   althought,	   interestingly	   with	   different	   diasteroselectivity	  
(Figure	   10).	   The	   biochemical	   characteristics	   of	   SyADH	   have	   not	   been	   extensively	  
investigated	  as	  much	  as	  for	  RasADH.	  	  
	  
Figure	  10	  –	  Representative	  asymmetric	  reductions	  of	  bulky-­‐bulky	  ketones	  catalysed	  by	  ADHs	  from	  RasADH	  and	  
SyADH.	  Adapted	  from	  Man	  and	  co-­‐workers(29).	  
However,	  it	  was	  hypothesised	  by	  Lavandera	  and	  co-­‐workers	  in	  2008	  (30)	  that,	  as	  
SyADH	  was	  able	  to	  reduce	  ‘bulky-­‐bulky’	  ketones	  its	  active	  site	  would	  be	  quite	  large	  
and	   was	   therefore	   able	   to	   non-­‐selectively	   oxidise	   racemic	   ‘small-­‐bulky’	   secondary	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as	  acetone,	  a	  KR	  of	  50%	  e.e.	  was	  achieved	  with	  rac-­‐2-­‐octanol.	  However	  when	  α-­‐halo	  
ketones	  were	  used,	  such	  as	  chloroacetone,	  complete	  conversion	  (>99%	  yield)	  could	  
be	  achieved.	  
	  
Figure	   11	   –	   Modified	   from	   Lavandera	   and	   co-­‐workers	   (30).	   Schematic	   of	   the	   quasi-­‐irreversible,	   complete	  
oxidation	   of	   secondary	   alcohols	   with	   the	   use	   of	   α-­‐halo	   ketones	   as	   hydrogen	   acceptors	   for	   biocatalytic	  
hydrogen	  transfer	  reaction	  using	  SyADH.	  
The	   improved	   activity	   towards	   α-­‐halo	   ketones	   is	   a	   consequence	   of	   exploiting	   the	  
chemistry	  of	  halohydrins.	   It	   is	  more	  energetically	   favourable	   for	   the	  hydrogenation	  
of	  α-­‐halo	  ketones	  than	  the	  formation	  of	  iso-­‐propanol.	  Furthermore,	  stability	  gained	  
from	   the	   new	   hydrogen	   bond	   formed	   from	   the	   alcohol’s	   proton	   and	   the	   α-­‐halo	  
group	   caused	   SyADH	   to	   be	   unable	   to	   reoxidise	   the	   halohydrin.	   Therefore	   a	   quasi-­‐
irreversible	   system	  was	   formed	  where	  complete	  oxidation	  of	   racemic	  alcohols	  was	  
achieved.	  	  
	  
1.3.3.	  Medium	  Chain	  Alcohol	  Dehydrogenases	  (MDRs)	  
	  
MDRs	   are	   composed	   of	   approximately	   350	   amino	   acids	   with	   a	   Rossmann	  
nucleotide	  binding	  motif	  for	  NAD(P)H.	  The	  enzymes	  typically	  contain	  two	  zinc	  atoms	  
in	   each	  monomer;	   utilising	   zinc	   both	   catalytically	   and	   structurally.	   MDRs	   can	   also	  
perform	  oxidoreductase	  reactions	  similar	  to	  that	  of	  SDRs.	  However	  the	  active	  site	  of	  
MDRs	  does	  not	  consist	  of	  a	  catalytic	  triad	  as	  seen	  with	  SDRs.	  Catalysis	  is	  aided	  by	  a	  
zinc	  atom,	  NADH	  and	  a	  catalytic	  serine	  (Figure	  12)	  as	  seen	  in	  the	  active	  site	  of	  horse	  
liver	  ADH	  (HLADH),	  PDB	  entry:	  6ADH.	  	  
The	  mechanism	  of	  action	  proposed	  initially	  by	  Eklund	  (31)	  for	  HLADH	  involves	  a	  
static	  zinc	  atom	  coordinated	  by	  Cys46,	  His67,	  Cys174	  and	  the	  hydroxyl	  group	  on	  the	  
OH
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bound	  substrate,	  dimethyl	  sulfide	  (DMS),	  in	  a	  tetrahedral	  geometry	  (Figure	  12).	  The	  




Figure	   12	   –	   The	   key	   catalytic	   residues	   shown	   for	   the	   medium	   chain	   alcohol	   dehydrogenase	   mechanism	   as	  
proposed	   by	   Eklund	   (31)	   as	   in	   HLADH.	   Cyan	   vectors	   represent	   the	   main	   catalytic	   interactions	   arranged	  
tetrahedrally	   with	   the	   zinc	   atom.	   Magenta	   dashed-­‐vectors	   represent	   other	   potential	   catalytically	   involved	  
interactions.	  Dimethyl	  sulphide	  (DMS)	  is	  bound	  in	  the	  active	  site.	  
	  
The	   reduction	  mechanism	   (Figure	   13)	   is	   again	   driven	   by	   the	   nicotinamide	   ring	  
regaining	  aromaticity;	  the	  nicotinamide	  hydride	  attacks	  the	  carbonyl	  carbon	  shifting	  
electron	  density	  to	  the	  oxygen	  allowing	  the	  oxygen	  to	  take	  the	  proton	  from	  Ser48.	  	  
After	  protonation	  from	  Ser48,	  a	  cascade	  of	  proton	  transfers	  occurs	  for	  the	  MDR	  to	  
adopt	   the	   most	   stable	   form;	   Ser48	   reprotonates	   itself	   from	   the	   proton	   of	   the	  
hydroxyl	   group	   on	   the	   2’	   position	   of	   the	   ribose	   ring	   bound	   to	   the	   nicotinamide	  
group,	   followed	   by	   2’	   hydroxyl	   of	   the	   reprotonation	   from	   the	   neighbouring	  
protonated	   N3-­‐His51.	   Finally	   His51	   reprotonates	   the	   N1	   nitrogen	   by	   proton	  
abstraction	  from	  Thr56.	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Figure	   13	   -­‐	   The	  medium	   chain	   alcohol	   dehydrogenase	  mechanism	  as	   proposed	  by	   Eklund	   (31)	   as	   in	  HLADH.	  
Again,	  regaining	  aromaticity	  of	  the	  nicotinamide	  ring	  facilitates	  the	  carbonyl	  reductase	  pathway.	  
In	  more	  recent	  studies	  of	  the	  MDR	  active	  site	  by	  Meijers	  and	  co-­‐workers	  in	  2001	  
(32)	  and	  Baker	  and	  co-­‐workers	  in	  2009	  (33),	  it	  has	  been	  noted	  that	  the	  catalytic	  zinc	  
atom	  is	  not	  static	  as	  previously	  thought.	  Catalysis	  is	  potentially	  water-­‐mediated	  and	  
Glu68	  in	  Liver	  ADH	  (LADH),	  PDB	  entries:	  1HEU,	  1HF3	  and	  1HET,	  is	  a	  potential	  ligand	  
for	  zinc;	  where	  zinc	   is	  now	  coordinated	  tetrahedrally	  with	  Cys46,	  His67,	  Glu68	  and	  
Cys174.	  Whether	  or	  not	  the	  catalysis	  is	  water-­‐mediated	  could	  be	  due	  to	  the	  size	  of	  
the	  active	   site;	  water	  may	  be	   required	   to	  complete	   the	   reaction	   if	   the	   substrate	   is	  
held	  too	  far	  for	  coordination	  (Figure	  14)	  with	  zinc	  as	  in	  glucose	  dehydrogenase	  (33).	  
	  
	  
Figure	  14	  –	  Schematic	  diagram	  of	  water	  mediated	  catalysis	  from	  Baker	  2009	  (33),	  viewed	  down	  the	  His	  63	  NE2–
Zn	   bond,	   of	   the	   zinc	   ligands	   in	   the	   NADP(H)/Zn	   complex	   (Left),	   NADP+/Zn/glucose	   complex	   (Centre),	   and	  
NADP+/Zn/gluconolactone	   complex	   (Right).	   The	   arrows	   give	   the	   direction	   of	   the	  movement	   of	   the	   zinc	   and	  
water	  between	  the	  complexes.	  PDB	  entries:	  2VWP,	  2VWQ,	  2VWH	  and	  2VWG.	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1.3.3.1.	  The	  MDR	  from	  Thermus	  sp.	  (TADH)	  
	  
Thermophilic	  and	  hyperthermophilic	  biocatalysts	  have	  been	  of	  particular	  interest	  
to	   industry.	   Their	   robust	   characteristics	   allow	   them	   to	   be	   used	   under	   reaction	  
conditions	  suitable	   for	   industrial	  processes	  and	  to	   remain	  stable.	  Enzymes	   that	  are	  
stable	   at	   high	   temperatures	   are	   often	   relatively	   stable	   in	   high	   concentration	   of	  
solvents.	  The	  use	  of	  high	  solvent	  concentration	  may	  not	  necessarily	  be	  required	  with	  
high	   temperature	   reactions,	   as	   higher	   temperatures	   may	   allow	   for	   increased	  
substrate	  solubility	  and	  rate	  of	  diffusion	  (34).	  However,	  the	  major	  downfall	  of	  many	  
MDRs,	  including	  thermophilic	  MDRs,	  is	  the	  limited	  substrate	  scope.	  	  
TADH	  is	  an	  NADH	  dependent,	  37	  kDa	  thermophilic	  MDR	  from	  Thermus	  sp.	  ATN1	  
with	  347	  amino	  acids.	  TADH	  has	  a	  remarkably	  wide	  substrate	  spectrum	  and	  highest	  
activities	  were	  observed	  with	  primary	  alcohols	  and	  aldehydes	  (35).	  Activity	  loss	  was	  
observed	   when	   acetone	   was	   used	   as	   a	   co-­‐substrate	   for	   cofactor	   regeneration;	  
however,	   this	   was	   still	   preferable	   over	   introducing	   a	   second	   enzyme	   system.	  
Interestingly	   TADH	   displays	   high	   dismutation	   activity,	   the	   simultaneous	   oxidation	  
and	  reduction	  of	  a	  single	  species	  with	  aldehydes,	  therefore	  TADH	  can	  be	  used	  as	  a	  
biocatalytic	   tool	   for	   accessing	   carboxylic	   acids	   (Figure	   15).	   Due	   to	   the	   irreversible	  
conversion	   from	  aldehyde	  to	  carboxylic	  acid,	  complete	  conversion	  can	  be	  achieved	  
over	  24	  hours.	  
	  
Figure	  15	  –	  Modified	  from	  Hollmann	  and	  co-­‐workers	  (35).	  Scheme	  of	  aldehyde	  dismutation	  reaction	  catalysed	  
by	  TADH.	  Acetone	  was	  used	  for	  cofactor	  regeneration.	  
Not	  only	  is	  TADH	  thermostable,	  but	  it	  is	  even	  active	  in	  10%	  (v/v)	  SDS	  and	  activity	  
was	  doubled	  in	  10%	  (v/v)	  Triton-­‐X100	  with	  cyclohexanol.	  	  TADH’s	  overall	  stability	  has	  
also	  allowed	  it	  to	  be	  coupled	  with	  a	  hydrogenating	  ruthenium	  based	  organometallic	  
catalysts	  to	  regenerate	  the	  nicotinamide	  cofactor	  (36).	  Activity	  assays	  performed	  at	  
relatively	   high	   temperatures	   of	   60°C,	   allowed	   for	   the	   organometallic	   catalyst	   to	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1.3.3.2.	  The	  MDR	  from	  Candida	  parapsilosis	  (CPCR2)	  
	  
Many	   ADH	   substrates	   of	   interest	   are	   quite	   often	   very	   hydrophobic	   and	   will	  
precipitate	   out	   of	   solution	   on	   contact	   with	   aqueous	   buffer	   due	   to	   limited	   water	  
solubility.	  This	   issue	  can	  occasionally	  be	  solved	  with	  organic	  co-­‐solvents	  or	  biphasic	  
systems,	  with	  the	  trade-­‐off	  of	  reduced	  activity	  and	  stability.	   In	  the	  case	  of	  ADH-­‐‘A’,	  
despite	  it	  tolerating	  neat	  solvent	  or	  co-­‐substrate,	  much	  of	  its	  activity	  was	  diminished.	  
	  
Figure	   16	   -­‐	   Modified	   from	   Jakoblinnert	   and	   co-­‐workers	   (37).	   Biocatalytic	   reduction	   of	   acetophenone	   using	  
lyophilised	  E.	  coli	  cells	  with	  overexpressed	  CPCR2	  in	  neat	  substrate	  with	  iso-­‐propanol	  as	  a	  co-­‐substrate.	  
CPCR2	  is	  an	  NADH	  dependent,	  36	  kDa	  MDR	  with	  336	  amino	  acids	  from	  Candida	  
parapsilosis	   DSM	   70125.	   CPCR2	   has	   a	   broad	   substrate	   spectrum	   producing	  
enantiomerically	  pure	  (S)-­‐alcohols.	  Purified	  CPCR2	  is	  particularly	  unstable	  and	  rapidly	  
degrades,	  however	  efforts	  to	  improve	  solvent	  and	  thermal	  stability	  by	  Site-­‐Directed	  
Mutagenesis	   (SDM)	  have	  been	  successful	   (38).	  CPCR2	  has	  been	  applied	  as	  a	  whole	  
cell	   catalyst	   (Figure	   16)	   due	   to	   the	   lack	   of	   additional	   expense	   required	   with	  
implementing	   cofactor	   regeneration	   systems,	   simplified	   product	   isolation	   and	  
increased	   solvent	   tolerance.	   Lyophilised	  E.	   coli	   cells	  with	  CPCR2	  overexpressed	  are	  
capable	   of	   retaining	   all	   of	   its	   activity	   in	   neat	   substrate	   (37),	   as	   in	   Figure	   14.	  
Therefore,	   CPCR2	   has	   opened	   up	   new	   biocatalytic	   routes	   to	   the	   production	   of	  
synthetically	  useful	  building	  blocks	  with	  substrates	  previously	  not	  accessible.	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1.4.	  Nicotinamide	  Cofactors	  
	  
ADHs	   utilise	   nicotinamide	   cofactors	   (Figure	   17),	   as	   mentioned	   in	   section	   1.3.	  
ADHs	  have	  a	  nucleotide	  recognition	  site,	  a	  Rossmann	  Fold	   (GxGxxG)	  allowing	  them	  
to	   bind	   NAD(P)H.	   The	   reduced	   form	   of	   the	   cofactor	   is	   used	   for	   the	   carbonyl	  
reductase	  reaction.	  
	  
	   	   	   	   	  
Figure	  17	  -­‐	  Chemical	  structures	  of	  the	  nicotinamide	  cofactors,	  shown	  above	  are:	  NAD+	  (left),	  NADP+	  (middle)	  
and	   an	   expanded	   view	   of	   the	   reduced	   form	   of	   the	   nicotinamide	   group	   with	   the	   prochiral	   hydrogens	  
stereospecifically	  labelled	  (right).	  
The	  reduced	  form	  of	  the	  nicotinamide	  group	  follows	  the	  Cahn-­‐Ingold-­‐Prelog	  (CIP)	  
priority	  rules	  (39,40)	  for	  α,β-­‐unsaturated	  carbonyls	  (enone)	  about	  the	  Cα	  (Figure	  	  18	  
-­‐	  left).	  	  
	  	   	   	  
Figure	  18	  –	  Schematic	  of	  a	  generic	  enone	  showing	  the	  CIP	  priority	  resulting	  in	  the	  prochirality	  of	  the	  HR	  and	  HS	  
hydrogens	  (left).	  Schematics	  of	  CIP	  equivalents	  of	  a	  carbonyl	  (middle)	  and	  an	  alkene	  (right).	  
Due	   to	   the	  CIP	   rules,	   assuming	   the	   substituent	  R’s	  priority	   is	   less	   than	  oxygen	   (i.e.	  
carbon	  or	  nitrogen),	  Cα-­‐C=O	  has	  a	  higher	  priority	  than	  Cα=C-­‐R;	  this	  is	  as	  the	  carbonyl	  
equates	   to	  a	  carbon	  being	  bound	  to	   two	  oxygens,	  whereas	  an	  alkene	  equates	   to	  a	  
carbon	  being	  bound	  to	   two	  carbons	   (Figure	   18	   	   -­‐	  middle	  and	   left).	  The	  CIP	  priority	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mentioned	   by	   Prelog	   in	   1946	   (41),	  which	   describes	   the	   interesting	   stereochemical	  
outcome	   for	   ADHs	   and	   their	   substrates.	   It	   was	   previously	   identified,	   by	   Bradshaw	  
and	   co-­‐workers	   in	   1991	   (42),	   that	   the	   different	   stereospecificities	   of	   alcohol	  
dehydrogenases	   arise	   from	   how	   the	   nicotinamide	   cofactor	   is	   bound;	   therefore	   a	  
specific	  hydride	  is	  delivered	  to	  a	  specific	  face	  (Figure	  19)	  of	  the	  carbonyl	  (either	  the	  




Figure	  19	  -­‐	  Modified	  from	  Bradshaw	  and	  co-­‐workers	  (42).	  Stereospecificity	  of	  ADHs	  where	  'S'	  is	  a	  small	  group	  
and	  'L'	  is	  a	  large	  group.	  
Enzymes	   that	   utilise	   these	   cofactors	   are	   often	   selective	   for	   one	   or	   the	   other.	  
Enzymes	  that	  are	  selective	  towards	  NADPH	  often	  have	  an	  arginine	  residue	  near	  the	  
phosphate	  group	  at	  the	  2’	  position	  of	  the	  adenine-­‐ribose	  ring;	  the	  positively	  charged	  
residue	   is	   effectively	   hugging	   the	   negatively	   charged	   phosphate	   group	   as	   with	  
Arg200	  in	  TbADH,	  PDB	  entry:	  1KEV.	  Enzymes	  that	  are	  selective	  towards	  NADH	  have	  a	  
glutamate	  or	  aspartate	  residue	  near	  the	  2’	  position	  of	  the	  adenine-­‐ribose	  ring;	  this	  
would	  repel	  any	  negatively	  charged	  phosphate	  groups	  from	  cofactor	  binding	  pocket	  
as	   with	   Asp223	   in	   HLADH.	   Cofactor	   preference	   and	   comparison	   can	   be	   seen	   for	  
TbADH	  and	  HLADH	  (Figure	  20).	  However,	  there	  are	  a	  few	  cases	  where	  enzymes	  are	  
able	  to	  utilise	  both	  cofactors.	  This	  is	  often	  due	  a	  glutamine	  residue	  (43)	  near	  the	  2’	  
position	   of	   the	   adenine-­‐ribose	   ring;	   which,	   due	   to	   its	   neutral	   charge,	   permits	   the	  
binding	  of	  both	  cofactors.	  
E1:	  pro-­‐R/si-­‐face,	  Pseudomonas	  sp.	  and	  Lactobacillus	  kefir	  ADH	  
E2:	  pro-­‐S/si-­‐face,	  Mucor	  jávanicus	  ADH	  
E3:	  pro-­‐R/re-­‐face,	  yeast	  ADH,	  HLADH	  and	  TbADH	  
E4:	  pro-­‐S/re-­‐Face,	  unknown	  (in	  1991)	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Figure	  20	  –	  Residues	  responsible	  for	  cofactor	  preference	  for	  TbADH	  (PDB	  entry:	  1KEV)	  and	  HLADH	  (PDB	  entry:	  
6ADH).	   TbADH	   and	   HLADH	   are	   superposed	   on	   their	   cofactors	   and	   only	   the	   cofactor	   from	   TbADH	   is	   shown.	  
HLADH	  would	  not	  allow	  NADPH	  to	  bind	  due	  to	  repulsion	  from	  Asp223,	  however	  in	  TbADH	  the	  phosphate	  and	  
Arg200	  makes	  a	  favourable	  interaction,	  therefore	  allowing	  binding.	  
Nicotinamide	   cofactors,	   despite	   their	   uses,	   are	   relatively	   expensive;	   however	  
NADH	  is	  a	  tenth	  of	  the	  price	  of	  NADPH	  and	  NAD+	  is	  a	  fifth	  of	  the	  price	  of	  NADP+.	  As	  
such,	   attempts	   to	   reengineer	   cofactor	   specificity	   preference	   towards	   NADH	   have	  
been	   attempted	   for	   ADHs	   (44)	   and	   other	   oxidoreductases	   (45,46),	   however	   it	   has	  
often	  proven	  no	  simple	  task	  to	  simply	  mutate	  one	  residue	  to	  create	  an	  unfavourable	  
interaction	   for	  one	  cofactor	  over	   the	  other.	  Reaction	  and	  conversion	   rates	  may	  be	  
significantly	   lowered	   simply	   due	   to	   the	   cofactor	   no	   longer	   binding	   in	   the	   same	  
position,	   creating	   a	   disturbance	   in	   preferential	   binding	   interaction	   between	   the	  
cofactor,	  enzyme	  and	  substrate.	  
If	  changing	  the	  cofactor	  specificity	  has	  not	  been	  successful,	   it	   is	  still	  possible	  to	  
use	  either	  cofactor	  efficiently	  at	  catalytic	  quantities	  with	  cofactor	  regeneration	  (47).	  
Regeneration	   strategies	   often	   involve	   two	   enzyme	   systems	   or	   if	   available	   co-­‐
substrates	  are	  used	  to	  regenerate	  the	  cofactor	  (Figure	  21).	  
	  
Figure	  21	  -­‐	  Generic	  cofactor	  regeneration	  strategies	  for	  the	  reductive	  reaction	  of	  a	  gene	  of	  interest.	  
In	   the	   case	   of	   some	   ADHs	   it	   may	   be	   applicable	   to	   use	   ethanol/ethanal	   or	   iso-­‐
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(18),	  co-­‐solvents	  can	  be	  used	   in	  high	  concentrations	  which	  may	  also	  help	  solubilise	  
hydrophobic	  substrates	  and	  benefit	  from	  cofactor	  regeneration.	  When	  co-­‐substrate	  
or	  co-­‐solvent	   is	  not	  available,	  a	  second	  enzyme	  (Figure	   22)	   is	  used	   in	   the	  reaction,	  
such	   as	   Formate	   Dehydrogenase	   for	   NAD+/NADH	   or	   Glucose-­‐6-­‐phosphate	  
Dehydrogenase	  for	  NADP+/NADPH.	  
	  	  
	  
Figure	  22	  –	  Reactions	  of	  the	  two	  typically	  used	  recycling	  systems.	  Formate	  Dehydrogenase	  (top)	  and	  Glucose-­‐6-­‐
phosphate	  Dehydrogenase	  (bottom).	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1.5.	  Aim	  of	  the	  Project	  
	  
The	  aim	  of	  this	  project	  is	  to	  gain	  an	  insight	  into	  the	  crystal	  structures	  of	  various	  
alcohol	  dehydrogenases	   received	   from	  collaborators	   that	  have	  been	  demonstrated	  
to	  have	  distinctly	  useful	  properties.	  This	  would	  enable	  us	  to	  rationalise	  the	  enzymes	  
substrate	  specificity	  and	  allow	  for	  further	  protein	  engineering.	  
The	  gene	  encoding	  the	  SDR	  from	  Ralstonia	  sp.,	  RasADH,	  was	  previously	  cloned,	  
expressed	  and	  purified	  by	  Justyna	  Külig	  from	  The	  Institute	  of	  Bio-­‐	  and	  Geosciences	  in	  
Jülich,	   Germany.	   Some	   crystallisation	   screening	   and	   optimisation	   had	   been	  
performed	  but	  with	  limited	  success.	  The	  first	  aim	  was	  to	  re-­‐establish	  expression	  and	  
purification	  protocols	  in	  a	  hope	  to	  crystallise	  the	  protein	  with	  more	  success	  and	  use	  
the	  crystal	  structure	  to	  attempt	  to	  engineer	  novel	  substrate	  specificity.	  	  
The	  gene	  encoding	  the	  SDR	  from	  Sphingobium	  yanoikuyae,	  SyADH,	  was	  cloned,	  
expressed,	  purified	  and	  crystallised	  by	  Kinga	  Kedziora	  from	  Universidad	  de	  Oviedo	  in	  
Oviedo,	  Spain.	  A	  dataset	  was	  obtained	  from	  the	  optimised	  crystals.	  The	  second	  aim	  
was	  to	  build	  the	  crystal	  structure	  and	  perform	  structural	  analysis,	  comparisons	  and	  
ligand	  docking	  with	  the	  structure	  of	  RasADH.	  
The	   gene	   encoding	   the	  MDR	   from	   Thermus	   sp.,	   TADH,	  was	   cloned,	   expressed,	  
purified	  and	   crystallised	  by	   Serena	  Gargiulo	   from	  Delft	  University	  of	   Technology	   in	  
Delft,	   The	   Netherlands.	   A	   dataset	   was	   obtained	   from	   the	   optimised	   crystals.	   The	  
third	   aim	   was	   to	   build	   the	   crystal	   structure	   and	   perform	   structural	   analysis	   and	  
comparisons	  with	  other	  thermophilic	  and	  mesophilic	  MDRs.	  
The	   gene	   encoding	   the	  MDR	   from	  Candida	  parapsilosis,	   CPCR2,	  was	   previously	  
cloned	  (into	  pET-­‐22b	  Strep-­‐tag	  vector),	  expressed	  and	  purified	  by	  Christoph	  Loderer	  
from	  Technische	  Universität	  Dresden	  in	  Dresden,	  Germany.	  Crystallisation	  screening	  
and	  optimisation	  had	  been	  performed	  on	   the	  Strep-­‐tag	  construct,	  however	   limited	  
success	  was	  observed.	  The	  fourth	  aim	  was	  to	  subclone	  CPCR2	  into	  the	  pET-­‐YSBLIC3C	  
vector	   (48),	   re-­‐establish	  expression	  and	  purification	  protocols	  and	  re-­‐crystallise	   the	  
protein	  to	  obtain	  a	  dataset	  and	  crystal	  structure	  with	  NADH.	  
In	  gaining	  the	  crystal	  structure	  for	  each	  of	  these	  ADHs,	  they	  will	  provide	  the	  basis	  
for	   rational	   engineering,	   to	   further	   improve	   the	   substrate	   specificity,	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enantioselectivity,	  cofactor	  preference	  and	  enzyme	  stability	  for	  the	  potential	  use	  of	  
industrial	  biotechnology.	   	  




The	   Structural	   Proteomics	   In	   Europe	   (SPINE)	   consortium	   was	   a	   collaboration	  
between	   14	   laboratories	   across	   Europe	   that	   developed	   a	   whole	   range	   of	   ligation	  
independent	   cloning	   (LIC)	   and	   In-­‐Fusion	   compatible	   E.	   coli	   vectors	   using	   high-­‐
throughput	   cloning	   methods,	   with	   a	   variety	   of	   cleavable	   and	   non-­‐cleavable	   tags	  
(49,50).	   Through	   SPINE,	   the	   pET-­‐YSBLIC	   and	   pET-­‐YSBLIC3C	   was	   developed.	   Both	  
vectors	  were	  adapted	  from	  pET-­‐28a,	  where	  a	  LIC	  site	  was	  incorporated	  to	  allow	  for	  
cloning	  without	  the	  use	  of	  restriction	  endonucleases	  or	  DNA	  ligases.	  LIC	  allows	  for	  a	  
faster	  and	  higher	  success	  rate	  of	  cloning.	  
Genes	  of	  interest	  were	  routinely	  cloned	  only	  using	  LIC	  (Figure	  23).	  The	  template	  
gene	  of	  interest	  received	  from	  collaborators	  was	  initially	  amplified	  with	  appropriate	  
primers	   designed	   using	   the	   HiTel	   Primer	   Design	   (http://bioltfws1.york.ac.uk/cgi-­‐
bin/primers.cgi)	  for	  LIC.	  	  
	  
Figure	   23	   –	   The	   schematic	   for	   preparation	   of	   the	   PCR	   fragment	   and	   annealing	   to	   the	   pET-­‐YSBLIC3C	   vector.	  
Adapted	  from	  Fogg	  and	  Wilkinson	  (48).	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2.1.1.	  Polymerase	  Chain	  Reaction	  (PCR)	  
	  
The	   gene	   of	   interest	   was	   amplified	   by	   polymerase	   chain	   reaction	   using	   a	   PCR	  
thermal	  cycler.	  The	  following	  components	  were	  used	  in	  the	  PCR:	  
	  
	  
The	  reaction	  was	  performed	  in	  a	  PCR	  thermal	  cycler	  using	  the	  following	  steps/cycles:	  
Temperature	   Time	   Step	   Cycles	  
94°C	   2	  min	   Initial	  denature	   1	  
94°C	   30	  s	   Denature	  
35	  50°C	   30	  s	   Anneal	  
72°C	   30	  s	   Extend	  
72°C	   3	  min	   Final	  extension	   1	  
4°C	   	  ∞	   Cool	   	  	  
	  
2.1.2.	  Fragment	  Analysis	  by	  Agarose	  Gel	  Electrophoresis	  
	  
Agarose	  gels	  are	  commonly	  used	  to	  analyse	  DNA	  fragments	  where	  the	  separation	  
is	  based	  on	  size.	  However	  for	  very	  large	  proteins	  >	  200	  kDa	  it	  may	  be	  appropriate	  to	  
use	  agarose	  gel	  electrophoresis	  (51).	  
	  
To	  0.6	  g	  agarose,	  60	  mL	  TAE	  buffer	  was	  added	  and	  the	  mixture	  was	  microwaved	  
at	  maximum	  heat	  for	  1	  min.	  Once	  cool	  enough	  to	  handle,	  1	  μL	  SYBR	  Safe	  was	  added	  
to	  the	  mixture	  and	  swirled.	  The	  agarose	  was	  then	  poured	  into	  a	  caster,	  where	  a	  6-­‐
well	  comb	  was	  inserted	  and	  allowed	  to	  set	  for	  1	  h.	  
Component	   DMSO	  Reaction	   Reaction	  
Template	  (50-­‐100	  ng/μL)	   1	  μL	   1	  μL	  
For	  Primer	  (20	  pmol/μL)	   1	  μL	   1	  μL	  
Rev	  Primer	  (20	  pmol/μL)	   1	  μL	   1	  μL	  
dNTPs	  (2	  mM)	   5	  μL	   5	  μL	  
MgSO4	  	   3	  μL	   3	  μL	  
KOD	  Polymerase	  Buffer	  (10x)	   5	  μL	   5	  μL	  
DMSO	   1	  μL	   0	  μL	  
KOD	  Polymerase	   1	  μL	   1	  μL	  
ddH2O	   32	  μL	   33	  μL	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After	  the	  gel	  was	  set,	  the	  comb	  was	  removed	  and	  the	  gel	  was	  placed	  in	  a	  gel	  tank	  
where	  sufficient	  buffer	  was	  added	  to	  submerge	  the	  gel.	  Samples	  were	  added	  to	  the	  
wells	  formed	  by	  the	  comb	  and	  the	  gel	  was	  run	  for	  1	  h	  at	  100	  V.	  
	  
2.1.3.	  Preparing	  Samples	  for	  Agarose	  Gel	  
	  
Prior	  to	  loading	  samples	  to	  the	  agarose	  gel,	  dye	  was	  added	  to	  the	  samples	  to	  be	  able	  
to	  image	  the	  sample	  on	  the	  gel.	  	  
	  
1.5	  μL	  of	  1	  kb	  DNA	  ladder	  was	  prepared	  by	  adding	  3	  μL	  ddH2O	  and	  3	  μL	  6x	  gel	  
loading	  dye.	  10	  μL	  gel	  loading	  dye	  was	  added	  to	  25	  μL	  reaction	  sample.	  
1	  kb	  DNA	  Ladder	  and	  6x	  (blue)	  gel	  loading	  dye	  was	  purchased	  from	  New	  England	  
BioLabs.	  
	  
2.1.4.	  DNA	  Purification:	  Gel	  Extraction	  (Spin-­‐Down	  Method)	  
	  
After	  a	  PCR	  has	  been	  completed,	  the	  amplified	  DNA	  must	  be	  purified.	  Purification	  
methods	   include	   PCR	   clean-­‐up	   and	   gel	   extraction.	   Gel	   extraction	   was	   the	   only	  
method	  used.	  
	  
For	  the	  following	  protocol,	  all	  centrifugation	  were	  performed	  at	  13.3k	  rpm:	  
	  
Successful	  DNA	  fragments	  analysed	  on	  agarose	  gel	  are	  excised	  and	  weighed.	  The	  
gel	  was	  dissolved	  with	  3	  gel	  volumes	  of	  solubilising	  solution,	  where	  1	  gel	  volume	  is	  
100	  μL	  solution	  for	  every	  100	  mg	  agarose.	  The	  mixture	  may	  be	  incubated	  with	  warm	  
water	   and	   vortexed	   to	   ease	   dissolution.	  Once	   dissolved	   the	   gel	  mixture	   should	   be	  
yellow.	   1	   gel	   volume	   of	   100%	   isopropanol	  was	   added	   to	   the	   gel	  mixture	   and	  was	  
mixed.	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The	   binding	   column	   was	   prepared	   whilst	   the	   gel	   is	   dissolving.	   500	   μL	   column	  
preparation	   solution	  was	   added	   to	   the	   binding	   column	   and	  was	   centrifuged	   for	   1	  
min.	  The	  flow	  through	  was	  discarded.	  
DNA	   was	   then	   bound	   to	   the	   column	   by	   loading	   the	   dissolved	   mixture	   to	   the	  
column	   and	   centrifuging	   for	   1	   min	   with	   discarding	   of	   the	   flow	   through.	   This	   was	  
repeated	  until	  all	  the	  mixture	  has	  eluted.	  	  After	  binding,	  the	  bound	  DNA	  was	  washed	  
with	  700	  μL	  wash	  solution	  and	  centrifuged	  for	  1	  min.	  
The	  binding	  column	  was	  transferred	  to	  a	  fresh	  collection	  tube	  with	  50	  μL	  ddH2O	  
(@	   60°C)	   added	   directly	   onto	   the	   membrane	   for	   30	   min.	   After	   30	   min,	   DNA	   was	  
eluted	   with	   centrifugation	   for	   1	   min.	   DNA	   concentration	   should	   be	   checked	   after	  
elution.	  
	  
2.1.5.	  T4	  DNA	  Polymerase	  Digest	  Reaction	  with	  Insert	  
	  
After	  a	  PCR	  clean	  up,	  the	  inserts’	  overhangs	  were	  digested	  to	  create	  sticky	  ends	  
to	   allow	   for	   annealing	   to	   the	   desired	   vector.	   To	   0.2	   pmol	   of	   insert,	   the	   following	  
components	  were	  added:	  
Volume	   Component	  
2	  μL	   T4	  Buffer	  (10x)	  
2	  μL	   dATP	  (25	  mM)	  
0.5	  μL	   DTT	  (100	  mM)	  
0.5	  μL	   T4	  DNA	  Polymerase	  
12	  μL	   ddH2O	  
	  
The	  reaction	  was	  incubated	  at	  20°C	  for	  30	  min,	  followed	  by	  75°C	  for	  20	  min.	  
	  
2.1.6.	  Annealing	  Insert	  to	  Vector	  (pET-­‐YSBLIC3C)	  
	  
Once	   the	   sticky	   ends	  were	   formed	   from	   the	   digest	   reaction,	   the	   insert	   can	   be	  
annealed	  to	  a	  linearised	  vector	  with	  complementary	  stick	  ends.	  LIC	  does	  not	  require	  
DNA	  Ligase	  for	  a	  ligation	  step	  as	  required	  with	  standard	  molecular	  cloning.	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3	  μL	  of	  insert	  was	  incubated	  with	  3	  μL	  linearised	  pET-­‐YSBLIC3C	  vector	  for	  10	  min	  
at	   room	   temperature.	   Following	   that,	   1.5	   μL	   EDTA	   (25	   mM)	   was	   added	   to	   the	  
mixture	  and	  left	  for	  another	  10	  min	  at	  room	  temperature.	  
	  
2.1.7.	  Preparing	  agar	  plates	  
	  
Agar	   plates	   are	   routinely	   used	   to	   selectively	   grow	   microorganisms.	   There	   is	   a	  
range	  of	  media	  available	  for	  agar	  plates,	  however	  only	  LB-­‐agar	  plates	  are	  used.	  
	  
200	  mL	  LB-­‐agar	  was	  microwaved	  at	  maximum	  heat	  in	  1	  min	  bursts	  with	  swirling	  
in-­‐between	   until	   all	   was	   dissolved.	   It	   was	   then	   allowed	   to	   cool	   until	   it	   could	   be	  
handled	   by	   hand,	   then	   antibiotics	   (i.e.	   at	   34	   mg/mL	   kanamycin	   and	   or	  
chloramphenicol)	  were	  added	  in	  a	  1	  in	  1000	  fold	  dilution	  and	  the	  agar	  was	  swirled	  to	  
mix.	   The	  agar	   could	   then	  be	  poured	  onto	  petri	  dishes	  using	  aseptic	   technique	  and	  
was	  allowed	  to	  set	  for	  approximately	  1	  h.	  
	  
2.1.8.	  Transformation	  into	  Cloning	  Strains	  
	  
Competent	  cells	  are	  routinely	  used	  for	  transformation	  –	  the	  uptake	  of	  DNA	  into	  
cells.	   There	   are	   many	   different	   strains	   of	   (E.	   coli)	   cells	   commercially	   available,	  
however	  the	  only	  cloning	  strain	  used	  were	  NovaBlue	  Singles	  competent	  cells.	  
	  
Once	  the	  annealing	  reaction	  was	  complete,	  it	  was	  transformed	  into	  cloning	  strain	  
cells.	   6	  μL	   annealing	   reaction	  was	   added	   to	   25	  μL	   cells	   (i.e.	  NovaBlue	   Singles)	   and	  
was	  left	  on	  ice	  for	  5	  min.	  The	  mixture	  was	  heat	  shocked	  at	  42°C	  for	  45	  s.	  Following	  
the	  heat	  shock,	  the	  cells	  were	  left	  on	  ice	  for	  another	  5	  min.	  150	  μL	  SOC	  (52)	  medium	  
was	  added	  to	  the	  mixture	  and	   left	   to	   incubate	  at	  37°C	  for	  1	  h	   in	  an	  orbital	  shaker.	  
The	  cells	  were	  spread,	  using	  aseptic	  technique,	  on	  kanamycin-­‐LB-­‐agar	  plates	  and	  was	  
left	  to	  incubate	  in	  a	  37°C	  oven	  overnight.	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2.1.9.	  Starter	  Culture	  
	  
A	   starter	   culture	   is	   routinely	   used	   prior	   to	   inoculating	   media	   for	   further	  
experimentation	  or	  for	  plasmid	  extraction.	  This	   is	  as	  bacteria	  utilise	  majority	  of	  the	  
nutrients	   available	   in	   the	   initial	   starter	   culture	   reaching	   the	   exponential	   phase.	  
Therefore	   a	   growing	   culture	  plucked	   from	  a	   single	   colony	   in	   a	   flask	  with	  1	   L	   of	   LB	  
medium	   would	   not	   only	   take	   a	   very	   long	   time	   to	   reach	   a	   satisfactory	   OD600	   for	  
induction,	  also	  a	  lot	  of	  the	  nutrients	  in	  the	  media	  would	  have	  been	  already	  used	  up,	  
thus	  expression	  of	  the	  desired	  protein	  is	  not	  as	  optimal	  as	  it	  could	  be.	  Upon	  scaling	  
up	   culture	   growth,	   starter	   cultures	   can	   be	  made	   in	   a	   1	   in	   100	   fold	   dilution	   of	   the	  
media	  volume;	  i.e.	  10	  mL	  starter	  culture	  for	  an	  intended	  1	  L	  culture.	  
	  
The	  following	  was	  performed	  with	  aseptic	  technique:	  
	  
5	  mL	  of	  autoclaved	  LB	  (53)	  medium	  with	  antibiotics	  (i.e.	  kanamycin	  at	  34	  mg/mL)	  
added	  in	  a	  1	  in	  1000	  fold	  dilution	  was	  added	  to	  a	  50	  mL	  Falcon	  tube.	  A	  colony	  from	  a	  
successful	  transformation	  on	  an	  agar-­‐plate	  was	  plucked	  using	  a	  pipette	  tip	  and	  was	  
ejected	   into	   the	   Falcon	   tube.	   The	   Falcon	   tubes	  were	   then	   incubated	   in	   an	   orbital	  
shaker	  at	  37°C	  overnight.	  
	  
2.1.10.	  Plasmid	  Extraction:	  Mini-­‐Prep	  
	  
Overnight	   cultures	   from	   the	  plasmid	   in	   the	   cloning	   strain	  are	  used	   to	  generate	  
more	   copies	   of	   the	   plasmid.	   The	   plasmids	   are	   then	   extracted	   from	   the	   cells	   and	  
purified,	  this	  allows	  the	  plasmid	  to	  be	  stored	  for	  future	  use.	  This	  is	  often	  performed	  
using	  a	  MiniPrep	  kit	  which	  is	  commercially	  available.	  
	  
For	  the	  following	  protocol,	  all	  centrifugations	  were	  performed	  at	  13.3k	  rpm:	  
	  
The	   starter	   culture	   was	   initially	   pelleted	   into	   a	   collection	   tube	   with	   the	  
supernatant	   discarded.	   The	   pellet	   was	   resuspended	   with	   200	   μL	   resuspension	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solution	   and	   vortexing.	   200	  μL	   lysis	   solution	  was	   added	   to	   the	   resuspended	  pellet	  
and	   was	   gently	   mixed	   by	   inverting	   the	   collection	   tube	   4-­‐6	   times.	   The	   lysate	   was	  
allowed	   to	   clarify	   for	   5	   min.	   After	   the	   lysate	   was	   clarified,	   350	   μL	   neutralising	  
solution	  was	   added	  and	  was	   gently	  mixed	  again	  by	   inversion.	   The	   lysate	  was	   then	  
centrifuged	  for	  10	  min	  to	  pellet	  the	  cell	  debris.	  	  
The	   binding	   column	   was	   prepared	   while	   the	   cell	   debris	   was	   pelleted;	   500	   μL	  
column	  preparation	  solution	  was	  added	  to	  the	  column	  in	  a	  collection	  tube	  and	  was	  
centrifuged	   for	   1	   min	   with	   the	   flow	   through	   discarded.	   The	   clear	   lysate	   was	  
transferred	   to	   the	   column	   and	   centrifuged	   for	   1	   min	   with	   the	   flow	   through	  
discarded.	  The	  column	  was	  centrifuged	  again	  for	  another	  1	  min	  to	  dry	  the	  column.	  
The	  column	  was	  transferred	  to	  a	  fresh	  collection	  tube	  and	  50	  μL	  ddH2O	  (at	  60°C)	  was	  
added	  directly	   to	   the	  membrane	   for	  30	  min.	   Finally	   after	  30	  min,	   the	  plasmid	  was	  
eluted	  by	  centrifuging	  for	  1	  min.	  dsDNA	  concentration	  was	  checked	  after	  this.	  
	  
2.1.11.	  Double	  Digest	  
	  
Double	  digests	  are	  often	  performed	  to	  check	  whether	  the	  insert	  has	  annealed	  to	  
the	  vector	  or	  not.	  The	  vector	  codes	  specific	  sites	  for	  cleavage	  by	  a	  specific	  enzyme.	  
As	   long	  as	  the	  gene	  of	   interest	  does	  not	  code	  for	  the	  same	  cleavage	  site,	   it	  can	  be	  
used	  for	  digestion.	  There	  are	  many	  resources	  available	  to	  check	  for	  these	  sites,	  such	  
as	  Serial	  Cloner	  by	  SerialBasics.	   If	   the	  double	  digest	   is	  successful,	   it	  can	  be	  sent	  for	  
sequencing	  for	  sequence	  analysis.	  
	  
After	  plasmid	  extraction	  7	  μL	  plasmid	  was	  required	  for	  the	  double	  digest.	  1	  μL	  5’	  
restriction	  digest	  enzyme	  (i.e.	  Nco	  1),	  1	  μL	  3’	   restriction	  digest	  enzyme	  (i.e.	  Nde	  1)	  
and	   1	   μL	   suitable	   buffer	   (i.e.	   Buffer	   4)	   was	   added	   to	   the	   plasmid.	   The	   reaction	  
mixture	  was	  then	  incubated	  for	  1-­‐3	  h	  (no	  longer	  than	  3	  h)	  at	  37°C.	  The	  samples	  were	  
prepared	  for	  DNA	  fragment	  analysis	  as	  mentioned	  in	  section	  2.1.3.	  then	  checked	  on	  
a	  1%	  agarose	  gel	  as	  mentioned	  in	  section	  2.1.2.	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2.2.	  Site-­‐Directed	  Mutagenesis	  (SDM)	  
	  
	   SDM	  is	  a	  commonly	  used	  technique,	  for	  example,	  to	  perform	  a	  substitution	  of	  an	  
amino	   acid	   in	   the	   active	   site.	   As	   well	   as	   eliminating	   activity,	   SDM	   can	   be	   used	   to	  
improve	   activity	   and	   or	   modify	   the	   size	   of	   the	   existing	   active	   site	   to	   specifically	  
accommodate	  a	  desired	  substrate.	   	  SDM	  also	  uses	  PCR,	  however	  it	  differs	   in	  that	  it	  
does	  not	  only	  amplify	  the	  gene	  or	  site	  of	  interest.	  SDM	  uses	  very	  specific	  primers	  to	  
amplify	  the	  whole	  plasmid.	  Therefore,	  the	  original	  plasmid	  is	  the	  template.	  
	   The	   mutant	   primers	   were	   designed	   using	   the	   Primer	   X	  
(http://www.bioinformatics.org/primerx/index.htm).	   Protein-­‐based	   primer	   design	  
with	  default	  options	  was	  selected	  for	  the	  mutation	  performed	  and	  mentioned	  in	  the	  
latter	  results.	  
	  
2.2.1.	  Mutagenesis-­‐PCR	   	  
	  
For	  mutagenesis-­‐PCR,	  the	  following	  reaction	  components	  were	  used:	  
Component	   Reaction	  
Template	  (50-­‐100	  ng/μL)	   1	  μL	  
For	  Primer	  (20	  pmol/μL)	   0.5	  μL	  
Rev	  Primer	  (20	  pmol/μL)	   0.5	  μL	  
dNTPs	  (2	  mM)	   5	  μL	  
Pfu	  Polymerase	  Buffer	  (10x)	   5	  μL	  
DMSO	   1	  μL	  
Pfu	  DNA	  Polymerase	   1	  μL	  
ddH2O	   36	  μL	  
	  
The	  reaction	  was	  performed	  in	  a	  PCR	  thermal	  cycler	  using	  the	  following	  steps/cycles:	  
Temperature	   Time	   Step	   Cycles	  
95°C	   5	  min	   Initial	  denature	   1	  
95°C	   1	  min	   Denature	  
30	  50°C	   1	  min	   Anneal	  
72°C	   10	  min	   Extend	  
95°C	   72	  s	  	   Final	  denature	   1	  
72°C	   5	  min	   Final	  extension	   1	  
4°C	   	  ∞	   Cool	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The	   reaction	   components	   and	   reaction	   parameters	   were	   modified	   based	   on	   the	  
protocol	  for	  Pfu	  DNA	  polymerase.	   	  
	  
2.2.2.	  Fragment	  Analysis	  by	  Agarose	  Gel	  Electrophoresis	  	  
	  
	   Agarose	  gels	  can	  be	  used	  to	  analyse	  the	  mutagenesis-­‐PCR	  products.	  It	  can	  be	  an	  
indication	  to	  whether	  the	  primers	  or	  PCR	  conditions	  were	  suitable.	  
10	  μL	  of	  the	  mutagenesis-­‐PCR	  products	  were	  taken	  for	  agarose	  gel	  analysis.	  The	  
gel	   was	   prepared	   as	   in	   (Section	   2.1.2.)	   and	   the	   samples	   prepared	   as	   in	   (Section	  
2.1.3.).	  
	  
2.2.3.	  Dpn1	  Digest	  
	  
After	   the	   mutagenesis-­‐PCR	   is	   complete,	   there	   is	   still	   a	   mixture	   of	   template	  
plasmid	   along	  with	   the	  mutant	   plasmid.	   DNA	   produced	   from	  E.	   coli	   (the	   template	  
plasmid)	   is	  methylated	  on	   the	  N6	  position	  of	   adenine	   (m6A)	  by	   enzymes	   in	  E.	   coli	  
such	  as	  methyltransferases.	  However	   the	  mutant	  plasmid	  produced	   in	   the	  PCR	  will	  
not	  be	  methylated,	  as	  the	  DNA	  polymerase	  used	  will	  not	  methylate	  DNA.	  Therefore	  
restriction	   digest	   enzymes	   such	   as	   Dpn1	   can	   be	   used	   to	   digest	   the	   methylated	  
template	   plasmid.	   The	   DNA	   recognition	   site	   for	   Dpn1	   is	   Gm6A-­‐TC,	   where	   Dpn1	  
cleaves	  between	  N6-­‐methyladenine	  and	  thymine.	  
	  
	   40-­‐50	  μL	  PCR	  product	  was	  taken	  for	  Dpn1	  digest.	  1.5	  μL	  Dpn1	  restriction	  enzyme	  
was	  added	  to	  the	  product	  and	  was	  incubated	  at	  37°C	  for	  up	  to	  6	  h.	  
	  
2.2.4.	  Transformation	  of	  Cloning	  Strains	  by	  Mutant	  Plasmids	  
	  
	   Typically	  4	  h	  is	  enough	  time	  for	  the	  Dpn1	  digest	  reaction	  to	  digest	  the	  template.	  
However	   it	   can	   be	   difficult	   to	   tell	   if	   the	   template	   plasmid	   has	   been	   sufficiently	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digested.	  Therefore,	  performing	   transformations	  at	  4	  hours	  and	  6	  hours	  will	  give	  a	  
better	  indication	  of	  sufficient	  template	  digestion.	  
	  
	   Kanamycin-­‐agar	  plates	  were	  prepared	  as	  in	  (Section	  2.1.7.).	  1.5	  μL	  digested	  PCR	  
product	   was	   taken	   to	   transform	   NovaBlue	   Single	   Cells,	   as	   in	   (Section	   2.1.8.),	   at	   4	  
hours	  and	  6	  h	  of	  the	  digest	  reaction.	  
	  
2.2.5.	  Starter	  Culture	  	  
	   Starter	  cultures	  of	  the	  mutant	  plasmid	  in	  NovaBlue	  Single	  Cells	  were	  made	  as	  in	  
(Section	  2.1.9.)	  from	  successfully	  grown	  colonies	  from	  (Section	  2.2.4.).	  
	  
2.2.6.	  Plasmid	  Extraction:	  Mini-­‐Prep	  	  
	   The	   plasmids	   from	   the	   starter	   cultures	  made	   in	   (Section	   2.2.5)	  were	   extracted	  
using	  a	  MiniPrep	  kit	  following	  the	  protocol	  in	  (Section	  2.1.1.10.).	  	  
The	   extracted	   mutant	   plasmid	   can	   now	   be	   made	   up	   to	   the	   appropriate	  
concentration	   for	   gene	   sequencing	   analysis	   and	   transformations	   in	   expression	  
strains.	  
	  
2.2.7.	  Double	  Digest	  
	  
	   A	   double	   digest	   can	   be	   optionally	   performed	   with	   the	   template	   plasmid	   as	   a	  
control	   and	   the	   mutant	   plasmid	   as	   in	   (Section	   2.1.11.)	   with	   fragment	   analysis	   by	  
agarose	  gel	  electrophoresis	  (Section	  2.1.2.)	  and	  sample	  preparation	  (Section	  2.1.3.).	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2.3.	  Gene	  Expression	  
	  
Expression	  of	  the	  gene	  of	  interest	  may	  often	  not	  be	  a	  simple	  matter;	  either	  low	  
yielding	   expression	   or	   majority	   of	   the	   expressed	   protein	   is	   insoluble.	   Proteins	  
overexpressed	  in	  E.	  coli	  are	  often	  insoluble	  and	  are	  contained	  in	  inclusion	  bodies;	  it	  
is	   possible	   to	   solubilise	   and	   re-­‐fold	   the	   protein,	   however	   this	   is	   often	   time	  
consuming.	  There	  are	  many	  other	  expression	  systems	  available,	  such	  as	  baculovirus	  
expression	   in	   insect	   cells	   for	   large	   protein	   complexes,	   Pichia	   pastoris	   and	   Bacillus	  
subtilis	   that	   allow	   for	   protein	   secretion	   into	   the	   media;	   these	   are	   only	   a	   few	  
examples	  of	  the	  many	  different	  options	  available,	  however	  each	  expression	  system	  
has	  its	  own	  advantages	  and	  disadvantages.	  	  
	  
2.3.1.	  Transformation	  of	  Expression	  Strains	  
	  
Transformations	   into	   expression	   strains	   such	   E.	   coli	   are	   similar	   to	   that	   of	  
transformation	   into	   cloning	   strains	   (Section	  2.1.8.),	   however	  expression	   strains	   are	  
optimised	  for	  expression.	  As	  such,	  the	  protocol	  differs	  slightly:	  
	  
1	  μL	  plasmid	  was	  added	  to	  25	  μL	  cells,	  such	  as	  BL21(DE3)	  or	  Rosetta	  2(DE3),	  and	  
was	  left	  on	  ice	  for	  20	  min.	  The	  mixture	  was	  heat	  shocked	  at	  42°C	  for	  45	  s.	  Following	  
the	  heat	  shock,	  the	  cells	  were	  left	  on	  ice	  for	  1	  min.	  1	  mL	  LB	  medium	  was	  added	  to	  
the	  mixture	  and	  left	  to	  incubate	  at	  37°C	  for	  1	  h	  in	  an	  orbital	  shaker.	  The	  cells	  were	  
pelleted	  by	  centrifuging	  at	  13.3k	  rpm	  for	  1	  min,	  800	  μL	  media	  was	  discarded	  and	  the	  
cells	  were	  resuspended	   in	   the	  remaining	  200	  μL	  media.	  100	  μL	  cells	  were	  taken	  to	  
spread,	   using	   aseptic	   technique,	   on	   each	   appropriate	   antibiotic-­‐LB-­‐agar	   plates	   and	  
was	  left	  to	  incubate	  in	  a	  37°C	  oven	  overnight.	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2.3.2.	  Buffer	  Components	  
	  
Buffers	   can	   dramatically	   change	   the	   activity	   and	   stability	   of	   proteins.	   Certain	  
buffers	  are	  known	  to	  change	  pKa	  on	   increasing	  or	  decreasing	   temperature	  and	  are	  
also	  known	  to	  inhibit	  certain	  enzymes	  activity	  and	  are	  seen	  in	  the	  crystal	  structure	  of	  
an	   enzymes	   active	   site.	   With	   very	   sensitive	   and	   unstable	   proteins,	   it	   may	   be	  
necessary	   to	   screen	   a	   range	   of	   buffers	   and	   optimise	   conditions	   prior	   to	   protein	  
purification.	  
	  
Tris	   buffers	  were	   used	   for	   all	   enzymes	   purified	   as	   it	   has	   a	   very	   large	   effective	  
buffering	   range	   between	   pH	   7.1	   and	   9.0.	   Glycerol	   is	   added	   to	   the	   buffers	   to	   help	  
stabilise	   sensitive	   proteins;	   glycerol	   is	   generally	   thought	   of	   to	   mimic	   the	   natural	  
viscous	  environment	  inside	  a	  cell.	  	  
Buffer	   A	   was	   used	   as	   the	   resuspension	   buffer;	   20	   mM	   imidazole	   was	  
incorporated	   to	   decrease	   non-­‐specific	   binding	   to	   IMAC	   columns	  when	   loading	   the	  
cell	  lysate.	  A	  gradient	  between	  buffer	  B	  and	  C	  was	  used	  to	  elute	  the	  protein	  bound	  
to	  the	  IMAC	  column.	  The	  following	  components	  were	  used	  for	  all	  buffers:	  
	   Buffers	  
Component	   A	   B	   C	  
NaCl	   500	  mM	   500	  mM	   500	  mM	  
Tris-­‐HCl	  pH	  8.0	   50	  mM	   50	  mM	   50	  mM	  
Imidazole	   20	  mM	   0	  mM	   500	  mM	  
Glycerol	   10%	  v/v	   10%	  v/v	   10%	  v/v	  
	  
1	  mM	  calcium	  chloride	  was	  added	  to	  all	  buffers	   for	  RasADH,	  as	   in	  Kulig’s	  study	  
(27),	  calcium	  chloride	  was	  seen	  to	  stabilise	  and	  increase	  activity	  for	  RasADH.	  
	  
2.3.3.	   Protein	   Analysis	   by	   Sodium	   Dodecylsulfate	   Polyacrylamide	   Gel	  
Electrophoresis	  
	  
Proteins	   are	   routinely	   denatured	   by	   Sodium	   dodecylsulfate	   (SDS)	   and	   are	  
analysed	  by	  SDS-­‐Polyacrylamide	  Gel	  Electrophoresis	  (SDS-­‐PAGE);	  which	  proteins	  are	  
separated	  on	  the	  basis	  of	  charge.	  SDS	  binds	  to	  the	  protein	  backbone	  unfolding	  and	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therefore	   denaturing	   the	   protein	   and	   in	   high	   concentrations	   micelles	   would	   be	  
formed	  around	  the	  protein	  backbone.	  When	  SDS	   is	  bound	  to	  the	  protein,	   it	  causes	  
the	  overall	  charge	  of	  the	  protein	  to	  be	  negative;	  this	  allows	  the	  denatured	  protein	  to	  
migrate	   by	   electrophoresis.	   The	   principle	   is	   similar	   to	   DNA	   fragment	   analysis	   by	  
agarose	  gel,	  however	  protein	  is	  too	  small	  be	  analysed	  by	  agarose	  due	  to	  larger	  pore	  
sizes	   in	   agarose.	   SDS-­‐PAGE	   is	   an	   easy	   method	   to	   analyse	   protein	   purity	   from	  
fractions	  obtained	  from	  purification.	  
	  
The	  mixture	  for	  a	  12%	  SDS-­‐PAGE	  gel	  is	  shown	  in	  the	  following	  table:	  
12%	  Polyacrylamide	  Gel	  
Resolving	  Gel	  Mixture	   Stacking	  Gel	  Mixture	  
2.5	  mL	  Resolving	  gel	  buffer	   1.3	  mL	  Stacking	  gel	  buffer	  
4.2	  mL	  Acrylamide	  Stock	   0.5	  mL	  Acrylamide	  stock	  
3.2	  mL	  ddH2O	   3.2	  mL	  ddH2O	  
16	  uL	  TEMED	   8	  uL	  TEMED	  
100	  uL	  10%	  APS	   100	  uL	  10%	  APS	  
	  
	   Initially	  a	  sandwich	  of	  glass	  plates	  with	  plastic	  gel	  spacers	  and	  aluminum	  backing	  
was	  made	   and	  mounted	   vertically	   into	   the	   gel	   stand.	   It	   was	   checked	   for	   leaks	   by	  
filling	  the	  assembly	  with	  ethanol	  between	  the	  glass	  plates.	  Once	  it	  was	  satisfied	  that	  
there	  were	  no	  leaks,	  ethanol	  was	  removed	  and	  the	  assembly	  was	  dried	  with	  nitrogen	  
air	  source.	  The	  resolving	  gel	  mix	  was	  poured	  between	  the	  glass	  plates	  approximately	  
two-­‐thirds	  full,	  the	  top	  was	  evened	  out	  with	  butanol	  and	  the	  gel	  was	  left	  to	  set	  for	  10	  
min.	  Once	  set,	   the	  butanol	  was	   removed	  and	  dried	  with	  a	  nitrogen	  air	   source,	   the	  
remainder	  of	  the	  glass	  plates	  was	  filled	  with	  stacking	  gel	  mix	  and	  the	  plastic	  gel	  comb	  
(10	  or	  15	  well)	  was	  immediately	  inserted.	  The	  stacking	  gel	  was	  left	  to	  set	  for	  10	  min.	  
The	  solidified	  gel	  was	  removed	  from	  the	  caster	  and	  placed	  into	  a	  gel	  tank	  where	  SDS	  
running	  buffer	  was	   filled	   to	   submerge	   the	  gel.	   The	  plastic	   comb	  was	   removed	  and	  
samples	  were	  loaded	  into	  the	  wells	  formed	  by	  the	  comb.	  The	  power	  pack	  was	  set	  to	  
200	  V	  and	  the	  gel	  was	  run	  for	  50	  min.	  
	   After	   the	   gel	   had	   finished	   running,	   the	   gel	   sandwich	   was	   removed	   from	   the	  
apparatus	   and	   the	   stacking	   gel	  was	   cut	   off	  with	   the	   spacer.	   The	   resolving	   gel	  was	  
placed	  in	  a	  plastic	  box,	  100	  mL	  Coommassie	  Brilliant	  Blue	  were	  added	  to	  the	  gel	  and	  
the	  dye	  was	  microwaved	  at	  maximum	  heat	  for	  2	  min	  to	  stain.	  The	  dye	  was	  removed	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and	  the	  gel	  was	  rinsed	  with	  cold	  water.	  100	  mL	  destain	  solution	  was	  added	  to	  the	  gel	  
and	  was	  microwaved	  for	  2	  min.	  Tissue	  was	  placed	  on	  top	  of	  the	  gel	  to	  help	  absorb	  
the	  dye	  from	  the	  gel	  for	  1	  h	  before	  imaging.	  
	  
2.3.3.1	  Sample	  preparation	  for	  SDS-­‐PAGE	  analysis	  
	  
	   Prior	   to	   loading	   the	  samples	   into	   the	  wells	   in	   the	  gel,	  dye	  must	  be	  added	  to	   the	  
protein	  samples	   in	  order	  to	  be	  able	  to	   image	  the	  protein	  and	  the	  samples	  must	  be	  
denatured	  for	  SDS-­‐PAGE	  analysis.	  
	  
	   10	  μL	  of	  2x	  SDS	  loading	  buffer	  with	  dye	  was	  added	  to	  each	  10	  μL	  protein	  sample	  in	  
PCR	   tubes.	   Samples	   were	   boiled	   for	   5	   min	   at	   94°C	   using	   a	   PCR	   thermal	   cycler,	  
including	  a	  10	  μL	  solution	  of	  low	  molecular	  weight	  ladder	  from	  Bio-­‐Rad.	  The	  samples	  
should	  be	  centrifuged	  at	  13.3k	   rpm	   for	  30	   seconds	   to	   collect	   the	  entire	  denatured	  
sample.	  The	   ladder	  was	  added	   to	   the	   first	  well	  on	   the	   left	  of	   the	  gel	  using	  a	  HPLC	  
syringe.	   The	   syringe	  was	  washed	   thoroughly	  with	   SDS	   running	  buffer	   and	  10	  μL	  of	  
the	  first	  protein	  sample	  was	  transferred	  to	  the	  well	  adjacent	  to	  the	  ladder.	  This	  was	  
repeated	  for	  the	  remaining	  protein	  samples.	  Finally	  the	  lid	  was	  placed	  on	  top	  of	  the	  
apparatus	  and	  the	  gel	  was	  ran	  for	  50	  min	  at	  200	  V.	  
	  
2.3.4.	  Optimising	  Gene	  Expression	  	  
	  
In	  cases	  where	  over	  expression	  yields	   low	  amounts	  of	  protein,	   it	   is	  common	  to	  
tests	   different	   expression	   strains	   at	   different	   temperatures.	   Once	   a	   satisfactory	  
strain	   and	  growth	   temperature	  has	  been	   found,	   it	  may	  be	   required	   to	  perform	  an	  
induction	  test	  to	  further	  optimise	  protein	  expression.	  It	  is	  often	  suggested	  to	  induce	  
the	   culture	   at	  OD600	   ≈	   0.6	  Abs,	   as	   it	   is	   said	   to	  be	   the	  mid-­‐log	  phase,	  which	   should	  
yield	  greatest	  expression;	  however	  this	  is	  not	  necessarily	  the	  case,	  in	  well-­‐controlled	  
conditions	  with	  plenty	  of	  aeration,	  such	  as	  using	  fermenters,	  inducing	  much	  later	  at	  
OD600	  ≈	  4.0	  Abs	  yields	  best	  results.	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2.3.4.1.	  Expression	  Test	  
	  
An	   expression	   test	   is	   a	   commonly	   performed	   experiment	   to	   optimise	   protein	  
expression	  in	  different	  strains	  and	  at	  different	  temperatures.	  It	  should	  be	  performed	  
before	  a	  scale	  up	  above	  10	  mL	  is	  attempted,	  such	  that	  optimal	  results	  are	  obtained.	  
	  
Prior	   to	   this	   experiment,	   a	   5	  mL	   starter	   culture	  was	  made	   as	   described	   in	   section	  
2.1.9.	  
	  
With	  aseptic	  technique:	  four	  50	  mL	  Falcon	  tubes	  with	  5	  mL	  autoclaved	  LB	  media	  
with	   antibiotics	   (in	   1	   in	   1000	   fold	   dilution)	   were	   prepared.	   Each	   Falcon	   tube	   was	  
inoculated	   with	   50	   μL	   starter	   culture	   (1	   in	   100	   fold	   dilution	   of	   the	   volume)	   and	  
incubated	  at	  37°C	  until	  OD600	  ≈	  0.6.	  Once	  a	  satisfactory	  optical	  density	  is	  achieved	  the	  
control	  was	  not	  induced	  and	  was	  incubated	  overnight	  at	  16°C.	  The	  remaining	  three	  
Falcon	   tubes	   were	   induced	  with	   1	  mM	   final	   concentration	   IPTG	   and	   incubated	   at	  
16°C,	  30°C	  and	  37°C	  overnight.	  
On	  the	  following	  day	  each	  sample	  was	  pelleted	  by	  centrifugation	  at	  13.3k	  rpm	  for	  
1	  min	  into	  separate	  2	  mL	  Eppendorf	  tubes.	  Each	  pellet	  was	  resuspended	  by	  vortexing	  
with	  500	  μL	  buffer	  A	  and	  was	  lysed	  by	  sonication	  whilst	  on	  ice	  throughout	  lysis.	  The	  
cell	   debris	   was	   then	   pelleted	   by	   centrifugation	   at	   13.3k	   rpm	   for	   5	   min	   and	   each	  
clarified	   lysate	   (soluble	   fraction)	   is	   transferred	   to	  a	  new	  2	  mL	  Eppendorf	   tube.	  The	  
remaining	  cell	  debris	  was	  resuspended	  by	  vortexing	  with	  500	  μL	  buffer	  A.	  10	  μL	  of	  
each	  fraction	  at	  each	  temperature	  was	  prepared	  and	  analysed	  by	  SDS-­‐PAGE	  analysis	  
as	  described	  in	  section	  2.2.3.	  and	  2.2.3.1.	  
	  
2.3.4.2.	  Induction	  Test	  
	  
After	  a	  suitable	  expression	  strain	  has	  been	  found	  and	  gene	  expression	  yields	  are	  
still	   not	   satisfactory,	   testing	   different	   points	   for	   induction	   can	   be	   performed	   to	  
further	  optimise	  gene	  expression	  without	  reengineering	  the	  gene.	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Prior	   to	   this	   experiment,	   one	  5	  mL	   starter	   culture	  of	   the	  desired	  expression	   strain	  
was	  made	  as	  described	  in	  section	  2.1.1.9.	  
	  
With	   aseptic	   technique:	   twelve	   50	   mL	   Falcon	   tubes	   with	   5	   mL	   autoclaved	   LB	  
media	  with	  antibiotics	   (in	  1	   in	  1000	  fold	  dilution)	  were	  prepared.	  Each	  Falcon	  tube	  
was	  inoculated	  with	  50	  μL	  starter	  culture	  (1	  in	  100	  fold	  dilution	  of	  the	  volume)	  and	  
incubated	  at	  37°C.	  Each	  culture	  was	  induced	  with	  1	  mM	  final	  concentration	  IPTG	  at	  
the	  following	  OD600:	  Negative	  control	  (no	  induction),	  positive	  control	  (induction	  upon	  
inoculation),	  0.2,	  0.4,	  0.6,	  0.8,	  1.0,	  1.2,	  1.4,	  1.6,	  1.8	  and	  2.0.	  Testing	  beyond	  OD600	  =	  
2.0	  may	  be	  detrimental	  to	  the	  growth	  and	  expression	  of	  cells	  in	  a	  culture	  flask.	  After	  
induction,	  the	  culture	  samples	  were	  incubated	  overnight	  in	  an	  orbital	  shaker	  at	  the	  
optimal	  temperature	  found	  in	  the	  expression	  test	  as	  mentioned	  in	  section	  2.2.4.1.	  
On	  the	  following	  day	  each	  sample	  was	  pelleted	  by	  centrifugation	  at	  13.3k	  rpm	  for	  
1	  min	  into	  separate	  2	  mL	  Eppendorf	  tubes.	  Each	  pellet	  was	  resuspended	  with	  a	  lysis	  
solution,	   i.e.	   BugBuster	   Protein	   Extraction	   Reagent,	   and	   the	   cell	   debris	   is	   then	  
pelleted	   by	   centrifugation	   at	   13.3k	   rpm	   for	   5	   min.	   10	   μL	   of	   each	   sample	   was	  
prepared	   and	   analysed	   by	   SDS-­‐PAGE	   analysis	   as	   described	   in	   section	   2.2.3.	   and	  
2.2.3.1.	  
	  
2.3.5.	  Scaling	  Up	  Protein	  Production	  
	  
Once	   optimised	   expression	   protocols	   have	   been	   established,	   experiments	   that	  
require	   larger	   quantities	   of	   protein	   can	   be	   performed	   by	   scaling	   up	   the	   culture	  
volume.	  However	  behaviour	  in	  a	  5	  mL	  culture	  can	  be	  quite	  different	  to	  a	  1	  L	  culture.	  	  
	  
For	  1	  L	  of	  LB	  media,	  25	  g	  LB	  media	  were	  added	  to	  1	  L	  ddH2O	  in	  a	  2	  L	  Erlenmeyer	  
flask.	  The	  flasks	  were	  stopped	  with	  foam	  bungs	  and	  covered	  with	  foil.	  
The	  flasks	  were	  then	  autoclaved	  and	  the	  flasks	  should	  be	  sufficiently	  cooled	  prior	  
to	  use	  with	  bacterial	  growth.	  For	  each	  flask	  of	  LB,	  starter	  cultures	  with	  1	  in	  100	  fold	  
dilution	  of	  the	  LB	  volume	  were	  made	  as	  described	  in	  section	  2.1.1.9.	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Antibiotics	   (at	   a	   1	   in	   1000	   fold	   dilution)	   were	   added	   to	   the	   flasks	   and	   were	  
inoculated	   with	   the	   starter	   cultures	   using	   aseptic	   technique.	   The	   flasks	   were	   the	  
incubated	  at	  37°C	  until	  a	  satisfactory	  OD600	  is	  achieved	  and	  induced	  with	  1	  mM	  final	  
concentration	   IPTG.	   The	   culture	   is	   then	   incubated	   at	   the	   optimal	   temperature	   as	  
investigated	  in	  section	  2.2.4.1.	  
	  
2.3.6.	  Cell	  Lysis	  
	  
There	  are	  many	  methods	  available	   for	   lysing	  cells;	  such	  as	  sonication	  or	  French	  
pressure	   cell	   press,	   which	   are	   mechanical	   lysis,	   whereas	   BugBuster	   Protein	  
Extraction	  Reagent	  and	  buffers	  with	   lysozyme	  and	  DNAse	  are	  chemical	  methods	  of	  
lysing.	  The	  method	  of	  lysis	  may	  be	  chosen	  based	  on	  the	  vector,	  as	  if	  the	  protein	  has	  
the	  PelB	  promoter	  it	  may	  only	  be	  necessary	  to	  lyse	  the	  cells	  with	  chemical	  methods	  
if	   the	   protein	   is	   secreted	   in	   between	   the	   cell	   membrane.	   However	   if	   protein	  
expression	   is	   within	   the	   cell	   cytoplasm	   a	   mechanical	   method	   may	   be	   required.	  
Certain	  organisms	  chosen	   for	  expression	  may	  not	   require	  cell	   lysis	   if	   the	  protein	   is	  
secreted	  into	  the	  media.	  	  
	  
Prior	   to	   lysing,	   cells	   are	   pelleted	   (i.e.	   8k	   rpm	   for	   15	  min	  on	   a	   JLA-­‐8.1000	   rotor)	   to	  




Each	   cell	   pellet	   formed	   from	   1	   L	   culture	   was	   resuspended	   in	   30	  mL	   buffer	   A.	  
Resuspended	  cells	  were	  sonicated	  using	  a	  suitable	  probe,	  between	  12-­‐14	  amplitude	  





Time	   Step	   Cycles	  
45	  secs	   Sonicate	  
10	  Cycles	  30	  secs	   Rest	  on	  Ice	  
1	  min	   Sonicate	   Once	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Following	  sonication,	  cell	  debris	  was	  pelleted	  with	  high-­‐speed	  centrifugation	  (i.e.	  20k	  




Each	  cell	  pellet	  formed	  from	  1	  L	  culture	  was	  resuspended	  in	  30	  mL	  buffer	  A	  with	  
the	   addition	   of	   15	   mg	   Lysozyme	   and	   1.5	   mg	   DNAse	   (per	   30	   mL	   of	   buffer).	   Cell	  
suspension	   was	   incubated	   in	   an	   icebox	   in	   an	   orbital	   shaker	   –	   alternatively	   in	   an	  
orbital	   shaker	   at	   4°C.	   Following	   lysis,	   cell	   debris	   was	   pelleted	   at	   high-­‐speed	  
centrifugation	  (i.e.	  20k	  rpm	  for	  15	  min	  on	  a	  SS34	  rotor).	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2.4.	  Protein	  Purification	  
	  
Depending	  on	  the	  protein,	  purification	  can	  be	  very	  challenging.	  The	  protein	  could	  
be	   sensitive	   to	   high	   concentrations	   of	   elution	   buffer	   causing	   protein	   aggregation.	  
High	   protein	   concentration	   could	   also	   cause	   protein	   aggregation.	   There	   are	  many	  
techniques	   available	   for	   protein	   purification,	   however	   due	   to	   the	   development	   of	  
fusing	   hexa	   histidine-­‐tags	   (His-­‐tags)	   to	   the	   protein	   on	   the	  DNA	   level	   (54),	   this	   has	  
greatly	   simplified	   the	   technique.	   As	   well	   as	   His-­‐tags	   there	   are	   many	   other	   tags	  
available,	   which	   can	   be	   fused	   to	   the	   protein	   on	   either	   N-­‐terminus	   or	   C-­‐terminus.	  
These	   tags	   have	   greatly	   eased	   and	   simplified	   purification,	   however	   achieving	  
satisfactory	  purification	  may	  still	  be	  a	  problem	  and	  other	  purification	  methods	  and	  
strategies	  may	  be	  required.	  The	  method	  for	  purifying	  tagged	  proteins	  are	  known	  as	  
affinity	   chromatography;	   as	   the	   tagged-­‐protein	   binds	   highly	   specifically	   to	   an	  
immobilised	  matrix	   and	   are	   eluted	  by	   an	   increasing	   concentration	  of	   a	   buffer	   that	  
will	  out	  compete	  the	  binding	  of	  the	  protein.	  
	  
2.4.1.	  Stripping	  and	  Recharging	  an	  IMAC	  Column	  
	  
Prior	   to	   reusing	   a	   column,	   it	   should	   be	   stripped	   and	   recharged	   to	   ensure	   any	  
impurities	   bound	   to	   the	   charged	   resin	   media	   will	   be	   removed.	   Columns	   such	   as	  
HisTrap	  Crude	  FF,	  HisTrap	  HP,	  HisTrap	  FF,	  HisTrap	  excel,	  HiTrap	  Chelating	  HP,	  HiTrap	  
IMAC	  HP	  or	  HiTrap	  IMAC	  Sepharose	  FF	  columns	  can	  be	  used	  for	  immobilised	  metal	  
affinity	  chromatography	  (IMAC).	  
	  
The	   columns	   are	   sequentially	  washed	  with	   5	   column	   volumes	   (CVs)	   of:	   ddH2O,	  
0.1	  M	  EDTA	  with	  0.5	  M	  NaCl,	  H2O,	  0.1	  M	  NiSO4	  or	  0.1	  M	  CoSO4	  and	  buffer	  A	  (or	  20%	  
ethanol	  for	  storage).	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2.4.2.	  Loading	  and	  Recycling	  Protein	  
	  
Protein	   lysate	   can	   be	   loaded	   onto	   a	   column	  using	   different	  methods,	   however	  
loading	   the	   lysate	   onto	   the	   column	   only	   once	   may	   not	   maximise	   the	   binding	  
efficiency.	   Therefore	   recirculating/recycling	   the	   lysate	   should	   maximise	   protein	  
binding	  to	  the	  column.	  Clarified	  lysate	  can	  be	  loaded	  onto	  a	  column	  with	  a	  peristaltic	  
pump,	   Superloop,	   injecting	   using	   a	   loop,	   using	   an	   AKTA	   sample	   valve	   or	   with	   a	  
combination	  of	  available	  methods.	  
	  
Clarified	  cell	  lysate	  was	  cooled	  throughout	  on	  ice	  and	  was	  loaded	  onto	  a	  column	  
(i.e.	   5	   mL	   HisTrap	   Crude	   FF)	   using	   a	   peristaltic	   pump	   at	   5	   mL/min.	   To	   maximise	  
binding	   of	   protein;	   the	   lysate	  was	   allowed	   to	   recirculate	   back	   into	   the	   lysate	   and	  
recycle	  onto	  the	  column	  (Figure	  24	  -­‐	  left),	  for	  every	  60	  mL	  of	  lysate	  would	  equate	  to	  
45	  min	  recirculation.	  
	  
	   	   	  
Figure	  24	  -­‐	  Schematic	  of	   recirculating	  protein	  onto	  a	  column	  (left)	  and	  schematic	  of	   ‘daisy-­‐chaining’	  columns	  
with	  recirculation	  (right).	  
If	  more	  of	  than	  3	  L	  of	  culture	  were	  grown,	  it	  is	  possible	  that	  the	  binding	  capacity	  
of	  the	  column	  is	  exceeded,	  ~	  40	  mg	  of	  protein	  per	  ml	  of	  medium	  (i.e.	  ~	  200	  mg	  for	  a	  
5	  mL	  column).	  Therefore	   it	  may	  be	  applicable	   to	   ‘daisy-­‐chain’	   columns	  and	   recycle	  
onto	  two	  columns	  as	  in	  the	  schematic	  (Figure	  24	  -­‐	  right).	  After	  loading,	  the	  columns	  
are	  purified	  separately	  on	  an	  AKTA,	  not	  to	   increase	  the	  void-­‐volume	  of	  the	  column	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the	   potential	   protein	   yield,	   it	   also	   allows	   for	   fewer	   impurities	   to	   bind	   to	   a	   single	  
column,	  therefore	  protein	  purity	  is	  significantly	  increased	  (Figure	  25).	  	  
	  
	  
Figure	  25	  -­‐	  12%	  SDS-­‐PAGE	  analysis	  of	  different	  purification	  strategies	  of	  nickel	  purification,	  both	  from	  180	  mL	  
lysate	  of	  the	  same	  construct:	  Single	  column	  recycling	  and	  purification	  (top)	  and	  'Daisy-­‐chaining'	  two	  columns	  
recycling	  and	  purification	  (bottom)	  
After	  recycling,	  the	  protein	  may	  be	  loaded	  onto	  the	  column	  again	  via	  the	  sample	  
valve/pump	  on	  the	  AKTA	  Explorer	  to	  further	  maximise	  any	  potential	  binding.	  This	  is	  
effectively	  the	  same	  as	  a	  Superloop,	  however	  the	  flow	  rate	  for	  protein	  binding	  to	  the	  
column	  is	  controlled	  by	  the	  AKTA	  better	  than	  a	  Superloop,	  preventing	  any	  pressure	  
issues.	  
	  
2.4.3.	  Cobalt/Nickel	  Purification	  
	  
By	  out-­‐competing	  the	  protein	  and	  impurities	  bound	  to	  the	  charged	  resin	  matrix	  
with	   a	   suitable	   buffer,	   it	   is	   possible	   to	   purify	   the	   protein.	   Therefore	   the	   standard	  
method	   for	   IMAC	   purification,	   are	  wash	   steps,	   followed	   by	   a	   gradient	   and	   then	   a	  
final	  wash	  step.	  
Buffers	  B	  (0	  mM	  imidazole)	  and	  C	  (500	  mM	  imidazole)	  are	  used	  to	  purify	  metal	  
affinity	  columns	  (Figure	  26).	  Typically,	  the	  first	  two	  wash	  steps	  are	  collected	  in	  5	  CV	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fractions	  in	  Falcon	  tubes	  and	  the	  rest	  is	  collected	  in	  96	  well	  plates.	  The	  fraction	  size	  
for	  the	  elution	  depends	  on	  the	  desired	  resolution	  and	  flow	  rate.	  	  
	  	  	   	  
Figure	   26	   –	   Schematic	   for	   IMAC	   purification	   strategy	   that	   was	   used	   on	   AKTA’s.	   Two	   initial	   washes	   are	  
performed	  by	  a	  step	  gradient	  to	  wash	  away	  any	  impurities,	  while	  the	  gradient	  purifies	  protein.	  
	  
2.4.4.	  Size	  Exclusion	  Chromatography	  (SEC)	  
	  
Size	   exclusion	   chromatography	   or	   gel	   filtration	   is	   based	   on	   separation	   of	   size.	  
This	   is	   a	  native	   technique,	   therefore	   if	   available,	   a	  multiangle	   laser	   light	   scattering	  
(MALLS)	   module	   can	   be	   added	   to	   an	   AKTA	   to	   gain	   more	   information	   about	   the	  
protein	   in	   solution	   whilst	   eluting,	   such	   as	  molecular	  mass.	   This	   can	   be	   useful	   if	   a	  
calibration	   curve	   is	   known	   for	   a	   SEC	   column	  and	   the	  protein	   is	   eluting	   in	   a	   region	  
heavier	  than	  it	  should	  be.	  This	  is	  quite	  common	  if	  the	  protein	  exists	  as	  an	  oligomer	  in	  
solution	   (ADHs	  are	  commonly	  known	  to	  be	  dimers	  and	  tetramers).	  Even	  after	  SDS-­‐
PAGE	   analysis,	   it	   is	   possible	   to	   still	   see	   bands	   double	   the	  molecular	  weight	   of	   the	  
monomer	   as	   the	   dimerisation	   or	   oligomerisation	   interaction	   may	   be	   very	   strong.	  
Occasionally	  monomers	   can	  be	   separated	   from	   the	  oligomers	  during	   SEC	  and	   they	  
can	  appear	  in	  very	  low	  concentrations,	  however,	  the	  monomer	  may	  not	  be	  a	  stable	  
form	  and	  may	  oligomerise	  or	  form	  aggregates.	  
	  
Prior	  to	  use,	  the	  SEC	  column	  must	  be	  equilibrated	  the	  night	  before.	  SEC	  columns	  
are	  stored	  in	  20%	  ethanol	  after	  use,	  therefore	  1	  CV	  wash	  of	  water,	  followed	  by	  1	  CV	  
buffer	  A	  was	  required	  to	  equilibrate	  the	  column	  (Figure	  27).	  To	  store	  the	  column	  in	  



















5	  CV	  wash	  @	  4%	  buffer	  C	  
5	  CV	  wash	  @	  10%	  buffer	  C	  
20	  CV	  gradient	  to	  60%	  buffer	  C	  
2	  CV	  wash	  @	  60%	  buffer	  C	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than	  1	  CV	  water.	  HiLoad	  16/60	  Superdex	  75	  PrepGrade	  column	  was	  used	  for	  SEC	  for	  
all	  proteins	  purified.	  
	  
Figure	   27	   –	   Schematic	   of	   a	   generic	   equilibration	   of	   SEC	   columns.	   Typically	   1	   column	   volume	   of	   water	   is	  
required,	  followed	  by	  1	  column	  volume	  of	  a	  buffer	  with	  0	  mM	  imidazole.	  
	  
The	   maximum	   load	   capacity	   for	   the	   HiLoad	   16/60	   Superdex	   75	   PrepGrade	  
column	  is	  ideally	  ≤	  2	  mL;	  loading	  is	  typically	  performed	  via	  injecting	  protein	  into	  a	  2	  
mL	   loop.	   The	   purification	   was	   performed	   by	   eluting	   with	   1	   CV	   of	   buffer	   A	   at	   0.8	  
mL/min	  flow	  rate,	  however	  if	  the	  column	  or	  AKTA	  presents	  pressure	  issues,	  the	  flow	  
rate	  can	  be	  reduced.	  The	  first	  20	  mL	  were	  collected	  in	  a	  Falcon	  tube,	  anything	  that	  
elutes	  at	  this	  region	  are	  usually	  aggregates	  or	  species	  larger	  than	  75	  kDa	  which	  was	  
exceeding	  the	  column’s	  limits	  of	  75	  kDa.	  After	  20	  mL,	  fraction	  sizes	  are	  chosen	  based	  
on	  flow	  rate	  and	  desired	  resolution,	  typically	  1-­‐2	  mL	  fraction	  sizes	  are	  used.	  
	  
2.4.5.	  HisTag	  Removal	  Purification	  
	  
The	   pET-­‐YSBLIC3C	   vector	   has	   a	   cleavable	   his-­‐tag	   that	   can	   be	   digested	   by	   3C	  





The	   sequence	   in	  bold	  and	  underlined	   is	   the	   site	   that	   the	  3C	  Protease	   (a	   serine	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be	  performed	  after	  SEC	  or	  after	  the	  initial	  IMAC,	  however	  if	   it	  was	  performed	  after	  
the	  initial	  IMAC,	  the	  samples	  imidazole	  should	  be	  dialysed	  out	  with	  the	  protease	  and	  
a	  0	  mM	  imidazole	  buffer	  or	  buffer	  exchanged	  into	  a	  0	  mM	  imidazole	  buffer	  prior	  to	  
the	  digest.	  The	  digest	  should	  be	  carried	  out	  at	  4°C	  overnight	  with	  minimal	  shaking.	  
The	  purification	  uses	  buffer	  B	  and	  buffer	  C	  again	   (Figure	   28).	  An	   IMAC	  column	  
was	  equilibrated	  with	  5	  CV	  buffer	  B,	  the	  digested	  protein	  sample	  was	  concentrated	  
to	   ~	   2	  ml	   and	  was	   injected	   via	   a	   loop	   onto	   an	   IMAC	   column.	   1	  ml	   fractions	  were	  
collected	   from	   the	   start	   for	   10	   CV,	   and	   then	   larger	   fraction	   sizes	   (~	   2-­‐4	  mL)	  were	  
collected	  on	  the	  gradient.	  
	   	  
Figure	  28	  -­‐	  Strategy	  for	  purifying	  proteins	  after	  cleaving	  the	  his-­‐tag	  
The	  protein	  of	  interest	  no	  longer	  has	  a	  his-­‐tag	  and	  should	  no	  longer	  bind	  to	  the	  
IMAC	   column,	   therefore	   it	   should	   quickly	   elute	   shortly	   after	   the	   void-­‐volume.	  
Fortunately	  the	  3C	  Protease	  is	  his-­‐tagged,	  thereby	  binding	  to	  the	  column	  and	  eluting	  
on	  the	  gradient.	  Another	  benefit	  of	  this	  is	  that,	  any	  impurities	  that	  still	  remain	  with	  
natural	  poly-­‐histidines	  will	  continue	  to	  bind	  to	  the	  column	  and	  elute	  on	  the	  gradient,	  
thus	   the	   protein	   of	   interest	   that	   has	   eluted	   within	   the	   first	   few	   fractions	   may	  
improve	  or	  retain	  its	  purity	  from	  the	  previous	  purification.	  
















10	  CV	  wash	  @	  0%	  buffer	  C	  
20	  CV	  gradient	  to	  100%	  buffer	  C	  
2	  CV	  wash	  @	  100%	  buffer	  C	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2.5.	  Protein	  Characterisation	  	  
	   There	  are	  many	  techniques	  and	  methods	  available	  for	  protein	  characterisation	  to	  
probe	   its	   biochemical	   or	   biophysical	   properties.	   However,	   ADHs	   are	   enzymes	  with	  
potential	   application	   for	   industrial	   biotechnology,	   it	   is	   important	   to	   investigate	  
enzyme	  kinetics	  and	  substrate	  specificity	  to	  determine	  their	  uses,	  as	  there	  are	  many	  
ADHs	  already	  commercially	  available.	  	  
	  
2.5.1.	  Enzyme	  Kinetics	  
	  
	   Enzymes	  such	  as	  ADHs	  can	  be	  characterised	  in	  solution	  by	  UV-­‐Vis	  spectrometry.	  
Methods	   for	   investigation	   by	   UV-­‐Vis	   have	   already	   been	   well	   established,	   such	   as	  
measuring	  the	  depletion	  or	  increase	  of	  absorbance	  for	  the	  nicotinamide	  cofactor	  at	  a	  
wavelength	   of	   340	   nm	   and	   both	   cofactors	   absorption	   extinction	   coefficient	   (ε)	   is	  
known;	  where	  ε	  =	  6220	  cm-­‐1mol-­‐1	  for	  NAD(P)H	  at	  340	  nm.	  Therefore,	  the	  parameters	  
can	  be	  applied	  to	  the	  Beer-­‐Lambert	  law,	  A	  =	  εcl	  (where	  A	  is	  the	  absorbance,	  c	  is	  the	  
concentration	  and	  l	   is	  the	  pathlength),	  to	  investigate	  the	  Michaelis-­‐Menten	  kinetics	  
(Figure	  29)	  parameters	  Km	  and	  Vmax	  for	  the	  enzymes	  and	  substrate	  of	  interest.	  	  
	  
Figure	  29	  –	  A	  schematic	  of	  a	  Michaelis-­‐Menten	  kinetics	  curve	  where	  Km	  is	  found	  at	  ½Vmax.	  
	   The	  Vmax	  for	  an	  enzyme	  and	  a	  novel	  substrate	  of	  interest	  is	  unknown.	  Typically	  a	  
wide	   range	   of	   substrate	   concentration	   is	   probed	   until	   saturation	   (Vmax)	   or	   when	  
substrate	   concentration	   is	   limited	   by	   solubility.	   The	   substrate	   concentrations	  
investigated	  at	  final	  concentration	  were:	  0	  mM	  (control),	  0.1	  mM,	  0.2	  mM,	  1	  mM,	  2	  
mM,	  4	  mM,	  8	  mM	  and	  10	  mM.	  Many	  substrates	  are	  only	  partially	  soluble	  in	  water,	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therefore	  at	  higher	  concentrations	  dissolution	  in	  water-­‐miscible	  solvent	  is	  required.	  
Ethanol	   is	   known	   to	   be	   a	   substrate	   for	  many	   ADHs,	   therefore	   it	  was	   not	   used	   for	  
dissolving	  substrates	  due	  to	  potential	  false	  readings.	  As	  such,	  DMSO	  was	  the	  solvent	  
of	  choice.	  
The	  total	  reaction	  volume	  was	  1	  mL	  and	  the	  kinetics	  buffer	  used	  was	  a	  solution	  
of	  50	  mM	  Tris	  at	  pH	  7.5	   (hereon	  the	  kinetics	  buffer).	  50	  μL	  of	  enzyme	  at	  1	  mg/mL	  
and	   1	   mM	   cofactor	   final	   concentration	   was	   used	   in	   each	   reaction.	   Even	   if	   the	  
substrate	  was	  dissolved	  in	  neat	  DMSO,	  it	  may	  not	  be	  enough	  to	  keep	  hydrophobic	  or	  
heavily	   aromatic	   substrates	   in	   solution	   for	   the	   reaction.	   Despite	   potential	   loss	   of	  
activity	   with	   the	   addition	   of	   solvents;	   DMSO	   was	   added	   from	   5%-­‐10%	   v.v.,	   to	  
attempt	  to	  keep	  the	  substrate	  in	  solution.	  	  
An	  absorbance-­‐time	  scan	  at	  340	  nm	  was	  performed	  to	  analyse	  the	  reaction.	  The	  
reference	  cell	  comprised	  1	  mL	  of	  kinetics	  buffer.	  The	  reaction	  cell	  with	  the	  kinetics	  
buffer	  was	  measured	  for	  30	  s,	  after	  which	  the	  substrate	  was	  pipetted	  and	  monitored	  
again	  for	  30	  s.	  Following	  the	  substrate,	  the	  cofactor	  was	  pipetted	  and	  monitored	  for	  
another	  30	  s,	   finally	  the	  enzyme	  was	  pipetted	   into	  the	  cell	  where	  the	  reaction	  was	  
then	   monitored	   for	   5	   min.	   This	   protocol	   was	   performed	   on	   all	   substrate	  
concentrations,	  where	  the	  reaction	  curve	  will	  be	  similar	  to	  the	  schematic	  (Figure	  30).	  
	  
Figure	  30	  –	  Schematic	  of	  kinetics	  by	  UV-­‐Vis	  analysis,	  where	  the	  depletion	  of	  the	  nicotinamide	  cofactor	  results	  
in	  the	  desired	  change	  in	  absorbance	  and	  change	  in	  time.	  	   Once	  each	  reaction	  has	  been	  performed,	  the	  depletion	  of	  cofactor	  will	  yield	  the	  
change	  in	  absorbance	  over	  a	  period	  of	  time.	  Through	  rearranging	  the	  Beer-­‐Lambert	  
law,	   the	   change	   in	   concentration	   and	   therefore	   the	   velocity	   can	   be	   found.	   The	  
velocity	  is	  then	  plotted	  against	  substrate	  concentration	  as	  in	  (Figure	  29)	  to	  find	  the	  
Vmax	  and	  Km	  for	  a	  particular	  substrate.	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2.5.2.	  Biotransformations	  
	  
	   Enzyme	  substrate	  specificity	  can	  be	  analysed	  by	  gas	  chromatography	  (GC)	  where	  
biotransformations	   are	   performed	  on	   a	  whole	   range	  of	   substrates.	   The	   reaction	   is	  
then	   quenched	   and	   extracted	   with	   a	   volatile	   solvent,	   such	   as	   ethylacetate	   to	   be	  
analysed	  by	  GC.	  The	  interaction	  between	  the	  GC	  column	  and	  the	  substrates	  is	  based	  
on	   polarity.	   This	   is	   a	   good	   analytic	   technique	   for	   investigating	   ADH	   substrate	  
specificity	   as	   alcohols	   and	   carbonyl	   compounds	   are	   easily	   distinguished	   by	   GC.	  
Alcohol’s	  are	  more	  polar	  than	  aldehydes	  and	  ketones	  due	  to	  greater	  intermolecular	  
hydrogen	  bonding.	  Therefore,	  alcohols	  interact	  more	  with	  the	  GC	  column	  and	  elute	  
with	  a	  later	  retention	  time	  than	  aldehydes	  and	  ketones	  (Figure	  31).	  
	  
Figure	  31	  –	  Schematic	  of	  GC	  analysis	  for	  alcohols	  and	  ketones.	  Typically	  the	  solvent	  peak	  (ethylacetate)	  elutes	  
early	  on,	  with	  carbonyl	  compounds	  such	  as	  acetone	  eluting	  before	  its	  alcohol	  counterpart,	  isopropanol,	  due	  to	  
alcohols	  exhibiting	  a	  higher	  degree	  of	  polarity	  from	  greater	  intermolecular	  hydrogen-­‐bonding.	  
	   The	  total	  reaction	  volume	  for	  a	  biotransformation	  was	  5	  mL.	  The	  buffer	  chosen	  
for	   biotransformations	  was	   the	   kinetics	   buffer.	   The	   reaction	   comprised	  of	   1	  mL	  of	  
enzyme	   at	   5	   mg/mL,	   substrate	   and	   cofactor	   at	   1	   mg/mL	   concentration	   and	   the	  
relevant	   cofactor	   recycling	   system.	   Biotransformations	   were	   only	   performed	   with	  
the	  SDRs,	  therefore	  a	  NADP(H)	  system.	  As	  such,	  glucose-­‐6-­‐phosphate	  dehydrogenase	  
(0.14	   mg/mL)	   and	   glucose-­‐6-­‐phosphate	   (0.52	   mg/mL)	   were	   used	   as	   the	   cofactor	  
recycling	   system.	  Controls	  were	   setup	  up,	  where	   the	   reaction	   conditions	  were	   the	  
same,	  however	  no	  enzyme	  of	   interest	  was	  present.	  Additional	   reactions	  containing	  
5%	  v.v.	  DMSO	  were	  setup	  up	  to	  aid	  the	  low	  solubility	  of	  certain	  substrates.	  
	   The	  biotransformation	  was	  quenched	  at	  0	  h,	  0.5	  h,	  1	  h,	  2	  h,	  4	  h,	  6	  h	  and	  24	  h.	  
Where	  500	  μL	  of	  the	  biotransformation	  was	  extracted	  into	  an	  Eppendorf	  tube	  with	  
600	   μL	   ethylacetate.	   The	   mixture	   was	   vortexed	   to	   homogenise	   the	   solution	   and	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centrifuged	   at	   13.3K	   rpm	   for	   2	   min	   to	   separate	   the	   two	   layers.	   Finally,	   the	   top	  
organic	  layer	  was	  extracted	  and	  pipetted	  into	  a	  GC	  vial,	  which	  was	  stored	  at	  4°C.	  
	   Once	  all	   reactions	  had	  been	  quenched	  and	  collected,	  the	  substrate	  at	  1	  mg/mL	  
final	  concentration	  in	  ethylacetate	  was	  analysed	  on	  GC	  as	  the	  standard.	  Appropriate	  
temperature	   and	   time	   parameters	  were	   established.	   These	   parameters	  were	   used	  
for	  isothermal	  analysis.	  All	  reaction	  samples	  were	  analysed	  for	  the	  same	  amount	  of	  
time	  and	  at	  the	  same	  temperature.	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2.6.	  X-­‐ray	  Crystallography	  
	  
Structure	  determination	  and	  characterisation	  of	  small	  molecules	  and	  protein	  by	  
X-­‐ray	  crystallography	  is	  technique	  that	  is	  now	  routinely	  used.	  The	  experimental	  data	  
obtained	   from	  the	  diffraction	  pattern,	   the	  electron	  density,	   can	   reveal	   information	  
about	   the	   crystallised	   protein	   or	   small	   molecule	   to	   the	   atomic	   level,	   such	   as	  
disordered	  regions	  of	  a	  molecule,	  bond	  lengths	  and	  at	  atomic	  resolutions	  (>	  1.00	  Å)	  
deformation	  of	  the	  electron	  density	  can	  be	  observed,	  serving	  as	  visual	  evidence	  for	  
polarised	  bonds.	  The	  electron	  density	  for	  atoms	  are	  visualised	  as	  spheres	  (Figure	  32	  -­‐	  
left)	  for	  oxy-­‐myoglobin	  at	  1.00	  Å	  resolution	  (PDB	  entry:	  1A6M).	  This	  is	  known	  as	  the	  
spherical-­‐atom	   approximation	   and	   is	   based	   on	   the	   Kappa-­‐Formalism	   to	   simplify	  
calculations	   for	   electron	  density.	   The	   spherical-­‐atom	  approximation	   is	   a	   very	   good	  
approximation,	  however	  this	  breaks	  down	  at	  >	  0.7	  Å	  when	  density	  can	  be	  observed	  
for	   hydrogen	   atoms	   due	   to	   density	   deformation	   (Figure	   32	   -­‐	   right)	   for	   crambin	   at	  
0.48	  Å	  resolution	  (PDB	  entry:	  3NIR).	  Hydrogen	  atoms	  are	  usually	  not	  observed	  in	  the	  
electron	  density	  as	  it	  diffracts	  X-­‐rays	  very	  weakly	  with	  one	  electron.	  
	  
Figure	  32	  –	  (Left)	  spherical-­‐atom	  approximation	  at	  1.00	  Å	  resolution	  of	  the	  active	  site	  in	  oxy-­‐myoglobin	  (PDB	  
entry:	   1A6M).	   (Right)	   deformation	   of	   electron	   density	   at	   0.48	  Å	   resolution	  of	   the	  Arg17	   residue	   in	   crambin	  
(PDB	  entry:	  3NIR).	  
Single	  molecules	  diffract	   very	  weakly.	   Proteins	   in	   solution	   are	  not	  ordered	   and	  
are	   constantly	   moving;	   therefore	   X-­‐ray	   diffraction	   analysis	   for	   structure	  
determination.	  Crystals	  are	  the	  most	  ordered	  form	  of	  matter.	  This	  is	  as	  the	  proteins	  
or	  small	  molecules	   in	  crystal	  are	  packed	  in	  a	  repeating	  and	  well-­‐ordered	  array.	  The	  
protein	   or	   small	  molecule	   crystal	   behaves	   as	   an	   amplifier	   for	   the	   protein	   or	   small	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molecule	   suitable	   for	   single-­‐crystal	   X-­‐ray	   diffraction;	   hence,	   crystals	   are	   used	   for	  
structural	   determination.	   The	   diffraction	   obtained	   from	   the	   single	   crystal	   is	   an	  
average	   image	  of	   the	  array	  of	  packed	  molecules;	   therefore	   if	   the	  crystal	  packing	   is	  
well	   ordered	  with	   very	   low	  mosaicity	   (Figure	   33	   –	   left),	   atomic	   resolution	   can	   be	  
achieved	  and	  well-­‐defined	  diffraction	  spots	  will	  be	  observed	  (Figure	  34	  –	  left)	  	  
	  	   	  
Figure	   33	   –	   Schematic	   of	   2-­‐demensional	   crystal	   packing	   with	   zero	   mosaicity	   (left)	   and	   a	   higher	   degree	   of	  
mosaicity	  (right).	  	  
High	  mosaicity	  (Figure	  33	  –	  right)	  causes	  issues	  when	  integrating	  the	  diffraction	  
data,	   as	   the	   imperfections	   in	   crystal	   packing	   causes	   the	   diffraction	   pattern	   to	  
become	  smeared.	  It	  becomes	  very	  difficult	  to	  define	  the	  intensity	  of	  a	  smeared	  spot	  
(Figure	  34	  –	  middle)	  or	   in	  extreme	  cases	  (Figure	  34	  –	  right).	  Therefore,	  for	  optimal	  
data	   quality	   well-­‐ordered	   crystals	   are	   required	   for	   single	   crystal	   X-­‐ray	   diffraction	  
analysis.	  
	   	   	   	   	  
Figure	   34	   –	   Schematic	   of	   diffraction	   spots.	  Well-­‐defined	   spot	   from	  a	   crystal	  with	  negligible	  mosaicity	   –	   left.	  
Poorly	   defined	   spot	   from	   a	   crystal	   with	   low	  mosaicity	   –	  middle.	   Very	   poorly	   defined	   smeared	   spot	   from	   a	  
crystal	  with	  high	  mosaicity	  –	  right.	  
Through	  the	  development	  of	  the	  Protein	  Data	  Bank	  (PDB)	  came	  the	  development	  
of	   the	   .pdb	   file	   format.	  A	   .pdb	   file	  contains	   information	  on	   the	  protein,	   such	  as	   its	  
basic	   function,	   experimental	   data,	   authors,	   refinement	   parameters	   and	   the	  
coordinate	   of	   the	   model.	   The	   PDB	   is	   not	   limited	   to	   structures	   by	   X-­‐ray	  
crystallography,	   but	   also	  Nuclear	  Magnetic	   Resonance	   (NMR),	   electron	  microscopy	  
and	  hybrid	  solutions.	   	  The	  universal	   file	   format	  allows	   for	   the	  ease	  of	  viewing	  with	  
any	  molecular	  graphics	  suite	  of	  choice.	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Structures	   obtained	   from	   X-­‐ray	   crystallography	   are	   not	   only	   important	   in	  
unveiling	   the	  active	   site	  of	   a	  protein	   for	   revealing	   the	  mechanism	  of	   a	  biocatalyst.	  
Structures	   also	   serve	   as	   a	   basis	   for	   further	   computational	   work	   such	   as	   ligand-­‐
docking	  studies,	  fragment	  based	  screening	  for	  designing	  new	  drugs	  against	  diseases	  
in	  the	  pharmaceutical	  industry.	  
	  
2.6.1.	  Protein	  Crystallisation	  
	  
Once	  satisfactory	  protein	  purity	  had	  been	  achieved	  and	  confirmed	  by	  SDS-­‐PAGE	  
analysis	   (2.2.3.),	   the	   protein	   is	   screened	   for	   a	   condition	   that	   it	   will	   crystallise	   in.	  
Currently	   there	   is	   no	   precise	   method	   for	   crystallising	   a	   novel	   protein,	   therefore	  
screening	  is	  required.	  INDEX	  from	  Hampton	  Research,	  PACT	  (55)	  and	  CSS	  1	  +	  2	  (56)	  
from	  Molecular	   Dimensions	   crystallisation	   screens	   were	   used	   with	   the	  mosquito®	  
Crystal	   (from	   TTP	   Labtech)	   to	   screen	   for	   protein	   crystals	   in	   a	   96-­‐well	   sitting	   drop	  
format.	  The	  300	  nL	  drops	  were	  setup	  in	  a	  1:1	  ratio	  of	  protein	  and	  mother	  liquor.	  	  
Once	  successful	  hits	  were	  observed	  from	  the	  screens,	  the	  conditions	  were	  scaled	  
up	  and	  optimised	  by	  varying	  precipitant	  concentrations	   in	  24	  well	  Linbro	  dishes	  by	  
hanging	   drop	   (vapour	   diffusion)	  method.	   The	   final	   volume	  of	   the	  mother	   liquor	   in	  
the	  well	  was	  1	  mL	  and	  the	  2	  μL	  drop	  suspended	  from	  siliconised	  glass	  coverslips	  was	  
set	  up	  in	  a	  ratio	  of	  1:1	  ratio	  of	  protein	  and	  mother	  liquor.	  
	  
2.6.2.	  Initial	  Testing	  and	  Data	  Collection	  
	  
Once	   protein	   crystals	   had	   been	   successful	   grown,	   they	   were	   tested	   in-­‐house	  
using	   a	   Rigaku	   Micromax-­‐007HF	   fitted	   with	   Osmic	   multilayer	   optics	   and	   a	  
Marresearch	  MAR	  345	  image	  plate	  detector.	  Initial	  testing	  was	  used	  to	  test	  whether	  
complex	  diffraction	  was	  observed	  and	   if	  a	   cryoprotectant	  was	   required	  due	   to	   ice-­‐
rings.	  	  
Cryoprotectants	   were	   composed	   of	   the	   same	   conditions	   as	   the	   mother	   liquor	  
with	   additional	   glycerol	   or	   ethylene	   glycol	   ranging	   from	   10-­‐30%	   v/v.	   If	   a	   complex	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with	   the	  appropriate	  nicotinamide	  cofactor	  was	   required,	   cofactor	  was	  added	   to	  a	  
final	  concentration	  of	  20	  mM	  for	  a	  soak	  or	  cryoprotectant	  solution.	  Co-­‐crystallisation	  
with	  cofactor	  had	   lead	  to	  no	  crystallogenesis	  or	  crystals	  with	  very	  poor	  diffraction.	  
The	   crystals	  were	   soaked	   for	  up	   to	  5	  min	  prior	   to	   testing	  or	   flash	   cooling	   in	   liquid	  
nitrogen.	  
Only	   crystals	   that	   diffracted	   greater	   than	   3.5	   Å	   were	   sent	   to	   Diamond	   Light	  
Source	   synchrotron	   in	  Oxford,	  Didcot.	  At	   the	  Diamond,	   the	   crystals	  were	   screened	  
using	  a	  grid	  scan	  or	  line	  scan	  (Figure	  35)	  for	  the	  best	  diffraction	  quality	  and	  the	  data	  
collection	  strategy	  was	  estimated	  and	  calculated	  by	  the	  automatic	  pipeline	  software	  
EDNA	  (57)	  with	  less	  than	  20	  images.	  	  
	   	  
Figure	  35	  –	  Schematic	  of	  grid	  scan	  (left)	  and	  line	  scan	  (right)	  screening	  on	  a	  protein	  crystal.	  The	  defined	  area	  is	  
tested	  for	  best	  diffraction	  quality.	  	  
	   Once	  the	  optimal	  position	  for	  diffraction	  quality	  was	  established,	  a	  full	  data	  set	  
can	   be	   collected	   with	   the	   strategy	   suggested	   by	   EDNA.	   The	   automatic	   software	  
pipeline	  allows	  for	   the	  data	  to	  be	  automatically	  processed	  by	  XIA2	  (58)	  which	  uses	  
the	  program	  XDS	  (59)	  within	  the	  pipeline	  for	  data	  processing.	  For	  all	  four	  enzymes,	  
the	   automatically	   processed	   data	   was	   used	   for	   structure	   solution	   and	   data	  
refinement.	  
	  
2.6.3.	  Structure	  Solution	  
	  
Atomic	  resolution	  is	  required	  for	  small	  molecule	  X-­‐ray	  crystallography	  and	  direct	  
methods,	   such	   as	   the	   Patterson	   method	   (60),	   can	   be	   used	   to	   solve	   the	   crystal	  
structure.	   However,	   this	   is	   mostly	   not	   applicable	   to	   macromolecular	   or	   protein	  
crystallography	  as	   the	  Patterson	  method	   is	   limited	   to	   very	   small	  proteins	  and	  very	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high	  resolution.	   In	  the	  case	  of	  protein	  crystallography	  solving	  the	  phases	  can	  be	  an	  
issue.	  In	  an	  X-­‐ray	  diffraction	  experiment	  the	  most	  vital	  information,	  the	  phase,	  is	  not	  
collected.	   Therefore	   calculating	   the	   structure	   factor	   is	   not	   possible	   without	   the	  
phases;	  this	  is	  known	  as	  the	  phase	  problem.	  With	  small	  molecules	  this	  is	  not	  so	  much	  
of	   an	   issue,	   as	  brute	   force	   calculations	   can	  be	  used	   to	   solve	   the	  phases.	  However,	  
there	  are	  methods	  for	  solving	  the	  phase	  problem	  for	  macromolecules	  and	  proteins.	  	  
Typically,	   isomorphous	   replacement,	   anomalous	   scattering	   or	   molecular-­‐
replacement	   are	   used	   to	   solve	   the	   phases.	   Anomalous	   scattering	   is	   a	   more	  
commonly	  used	  technique	  over	  isomorphous	  replacement	  as	  it	  is	  more	  convenient.	  
However	  for	  a	  superfamily	  of	  enzymes	  that	  has	  been	  extensively	  investigated,	  such	  
as	   the	   ADHs,	   molecular-­‐replacement,	   using	   the	   program	  MOLREP	   (61),	   can	   be	   an	  
option	   due	   to	   high	   sequence-­‐structure	   conservation.	   Therefore,	   models	   from	  
chainsaw	   modelling	   generated	   from	   available	   PDB	   structures	   with	   high	   sequence	  
similarity	   (percentage	   homology),	   models	   generated	   from	   homology	   modelling	   or	  
models	  generated	  from	  secondary	  structure	  prediction	  servers	  could	  be	  used	  to	  find	  
some	  correct	  phases	  to	  solve	  the	  structure.	  The	  program	  CHAINSAW	  (62)	  generates	  
a	  chainsaw	  model	  that	  is	  suitable	  for	  molecular	  replacement,	  by	  aligning	  a	  target	  and	  
model	   sequence	   and	   modifies	   the	   models	   .pdb	   file	   by	   cropping	   non-­‐conserved	  
residues.	   Alternatively	   the	   program	   BALBES	   (63),	   molecular-­‐replacement	   pipeline,	  
could	  be	  used.	  BALBES	  will	  attempt	  to	  generate	  a	  structure	  solution	  from	  structures	  
deposited	   in	   the	   PDB	   database,	   automatically	   generating	   the	   relevant	   chainsaw	  
models	  and	  splicing	  appropriate	  domains	  without	  the	  users	  intervention.	  
	  
2.6.4.	  Structural	  Refinement	  
	  
	   Once	  the	  structure	  solution	  is	  found,	  structure	  building	  with	  COOT	  (64)	  can	  begin	  
by	  initially	  amending	  the	  model	  with	  the	  relevant	  sequence,	  checking	  for	  side	  chains	  
and	   backbone	   are	   in	   the	   correct	   position	   relative	   to	   the	   electron	   density	   and	   are	  
chemically	   correct	   in	   terms	  of	   potential	   neighbouring	   interactions.	  Once	   the	   initial	  
model	  is	  built,	  the	  reliability	  of	  the	  model,	  the	  reliability	  factor	  (R-­‐factor)	  is	  calculated	  
by	   comparing	   the	   structure	   factors	   from	   the	   experimental	   X-­‐ray	   data	   and	   the	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structure	  factors	  calculated	  from	  the	  model.	  The	  refinement	  program	  REFMAC	  5	  (65)	  
was	  used;	  REFMAC	  5	  attempts	  to	  minimise	  the	  structure	  factor	  difference	  from	  the	  
experimental	   X-­‐ray	   data	   and	   the	   model	   by	   performing	   rigid	   body,	   restrained	   or	  
unrestrained	   refinement	   against	   the	   experimental	   data	   and	   the	   model.	   Iterative	  
cycles	  of	  model	  building	  and	  refinement	  are	  performed	  (Figure	  36)	  to	  minimise	  the	  
R-­‐factor	  until	  satisfactory	  data	  is	  obtained.	  	  
	  
Figure	  36	  –	  Schematic	  of	  the	  refinement	  with	  iterative	  cycles	  of	  model	  building	  and	  model	  refinement.	  
	   The	   ideal	   R-­‐factor	   is	   zero;	   this	   assumes	   it	   is	   a	   perfect	  model	   that	  matches	   the	  
experimental	  data	  perfectly.	  Only	  data	  small	  molecule	  crystallography	  will	  be	  close	  
to	   zero.	   The	   initial	  model	   for	   small	  molecules	  will	   have	   an	  R-­‐factor	   of	   0.05	   (5%)	   –	  
0.10	  (10%),	  once	  hydrogens	  atoms	  have	  been	  added	  with	  appropriate	  B-­‐factors	  and	  
final	  refinement	  performed,	  the	  R-­‐factors	  will	  typically	  be	  between	  0.02	  (2%)	  –	  0.04	  
(4%)	   for	   a	   very	   good	   dataset.	   This	   is	   only	   possible	   with	   atomic	   resolution	   crystal	  
structures	   and	   small	  molecule	   crystals	   that	  diffract	   to	  1.5	  Å	  are	  normally	   rejected;	  
this	   is	   the	   reason	   for	   requiring	   atomic	   resolution	   structures	   for	   small	   molecule	  
crystallography.	  
	   The	  R-­‐factors	  for	  proteins	  will	  vary.	  For	  a	  well	  diffracting	  protein	  crystal,	  1.5	  Å,	  a	  
fully	   refined	   finished	   structure	   could	   have	   R-­‐factors	   of	   10%.	   However	   due	   to	  
disordered	   regions	   such	  as	   loops	  and	  density	   that	   cannot	  be	   rationally	  assigned	  or	  
built,	  the	  R-­‐factors	  for	  a	  1.5	  Å	  structure	  could	  range	  from	  12%	  to	  as	  low	  as	  20%	  for	  
incomplete	   structures	   due	   to	   disorder.	   Despite	   this,	   the	   structures	   are	   still	  
acceptable	  for	  deposition	  and	  further	  analysis.	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2.7.	  Computational	  Modelling	  
	  
Co-­‐crystallisation	   with	   ligands	   can	   often	   prove	   unsuccessful,	   as	   can	   soaking	   with	  
ligands,	   therefore	   obtaining	   a	   crystal	   structure	   with	   the	   desired	   ligand	   for	  
mechanistic	  or	  inhibition	  studies	  can	  be	  very	  difficult.	  Computational	  modelling	  use	  
to	   require	   supercomputers	   for	   data	   processing,	   calculations	   and	   simulations,	  
however	  technology	  has	  greatly	  advanced	  in	  that	  the	  processing	  power	  of	  a	  standard	  
desktop	  computer	  can	  perform	  these	  simulations	  and	  calculations.	  Therefore	  these	  
programs	  have	  now	  become	  accessible	  to	  everyone.	  There	  are	  many	  different	  search	  
algorithms	  available	  for	  ligand	  docking,	  however	  the	  Lamarckian	  Genetic	  algorithm	  is	  
commonly	  used	  for	  most	  docking	  programs	  as	   it	  provides	  the	  most	  efficient	  search	  
method	  based	  on	  conformation	  (66).	  
	  
2.7.1	  Ligand	  Building	  
	  
The	  CCP4	  ligand	  library	  has	  a	  premade	  dictionary	  for	  common	  ligands	  and	  cofactors	  
such	   as	   the	  nicotinamide	   cofactor.	  However	   for	   novel	   ligands	   and	   ligands	   that	   are	  
not	   available	   in	   the	   CCP4	   ligand	   library	  
(http://www.ccp4.ac.uk/html/refmac5/dictionary/list-­‐of-­‐ligands.html),	   they	   will	  
have	   to	   be	   built	   and	   energy	  minimised.	   Ligands	   are	   initially	   built	   using	   the	   COOT	  
Ligand	   Builder;	   the	   ligand	   is	   then	   saved	   as	   a	   .mol	   file	   and	   is	   imported	   into	   the	  
program	  PRODRG	  (67)	  in	  the	  CCP4	  interface	  (68),	  where	  the	  .pdb	  coordinates	  and	  .cif	  
topology	  files	  are	  generated	  (Figure	  37).	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Figure	  37	  –	  Schematic	  for	  ligand	  building	  for	  ligands,	  such	  as	  PPK,	  not	  available	  in	  the	  CCP4	  ligand	  library.	  
PRODRG	  carries	  out	  the	  necessary	  restraints	  and	  energy	  minimisation	  on	  the	  ligand,	  
which	  allow	  for	  successful	  refinement	  in	  REFMAC5	  or	  ligand	  docking.	  
	  
2.7.2.	  Ligand	  Docking	  
	  
AutoDock	  suite	  (69)	  was	  used	  to	  dock	  ligands	  into	  the	  active	  site	  of	  the	  protein.	  
AutoDock	  requires	  PDBQT	  files,	  which	  is	  an	  extension	  of	  the	  PDB	  file	  format.	  As	  well	  
as	   the	   normal	   PDB	   file	   headers,	   PDBQT	   includes	   information	   for	   polar	   hydrogen	  
atoms,	   partial	   charges,	   atom	   types	   and	   information	   on	   the	   articulation	   of	   flexible	  
molecules.	   One	   of	   the	   topology	   files	   that	   PRODRG	   can	   generate	   for	   ligands	   (as	  
mentioned	   in	   section	   2.5.1.)	   are	   PDBQT	   files	   suitable	   for	   AutoDock.	  However	   they	  
can	  also	  be	  generated	  within	  AutoDockTools.	  
The	  first	  step	  was	  to	  prepare	  the	  protein’s	  coordinate	  file	   in	  AutoDockTools,	  by	  
removing	  all	  water	  molecules	  and	  adding	  hydrogens	  to	  the	  protein.	  The	  ligand	  was	  
prepared	   (Figure	   38)	   by	   detecting	   the	   torsional	   root,	   choosing	   the	   torsions,	   then	  
setting	   the	   number	   of	   torsions;	   the	   ligand	   was	   then	   saved	   as	   a	   PDBQT	   file.	   The	  
protein	  was	  chosen	  to	  be	  a	  rigid	  receptor	  which	  merges	  non-­‐polar	  hydrogen	  atoms	  
and	  charges,	  assign	  aromatic	  carbons	  and	  allow	  the	  protein	  to	  be	  saved	  as	  a	  PDBQT.	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Figure	  38	  –	  Preparing	  the	  ligand	  PPK	  in	  Autodock	  Tools,	  with	  auto	  detection	  of	  the	  torsional	  root.	  
Prior	  to	  docking,	  AutoDock	  requires	  pre-­‐calculated	  grid	  maps,	  one	  for	  each	  atom	  
type	   present	   in	   the	   ligand	   being	   docked.	   These	   maps	   are	   calculated	   by	   AutoGrid	  
(Figure	   39),	   which	   is	   part	   of	   the	   AutoDock	   suite.	   A	   grid	   map	   consists	   of	   a	   three-­‐
dimensional	  lattice	  of	  regularly	  spaced	  points,	  which	  can	  be	  either	  entirely	  or	  partly	  
centred	  on	  a	  region	  of	  interest	  of	  the	  macromolecule/protein.	  	  
	  
Figure	  39	  –	  Defining	  the	  area	  in	  the	  protein	  to	  be	  dock	  with	  ligand	  using	  AutoGrid.	  Either	  the	  whole	  protein	  or	  
just	  the	  active	  site	  can	  be	  defined	  for	  docking.	  
After	   a	   grid	   box	   has	   been	   specified,	   the	   ligand	   can	   be	   docked	  with	   AutoDock.	  
AutoDock	  can	  use	  the	  Lamarckian	  Genetic	  algorithm	  to	  explore	  the	  conformational	  
state	   is	   a	   flexible	   ligand,	   using	   the	   maps	   generated	   by	   AutoGrid	   to	   evaluate	   the	  
ligand-­‐protein	  interaction	  at	  each	  point	  in	  the	  docking	  simulation	  (Figure	  40).	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Figure	  40	  –	  Defining	  the	  docking	  algorithm	  to	  be	  used	  with	  the	  relevant	  docking	  parameters.	  
Instead	  of	  using	  AutoDock,	  AutoDockVina	  can	  be	  used,	  which	  utilises	  a	  multicore	  
processor	   computer	   and	   docks	   significantly	   faster	   with	   greater	   accuracy	   than	  
AutoDock.	  Another	   benefit	   is	   that	   the	   files	   generated	  by	  AutoDockVina	   can	   assess	  
neighbouring	  residues	  and	   interactions;	  AutoDockVina	  calculates	  these	   interactions	  
and	   therefore	   they	   provide	   a	   less	   biased	   assessment	   of	   the	   neighbouring	   residues	  
rather	  than	  picking	  residues	  by	  eye	  (Figure	  41).	  
	  
Figure	  41	  -­‐	  The	  docking	  outcome	  with	  AutoDock	  vina	  showing	  potential	  interacting	  residues	  and	  cofactor,	  with	  
the	  ligand	  PPK	  being	  ranked	  in	  vina	  energy.	  




RasADH	   is	   an	   SDR	   from	   Ralstonia	   sp.	   Justyna	   Kulig	   from	   Institute	   of	   Bio-­‐	   and	  
Geosciences	   in	   Jülich	   cloned	   the	   gene	   encoding	   RasADH	   into	   the	   pET-­‐YSBLIC3C	  
vector,	  expressed	  and	  purified	  the	  enzyme	  but	  had	  little	  success	  with	  crystallisation.	  
RasADH	  was	  found	  to	  be	  able	  to	  accept	  ‘bulky-­‐bulky’	  ketones	  (24)	  and	  reduces	  them	  
selectively	   to	   the	   (S)-­‐alcohol	  with	  e.e.s	   ≥99%	   (26)	   utilising	  NADPH	   as	   the	   cofactor.	  
Many	  drug	  compounds	  have	  bioactive	  benzyl	  alcohol	  derivatives	  (Figure	  42);	  hence	  
RasADH	   could	   be	   used	   to	   accept	   bulky	   ketones	   as	   the	   precursors	   (23).	   Despite	  
RasADH	   being	   a	   SDR,	   it	   was	   seen	   to	   have	   an	   affinity	   for	   calcium	   for	   activity	   and	  
protein	  stabilisation	  (27)	  and	  thus,	  not	  dependent	  on	  divalent	  metal	  ions	  for	  activity.	  
	  




An	   induction	   test	   (Figure	   43)	   was	   performed	   in	   order	   to	   optimise	   expression	  
(Section	  2.3.4.2).	  The	  gel	  suggests	  later	  induction	  at	  OD600	  ≥	  1.4	  yields	  more	  soluble	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Figure	   43	   -­‐	   Induction	   Test	   for	   RasADH	   to	   optimise	   protein	   production	   analysed	   on	   a	   12%	   SDS-­‐PAGE	   gel	   as	  
described	  in	  section	  2.2.3.	  Lane	  1	  is	  the	  Low	  Molecule	  Weight	  Ladder	  from	  BioRad.	  Lanes	  2-­‐4	  are	  the	  insoluble	  
fractions	  for	  the	  control,	  induction	  at	  0.6	  Abs	  and	  2.0	  Abs	  respectively.	  Lanes	  5-­‐13	  are	  the	  soluble	  fractions	  for	  




Prior	  to	  purification,	  the	  clarified	  cell	  lysate	  (from	  6	  L	  of	  culture)	  was	  recirculated	  
onto	  two	  5	  mL	  HisTrap	  Crude	  FF	  columns,	  charged	  with	  nickel	  and	  joined	  end-­‐on-­‐end	  
using	   a	   peristaltic	   pump	   (2.4.2.).	   RasADH	   benefited	   from	   this	   purification	   strategy	  
significantly,	  as	  previous	  attempts	  had	  proven	  difficult	  and	  even	  after	  SEC,	  the	  purity	  
was	   not	   satisfactory.	   Each	   column	   was	   purified	   separately.	   Following	   nickel	  
purification,	  purity	  was	  analysed	  by	  SDS-­‐PAGE	  (Figure	  44).	  
	  
Figure	   44	   -­‐	   SDS-­‐PAGE	   analysis	   for	   the	   nickel	   purifiaction	   of	   RasADH.	   The	   SDS-­‐PAGE	   gel	   and	   samples	   were	  
prepared	  as	  described	  in	  sections	  2.2.3.	  and	  2.2.3.1.	  Lane	  1	  is	  the	  Low	  Molecular	  Weight	  Ladder	  from	  BioRad	  
and	  lanes	  2-­‐25	  are	  the	  samples	  obtained	  from	  the	  elution	  gradient	  of	  the	  purification.	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RasADH	   could	   only	   be	   concentrated	   to	   5	   mg/mL	   before	   the	   protein	   began	   to	  
aggregate.	  Previous	  attempts	  to	  dialyse	  the	  protein	  into	  buffer	  B	  were	  unsuccessful;	  
dialysis	  overnight	  caused	  the	  protein	  to	  precipitate.	  The	  appropriate	  fractions	  were	  
pooled	  and	  concentrated	  for	  SEC	  (Figure	  45)	  and	  purified	  in	  batches.	  
	  
Figure	  45	  -­‐	  Chromatagram	  for	  the	  SEC	  of	  RasADH	  after	  nickel	  affinity	  purification.	  Samples	  from	  40-­‐60	  ml	  of	  the	  
SEC	  were	  taken	  for	  analysis	  on	  SDS-­‐PAGE.	  
	  
Figure	   46	   –	   Protein	   purity	   analysis	   by	   SDS-­‐PAGE	   after	   SEC.	   Samples	   and	   SDS-­‐PAGE	   gel	   were	   prepared	   as	  
described	   in	   sections	  2.2.3.1.	  and	  2.3.3.	   Lane	  1	  of	   the	  SDS-­‐PAGE	  gel	   is	  a	  Low	  Molecular	  Weight	  Ladder	   from	  
BioRad,	  lanes	  2-­‐10	  were	  samples	  every	  second	  fraction	  of	  the	  peak	  between	  40-­‐60	  ml.	  
The	  protein	  analysed	  by	  SDS-­‐PAGE	  (Figure	  46)	  was	  sufficiently	  pure	  after	  SEC	  to	  
proceed	  with	  crystallisation	  screening.	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3.1.3.	  Crystallisation	  
	  
After	  RasADH	  was	  purified,	  it	  could	  be	  concentrated	  above	  5	  mg/mL	  without	  any	  
signs	   of	   precipitation.	   Initial	   crystallisation	   screen	   of	   RasADH	   was	   performed	   at	   5	  
mg/mL	   in	   INDEX,	   PACT	   and	   CSS	   1	   +	   2.	   The	  most	   promising	   hits	   were	   observed	   in	  
PACT,	  however	  these	  were	  only	  needle-­‐like	  crystals.	  RasADH	  was	  rescreened	  in	  PACT	  
at	  21	  mg/mL,	  with	   the	  most	  promising	  crystals	  appearing	   in	  PACT-­‐G4	  with	   rod-­‐like	  
morphology.	  These	  rod-­‐like	  crystals	  were	  successfully	  optimised	  using	  hanging	  drop	  
vapour	  diffusion	  method	  (Section	  2.6.1.)	  with	  additives	  producing	  much	  larger	  rods	  
with	   less	  striation	   than	  the	  crystals	   from	  the	  screen.	  The	  best	  crystals	   (Figure	   47	  –	  
left)	  were	  obtained	  in	  0.1	  M	  Bis-­‐tris	  propane	  pH	  8.0,	  containing	  16%	  (w/v)	  PEG	  3350,	  
0.2	   M	   potassium	   isothiocyanate	   and	   5%	   (w/v)	   ethylene	   glycol	   at	   a	   protein	  
concentration	   of	   24	   mg/mL.	   The	   crystals	   were	   soaked	   for	   5	   min	   with	   a	  
cryoprotectant	  comprised	  of	   the	  mother	   liquor	  with	  20%	   (v.v.)	  ethylene	  glycol	  and	  
10	   mM	   NADPH,	   attempting	   to	   obtain	   a	   NADPH	   complex.	   The	   crystals	   were	  
subsequently	   flash	   cooled	   in	   liquid	   nitrogen	   prior	   to	   in-­‐house	   (Section	   2.6.2)	  
diffraction	   analysis	   (Figure	   47	   –	   Right).	   Once	   satisfactory	   diffraction	   had	   been	  
observed	   in-­‐house,	   the	   NADPH	   complex	   (holo-­‐)	   dataset	   was	   collected	   at	   Dimond,	  
Didcot,	  on	  the	  I04	  beamline	  on	  2nd	  February	  2013.	  
	  
Figure	  47	  -­‐	  RasADH	  crystals	  obtained	  from	  PACT-­‐G4	  additive	  optimisation	  (left)	  with	  its	  diffraction	  pattern	  in-­‐
house	  (right).	  
More	  crystals	  had	  formed	  at	  a	  much	  later	  date	  in	  the	  same	  PACT	  rescreen	  at	  21	  
mg/mL.	   The	   crystal	   hit	   was	   in	   PACT-­‐H10	   and	   it	   did	   not	   have	   the	   same	   rod-­‐like	  
morphology	  has	  mentioned	  previously,	  however	  the	  conditions	  were	  similar	  to	  those	  
in	  PACT-­‐G4.	  The	  crystals	  had	  a	  shard-­‐like	  morphology	  (Figure	  48	  –	  left).	  The	  crystals	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in	   PACT-­‐H10	   were	   successfully	   optimised	   by	   the	   hanging-­‐drop	   method	   (Section	  
2.6.1.).	  The	  best	  crystals	  were	  obtained	  in	  0.1	  M	  Bis-­‐tris	  propane	  pH	  7.0	  containing	  
20%	   (w/v)	   PEG	   3350	   and	   0.02	   M	   sodium-­‐potassium	   phosphate	   at	   a	   protein	  
concentration	  of	  24	  mg/mL.	  The	  crystals	  were	  soaked	  in	  a	  solution	  of	  mother	  liquor	  
with	  additional	  20%	  (v.v)	  ethylene	  glycol	  as	  a	  cryoprotectant.	  The	  crystals	  were	  flash	  
cooled	  in	  liquid	  nitrogen	  prior	  to	  in-­‐house	  diffraction	  analysis	  (Figure	  48	  –	  right).	  In-­‐
house	   observed	   diffraction	   was	   already	   at	   a	   much	   higher	   resolution	   than	   the	  
previous	  collected	  NADPH	  dataset.	  The	  apo-­‐crystals	  were	  sent	  to	  Diamond,	  Didcot,	  
and	  a	  full	  dataset	  was	  collected	  on	  the	  I02	  beamline	  on	  28th	  February	  2013.	  
	  
Figure	   48	   -­‐	   RasADH	   crystals	   obtained	   from	  well	   PACT-­‐H10	   optimisation	   (left)	  with	   its	   diffraction	   pattern	   in-­‐
house	  (right).	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Data	  collection	  and	  refinement	  statistics	  for	  the	  apo-­‐	  and	  NADPH	  complex	  of	  RasADH	  
(29)	  are	  shown	  below	  (Table	  1).	  
	  
	   RasADH	  (apo)	   RasADH	  (NADPH	  complex)	  
Beamline	   Diamond	  I02	  on	  28/2/2013	   Diamond	  I04	  on	  2/2/2013	  
Wavelength	  (Å)	   0.97950	   0.97950	  
Resolution	  (Å)	   60.86-­‐1.52	  (1.57-­‐1.52)	   74.54-­‐2.89	  (2.93-­‐2.89)	  
Space	  Group	   C21	   C21	  
Unit	  Cell	  (Å)	   a	  =	  136.5;	  b	  =	  52.5;	  c	  =	  151.5;	  α	  =	  γ	  =	  90.0;	  β	  =	  116.6	  
a	  =	  192.3;	  b	  =	  135.6;	  c	  =	  93.6;	  α	  
=	  γ	  =	  90.0;	  β	  =	  100.1	  
No.	  of	  molecules	  in	  the	  
asymmetric	  unit	   4	   6	  
Unique	  reflections	   149646	  (45160)	   52465	  (2880)	  
Completeness	  (%)	   97.7	  (96.8)	   99.2	  (98.8)	  
Rmerge	  (%)	   0.03	  (0.25)	   0.18	  (0.73)	  
Rp.i.m.	   0.03	  (0.23)	   0.16	  (0.64)	  
Multiplicity	   3.3	  (3.5)	   4.2	  (4.2)	  
<I/σ(I)>	   15.6	  (4.9)	   7.4	  (2.0)	  
CC1/2	   1.00	  (0.95)	   0.98	  (0.74)	  
Overall	  B	  factor	  from	  
Wilson	  plot	  (Å2)	   24	   41	  
Rcryst/Rfree	  (%)	   15.8/18.8	   26.8/29.3	  
No.	  protein	  atoms	   6942	   11081	  
No.	  water	  molecules	   846	   37	  
r.m.s.d.	  1-­‐2	  bonds	  (Å)	   0.02	   0.01	  
r.m.s.d.	  1-­‐3	  bonds	  (°)	   1.69	   1.6	  
Avge	  main	  chain	  B	  (Å2)	   20	   35	  
Avge	  side	  chain	  B	  (Å2)	   23	   36	  
Avge	  water	  B	  (Å2)	   33	   14	  
Avge	  ligand	  B	  (Å2)	   -­‐	   32	  
PDB	  entry	   4BMN	   4BMS	  	  
Table	   1	   -­‐	   Data	   collection	   and	   Refinement	   Statistics	   for	   RasADH	   apo	   and	   NADPH	   complex	   with	   numbers	   in	  
brackets	  referring	  to	  data	  in	  the	  highest	  resolution	  shell.	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3.1.4.	  Structure	  Solution	  and	  Model	  Building	  	  
	   The	   holo-­‐dataset	   was	   solved	   with	   MOLREP,	   using	   a	   monomer	   model	   derived	  
from	   the	   tetrameric	   structure	   of	   Rhizobium	   etli	   CFN	   42	   (PDB	   entry:	   4FGS).	   The	  
solution	  contained	  six	  molecules	  in	  the	  asymmetric	  unit,	  representing	  one	  and	  a	  half	  
tetramers	  (Figure	  49	  –	  left).	  The	  holo-­‐structure	  was	  built	  and	  refined	  to	  Rcryst	  and	  Rfree	  
values	   of	   26.8%	   and	   29.3%	   respectively.	   Subsequently,	   a	  monomer	  model	   derived	  
from	   the	  holo-­‐model	  was	   used	   to	   solve	   the	  apo-­‐structure	   (Figure	   49	   –	   right).	   The	  
apo-­‐structure	   was	   built	   and	   refined	   to	   Rcryst/Rfree	   values	   of	   15.8%/18.8%.	   Despite	  
ambiguity	   present	   with	   the	   lower	   quality	   NADPH	   complex	   model	   (Rcryst/Rfree	   =	  
26.8%/29.3%),	   much	   of	   the	   ambiguity	   can	   be	   clarified	   when	   comparing	   and	  
superposing	  with	  the	  higher	  quality	  apo-­‐model.	  
	  
Figure	  49	  -­‐	  RasADH	  holo-­‐asymmetric	  unit	  (left)	  and	  apo-­‐asymmetric	  unit	  (right).	  Holo-­‐subunits	  labelled	  Rh,	  apo-­‐
subunits	  labelled	  Ra.	  	  
A	   monomer	   of	   RasADH	   is	   made	   up	   of	   a	   classical	   Rossman	   fold,	   as	   seen	   with	  
subunit	   Rh1	   (Figure	   50),	   with	   a	   central	   β-­‐sheet	   composed	   of	   seven	   β-­‐strands:	   β1	  
(residues	  8-­‐13),	  β2	  (33-­‐37),	  β3	  (54-­‐58),	  β4	  (83-­‐87),	  β5	  (131-­‐135),	  β6	  (174-­‐180)	  and	  β7	  
(239-­‐242).	   The	  β-­‐sheet	  was	   encompassed	  by	   seven	   alpha	  helices:	   α1	   (residues	   17-­‐
30),	  α2	  (40-­‐50),	  α3	  (64-­‐77),	  α4	  (101-­‐126),	  α5	  (148-­‐168),	  α6	  (195-­‐208)	  and	  α7	  (217-­‐
228).	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Figure	  50	  -­‐	  RasADH	  Rossman	  fold	  represented	  by	  subunit	  Rh1.	  The	  helicies	  are	  represented	  by	  α1-­‐7	  and	  the	  β-­‐
sheets	  are	  represented	  by	  β1-­‐7.	  
The	  majority	  of	  the	  secondary	  structure	  is	  conserved	  between	  the	  holo-­‐	  and	  apo-­‐
structure.	   However,	   the	  most	   noticeable	   difference	  was	   seen	   is	   highlighted	   in	   the	  
green	   box	   (Figure	   51).	   In	   the	   apo-­‐structure,	   there	   is	   no	   electron	   density	   present	  
between	  the	  loop	  region	  (λ2).	  Furthermore,	  when	  this	  region	  is	  superposed	  with	  the	  
holo-­‐structure,	  it	  becomes	  apparent	  that	  it	  is	  a	  domain	  shift.	  The	  domain	  movement	  
of	  the	  helix	  (α6)	  and	  loop	  (λ1)	  suggests	  that	  helix	  (α6)	  is	  a	  ‘lid’	  for	  cofactor	  binding.	  
	  
Figure	  51	   -­‐	  RasADH	  overlay	  of	  apo-­‐	  and	  holo-­‐structure,	   residues	  173-­‐229	  shown	  with	   the	   rest	  of	   the	  protein	  
greyed	  out.	  Loops	  are	  denoted	  as	  λ.	  α1	  is	  no	  longer	  present	  in	  the	  apo-­‐structure	  as	  it	  becomes	  λ2.	  The	  electron	  
density	  for	  NADPH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  
refinement	  in	  the	  absence	  of	  NADPH.	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The	  active	  site	  of	  RasADH	  (Figure	  52)	  is	  formed	  at	  the	  top	  of	  the	  central	  β-­‐sheet	  
of	   the	  Rossman	   fold	   that	   is	   partially	   covered	  by	   the	  helix	  α6.	   The	  most	  noticeable	  
feature	  is	  the	  active	  site	  is	  lined	  by	  residues	  Tyr150	  (the	  likely	  proton	  donor),	  Ser137,	  
Phe205,	   Leu144,	   Leu142,	   Leu201,	   Val138,	   Ile91,	   His147	   and	   Gln191	   forming	   a	  
hydrophobic	   tunnel.	   The	   nicotinamide	   ring	   of	   NADPH	   sits	   at	   the	   base	   of	   this	  
hydrophobic	   tunnel.	   Residues	   Arg38	   and	   Arg39	   govern	   RasADHs’	   strict	   specificity	  
towards	  NADPH	  by	  close	  interactions	  with	  the	  2’-­‐phosphate	  on	  the	  adenine-­‐ribose	  of	  
NADPH,	  as	  well	  as	  Arg38	  π-­‐stacking	  interactions	  with	  adenine	  ring.	  
	  
Figure	  52	   -­‐	  Hydrophobic	  active	  site	  of	  RasADH	  represented	  by	  residues:	  by	  residues	  Tyr150,	  Ser137,	  Phe205,	  
Leu144,	  Leu142,	  Leu201,	  Val138,	  Ile91,	  His147	  and	  Gln191.	  
Despite	   the	  difference	   in	   cofactor	  binding,	  upon	   superposing	   the	  apo-­‐structure	  
and	  NADPH	  complex,	  the	  structures	  are	  highly	  conserved	  with	  an	  RMSD	  of	  only	  0.41	  
Å	  over	  458	  atoms.	  PISA	  (70)	  analysis	  suggests	  that	  there	  is	  little	  difference	  between	  
any	  of	   the	  dimer	   interfaces	   for	   potential	   interactions	   in	  RasADH.	   Further	   evidence	  
was	   observed	   with	   the	   little	   difference	   in	   Gibbs	   free	   energy	   for	   any	   dimerising	  
interface.	   This	   leads	   to	   suggestions	   that	   RasADH	   could	   predominantly	   exist	   as	   a	  
tetramer	  over	  the	  more	  common	  dimer	  like	  many	  ADHs.	  	  
Other	  than	  the	  structure	  of	  RasADH	  solved	  by	  Lerchner	  (PDB	  entry:	  4I5E)	  and	  the	  
model	   used	   for	   the	   structure	   solution	   (PDB	   entry:	   4FGS);	   using	   the	  apo-­‐structure,	  
DALI	   (71)	   server	   identified	   3-­‐oxoacyl-­‐[acyl-­‐carrier	   protein]	   reductase	   (FabG)	   from	  
Listeria	  monocytogenes	  (PDB	  entry:	  4JRO)	  which	  is	  also	  a	  tetramer	  in	  crystallographic	  
space	  and	  has	  a	  sequence	  similarity	  of	  36%	  and	  an	  RMSD	  of	  1.1	  Å	  over	  247	  residues.	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Also	   the	   3-­‐oxoacyl-­‐[acyl-­‐carrier	   protein]	   reductase	   from	   Synechococcus	   elongates	  
PCC	   7942	   (PDB	   entry:	   4DMM)	   which	   is	   a	   dimer	   in	   crystallographic	   space	   has	   a	  
sequence	   similarity	   of	   35%	   and	   an	   RMSD	   of	   1.3	   Å	   over	   237	   residues.	   The	   two	   3-­‐
oxoacyl-­‐[acyl-­‐carrier	  protein]	  reductase	  identified	  by	  DALI	  exhibit	  several	  similarities	  
to	   SDRs,	   in	   that	   they	   are	   dimers	   or	   tetramers	   and	   utilise	   NADPH	   as	   the	   cofactor	  
which	  most	  likely	  display	  general	  dehydrogenase	  or	  reductase	  activity.	  
Using	   the	   holo-­‐structure	   for	   DALI	   analysis,	   DALI	   further	   identified	   a	   putative	  
tetrameric	   oxidoreductase	   from	   Sinorhizobium	   meliloti	   1021	   (PDB	   entry:	   4ESO)	  
which	  has	  a	  sequence	  similarity	  of	  40%	  and	  an	  RMSD	  of	  1.4	  Å	  over	  251	  residues.	  This	  
was	   not	   identified	   by	   DALI	   with	   the	   apo-­‐structure.	   This	   is	   most	   likely	   due	   to	   the	  
missing	   lid	   domain	   in	   the	   absence	   of	   the	   cofactor.	   The	   tetrameric	   pyridoxal	   4-­‐
dehydrogenase	   from	   Mesorhizobium	   loti	   (PDB	   entry:	   3RWB)	   was	   also	   identified	  
when	   using	   the	   holo-­‐structure;	   the	   pryidoxal	   4-­‐dehydrogenase	   has	   a	   sequence	  
similarity	   of	   31%	   and	   an	   RMSD	   of	   1.3	   Å	   over	   247	   residues.	   Both	   of	   the	   targets	  
identified	  by	  DALI	  also	  display	  similar	  properties	  to	  SDRs,	  exhibiting	  similar	  enzyme	  
classification	  and	  Rossmann	  fold	  for	  the	  nicotinamide	  cofactor	  binding.	  Hence,	  they	  
also	  display	  dehydrogenase	  activity.	  
Interestingly	   at	   higher	   resolutions,	   buffer	   components	   and	   crystallisation	  
precipitants	  like	  Tris	  and	  ethyleneglycol	  can	  be	  seen,	  however	  they	  are	  not	  bound	  in	  
the	   active	   sites.	   Despite	   RasADH	   having	   an	   affinity	   for	   calcium,	   it	   could	   not	   be	  
rationally	  assigned	  and	  refined	  with	  COOT	  and	  REFMAC5,	  even	  at	  1.4	  Å.	  However	  it	  
was	  to	  be	  expected	  that	  calcium	  would	  not	  be	  present	  in	  the	  active	  site	  as	  an	  SDR.	  
Most	   likely	  the	  addition	  of	  calcium	  chloride	  would	  be	  a	   ‘salting-­‐in’	  effect,	  seeing	  as	  
protein	   aggregation	   is	   observed	   at	   lower	   salt	   concentrations	   (sodium	   chloride).	  
RasADH	   appeared	   most	   soluble	   at	   higher	   salt	   concentrations	   (500	   mM	   sodium	  
chloride).	   Therefore	   it	   is	   possible	   that	   calcium	   chloride	   behaves	   as	   a	   kosmotrope	  
stabilising	  any	  intermolecular	  interactions.	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3.2.	  SyADH	  
	  
SyADH	  is	  an	  SDR	  from	  Sphingobium	  yanoikuyae.	  Kinga	  Kedziora	  from	  Universidad	  
de	  Oviedo	  in	  Oviedo	  cloned	  the	  gene	  encoding	  SyADH	  into	  pET-­‐YSBLIC3C,	  expressed	  
and	  purified	  the	  protein	  and	  crystallised	  it.	  Like	  RasADH,	  SyADH	  is	  also	  able	  to	  accept	  
‘bulky-­‐bulky’	  ketones	  and	  selectively	  reduce	  them	  to	  the	  (S)-­‐alcohol	  with	  e.e.s	  ≥99%;	  
however	  SyADH	  differs	  in	  diastereoselectivity	  to	  RasADH.	  Thus,	  SyADH	  and	  RasADH	  
are	  diastereocomplementary.	  
	  
The	  data	  collection	  and	  refinement	  statistics	  for	  SyADH	  in	  complex	  with	  NADPH	  (29)	  
are	  shown	  below	  (Table	  2):	  
	   SyADH	  
Beamline	   Diamond	  I02	  
Wavelength	  (Å)	   0.97949	  
Resolution	  (Å)	   139.0-­‐2.5	  (2.56-­‐2.50)	  
Space	  Group	   P21	  
Unit	  Cell	  (Å)	   a	  =	  144.9;	  b	  =	  86.8;	  c	  =	  155.6;	  α	  =	  γ	  =	  90.0;	  β	  =	  106.4	  
No.	  of	  molecules	  in	  the	  
asymmetric	  unit	   10	  
Unique	  reflections	   133601	  (10900)	  
Completeness	  (%)	   99.7	  (99.8)	  
Rmerge	  (%)	   0.14	  (0.54)	  
Rp.i.m.	   0.12	  (0.46)	  
Multiplicity	   4.2	  (4.3)	  
<I/σ(I)>	   8.2	  (3.0)	  
CC1/2	   0.99	  (0.82)	  
Overall	  B	  factor	  from	  
Wilson	  plot	  (Å2)	   43	  
Rcryst/Rfree	  (%)	   23.4/25.1	  
No.	  protein	  atoms	   18948	  
No.	  water	  molecules	   290	  
r.m.s.d.	  1-­‐2	  bonds	  (Å)	   0.01	  
r.m.s.d.	  1-­‐3	  bonds	  (°)	   1.6	  
Avge	  main	  chain	  B	  (Å2)	   35	  
Avge	  side	  chain	  B	  (Å2)	   37	  
Avge	  water	  B	  (Å2)	   20	  
Avge	  ligand	  B	  (Å2)	   30	  
PDB	  entry	   4BMV	  
	  
Table	  2	  –	  The	  data	  collection	  and	  refinement	  statistics	  for	  SyADH	  in	  complex	  with	  NADPH.	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3.2.1.	  Structure	  Solution	  and	  Model	  Building	  
	  
The	  structure	  of	  SyADH	  was	  solved	  using	  the	  automated	  molecular	  replacement	  
pipeline	  BALBES,	  which	  derived	  a	  monomer	  model	  from	  the	  NADPH-­‐dependent	  blue	  
fluorescent	  protein	   from	  Vibrio	  vulnificus	   (PDB	  entry:	  3P19).	  The	  structure	  solution	  
contained	   five	   dimers	   in	   the	   asymmetric	   unit.	   The	   structure	  was	   built	   and	   refined	  
with	   iterative	   cycles	   of	   COOT	   and	   REFMAC5	   with	   local	   NCS	   restraints.	   Once	   the	  
model	  for	  SyADH	  was	  built	  and	  refined	  to	  a	  satisfactory	  level,	  the	  omit	  map,	  revealed	  
residual	  electron	  density	   for	  NADPH	  to	  be	  rationally	  assigned	  and	  refined	   in	  all	   ten	  
active	   sites.	   SyADH	   was	   built	   (Figure	   53)	   and	   refined	   to	   Rcryst/Rfree	   values	   of	  
26.8%/29.3%.	  
	  
Figure	   53	   -­‐	   The	   structure	   of	   SyADH	  with	   10	   subunits	   in	   the	   asymmetric	   unit,	   each	   subunit	   is	   denoted	   as	   S.	  
SyADH	  asymmetric	  unit	  forms	  a	  quinary	  structure	  resembling	  a	  helix.	  
The	  monomer	  of	  SyADH,	  subunit	  S1	  (Figure	  54),	   features	  a	  Rossman	  fold	  with	  a	  
central	  β-­‐sheet	  of	  seven	  strands:	  β1	  (residues	  6-­‐11),	  β2	  (31-­‐34),	  β3	  (56-­‐58),	  β4	  (82-­‐
88),	   β5	   (134-­‐138),	   β6	   (177-­‐181)	   and	   β7	   (224-­‐225).	   The	   central	   β-­‐sheet	   is	   again	  
surrounded	  by	  seven	  α-­‐helicies:	  α1	  (residues	  15-­‐27),	  α2	  (38-­‐52),	  α3	  (66-­‐78),	  α4	  (102-­‐
130),	   α5	   (151-­‐171),	   α6	   (190-­‐194)	   and	   α7	   (207-­‐220).	   SyADH	   differs	   to	   a	   normal	  
Rossman	  fold	  in	  that	  an	  additional	  helix	  α8	  (234-­‐248)	  extending	  to	  the	  C-­‐terminus.	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Figure	  54	  -­‐	  A	  monomer	  of	  SyADH,	  represented	  by	  subunit	  S1,	  displaying	  helicies	  α1-­‐8	  and	  β-­‐sheets	  β1-­‐7.	  
The	   C-­‐terminal	   helix,	   α8	   (Figure	   54),	   participates	   in	   monomer-­‐monomer	  
interaction	   aiding	   the	   formation	   of	   a	   dimer	   (Figure	   55).	   Not	   only	   are	   there	  
interlocking	   and	   crossing-­‐over	   C-­‐termini	   helicies	   (δ1)	   and	   loops	   (δ2-­‐δ4),	   but	   also	  
these	   interactions	  extend	  as	   far	  as	  contributing	  to	  the	  binding	  pocket	  as	  seen	  with	  
the	  pink	  residues	  (Figure	  56).	  
	  
Figure	  55	  –	  Subunits	  5	  and	  6	  representing	  the	  major	  dimer	  interface	  of	  SyADH.	  Dimer	  interfaces	  denoted	  as	  δ;	  
δ1	  are	  the	  interlocking	  N-­‐termini	  helicies	  providing	  the	  predominant	  interaction,	  δ2-­‐δ4	  illustrate	  weaker	  dimer	  
interactions	  between	  helicies	  and	  loops.	  The	  electron	  density	  for	  NADPH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐
Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADPH.	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Residues	   B/Gln251	   and	   B/Ile249	   (Figure	   56)	   from	   the	   adjacent	   dimer	   aid	   the	  
formation	  of	  a	  hydrophobic	  pocket	  with	  Ala92,	  Val142,	  Phe148	  and	  Trp191	  as	  well	  as	  
the	   conserved	   potential	   catalytic	   residues	   Ser140,	   Try153	   and	   Lys157.	   Arg36	   in	  
SyADH	  mirrors	   the	   location	   and	   function	   of	   Arg	   38	   in	   RasADH,	   however	   Arg39	   in	  
RasADH	   is	   replaced	   by	   Asp37	   in	   SyADH	   that	   points	   away	   from	   the	   2’-­‐ribose	  
phosphate	  in	  NADPH,	  as	  such,	  the	  cofactor	  specificity	  for	  SyADH	  does	  not	  appear	  as	  
strict	  as	  RasADH.	  
	  
Figure	  56	   -­‐	  The	  binding	  pocket/groove.	  Catalytic	   triad	   in	   ice	  blue:	  Ser-­‐Try-­‐Lys	  other	   residue	  of	   the	  monomer	  
contributing	   to	   the	  binding	  pocket	   are	   in	  Green.	  Residues	   from	   the	  monomer	  are	  denoted	  as	   “A”.	  Residues	  
from	  the	  adjacent	  subunit	  of	  a	  dimer	  denoted	  as	  “B”	  and	  in	  pink	  are	  gln	  and	  ile,	  which	  are	  from	  the	  N-­‐terminus	  
helix.	  The	  electron	  density	  for	  NADPH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  
was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADPH.	  
Further	   evidence	   for	   the	   extensive	   contribution	   is	   observed	  with	   PISA	   analysis.	  
For	   the	  major	   dimer	   interface,	   potentially	   43	   hydrogen	   bonds	   and	   14	   salt	   bridges	  
contribute	  to	  the	  dimerising	   interaction.	  This	   is	  even	  further	  supported	  by	  the	  free	  
energy	  for	  the	  dimerisation,	  where	  ΔG	  =	  -­‐53.9	  kcal/M.	  
DALI	   analysis	   shows	   that	   there	   are	   structures	   available	   with	   only	   limited	  
sequence	   homology	   for	   SyADH.	   Even	   the	  model	   for	   the	   structure	   solution	   derived	  
from	   the	   NADPH-­‐dependent	   blue	   fluorescent	   protein	   (PDB	   entry:	   3P19)	   has	   a	  
relatively	   low	  sequence	  similarity	  of	  29%	  and	  an	  RMSD	  of	  2.0	  Å	  over	  239	  residues.	  
The	  tetrameric	  sepiaterin	  reductase	  from	  Chlorobium	  tepidum	   (PDB	  entry:	  2BD0)	   is	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also	  a	  NADPH-­‐dependent	  oxidoreductase	  that	  has	  a	  low	  sequence	  similarity	  of	  25%	  
with	   an	   RMSD	   of	   2.0	   Å	   over	   240	   residues.	  Many	   of	   the	   targets	   identified	   by	   DALI	  
have	   similar	   function	   to	   the	   SDR	   family,	   in	   that	   they	   have	   evolved	   to	   accept	   very	  
bulky	  substrates	  such	  as	  steroids,	  like	  the	  11β-­‐hydroxysteroid	  dehydrogenase	  type	  1	  
from	   Mus	   musculus	   (PDB	   entry:	   3GMD).	   However,	   the	   11β-­‐hydroxysteroid	  
dehydrogenase	  only	  has	  a	  sequence	  similarity	  of	  18%	  and	  an	  RMSD	  of	  3.0	  Å	  over	  264	  
residues.	   As	   such,	   the	   fold	   that	   SyADH	   exhibits	   appears	   to	   resemble	   the	   ability	   to	  
accept	  bulky	  substrates.	  
	   The	  superimposition	  of	  active	  sites	  (Figure	  57)	  for	  RasADH	  (ice	  blue)	  and	  SyADH	  
(coral)	  illustrate	  the	  side-­‐chain	  components	  of	  the	  hydrophobic	  tunnel	  in	  both	  active	  
sites.	  NADPH	  sits	  at	  the	  base	  of	  the	  tunnel	   for	  both	  enzymes	  with	  residues	  sharing	  
significant	   homology:	   Tyr153	   (RasADH-­‐Tyr150),	   Ser140	   (Ser137),	   Met150	   (His147)	  
and	  Val141	  (Val138)	  are	  conserved	  with	  respect	  to	  steric	  bulk.	   Interestingly	   in	  both	  
cases,	   phenylalanine	   and	   leucine	   appears	   to	   play	   a	   role	   in	   closing	   the	   top	   of	   the	  
hydrophobic	   tunnels.	  However	   they	  are	  mirrored	   in	  each	  enzyme,	  with	  Phe205	  on	  
the	   left	   and	   Leu144	   on	   the	   right	   in	   RasADH,	   whereas	   Phe148	   is	   on	   the	   right	   and	  
Leu201	  is	  on	  the	  left	  in	  SyADH.	  
	  
Figure	  57	  –	  Comparison	  of	  active	  site	  with	  RasADH	  (ice	  blue)	  and	  SyADH	  (coral).	  Majority	  of	  the	  residues	  share	  
significant	  homology,	  however	  residues	  Phe205	  and	  Leu144	  in	  RasADH	  are	  opposite	  locations	  to	  Phe148	  and	  
Leu201	  in	  SyADH.	  
Despite	  these	  similarities	  in	  the	  active	  site,	  there	  are	  three	  residues	  that	  give	  rise	  to	  
larger	   steric	   bulk	   in	   RasADH	   (Figure	   58):	   Ala92	   (equivalent	   to	   Ile91	   in	   RasADH),	  
Ala146	  (Leu142)	  and	  Ala194	  (Gln191).	  This	  suggests,	  at	  least	  superficially,	  that	  SyADH	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has	   the	   greater	   active	   site	   volume	   and	   would	   bind	   substrates	   less	   tightly	   than	  
RasADH	  which	  could	  be	  the	  basis	  for	  observing	  lower	  enantioselectivies.	  
	  
Figure	  58	  -­‐	  Steric	  bulk	  differences	   in	  the	  active	  sites	  of	  RasADH	  (ice	  blue)	  and	  SyADH	  (coral).	  Where	  RasADH	  
has	  larger	  steric	  bulk	  with	  residues	  Gln191,	  Ile91	  and	  Leu142	  compared	  to	  Ala194,	  Ala92	  and	  Ala	  145	  in	  SyADH.	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3.3.	  Modelling	  with	  AutoDock4	  
	  
Both	   RasADH	   and	   SyADH	   were	   subjected	   to	   modelling	   (Section	   2.7.)	   with	  
AutoDock4	  and	  AutoDock	  Vina	   in	  an	  attempt	   to	   rationalise	   the	  molecular	  basis	   for	  
recognition	   of	   ‘bulky-­‐bulky’	   ketones.	   The	   ligand	   PPK	   (Figure	   59)	   was	   used	   as	   the	  





Figure	  59	  –	  Due	  to	  the	  solubility	  in	  water	  of	  the	  substrate	  n-­‐Phenyl	  pentyl	  ketone	  (PPK),	  it	  was	  not	  possible	  to	  
use	  for	  co-­‐crystallisation	  experiments.	  As	  such,	  PPK	  was	  modelled	  into	  the	  active	  site	  using	  the	  docking	  suite	  
AutoDock	  (Section	  2.7.2.).	  	  
The	  ligand	  was	  built	  using	  methods	  described	  in	  (Section	  2.7.1.)	  to	  generate	  the	  
appropriate	  coordinate	  files	  and	  REFMAC5	  dictionary.	  RasADH,	  SyADH	  and	  PPK	  were	  
prepared	  in	  AutoDockTools	  (Section	  2.7.2.),	  and	  then	  docking	  into	  the	  active	  site	  was	  
attempted.	   AutoDock	   Vina	   had	   yielded	   more	   accurate	   results	   than	   AutoDock4	   as	  
well	   as	   providing	   additional	   information	   on	   potential	   interacting	   residues.	   The	  
docking	  results	  are	  shown	  below	  (Figure	  60	  and	  Figure	  61):	  
O
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Figure	  60	  -­‐	  SyADH	  docking	  with	  PPK.	  Key	  catalytic	  residue	  distances	  are	  shown	  with	  closely	  interacting	  residues	  
as	   calculated	   from	  AutoDockVina.	   Again,	   PPK	   bound	   in	   a	   hydrophobic	   pocket,	   however	   PPK	   is	   able	   to	   fully	  
extend	  its	  alkyl	  chain.	  
The	  most	  noticeable	  feature	  is	  that	  PPK	  is	  bound	  in	  a	  hydrophobic	  pocket	  in	  both	  
enzymes	  with	   residues	   of	   similar	   function.	   SyADH’s	   active	   site	   (Figure	   60)	   exhibits	  
potential	   π-­‐stacking	   interaction	  with	   PPK	   and	   Phe148	  which	  would	   allow	   aromatic	  
substrates	  to	  bind	  in	  a	  fixed	  conformation.	  Where	  as	  in	  RasADH	  (Figure	  61),	  the	  main	  
driving	  force	  for	  binding	  PPK,	  besides	  the	  catalytic	  residues,	   is	  due	  to	  the	  potential	  
hydrophobic	   interactions	  with	   the	  binding	  pocket.	   In	  both	  cases,	   the	  alkyl	   chain	  of	  
PPK	  is	  fixed	  in	  the	  hydrophobic	  tunnel	  allowing	  for	  the	  re-­‐face	  to	  be	  presented	  to	  the	  
active	  residues	  resulting	  in	  the	  (S)-­‐alcohol	  product.	  However	  SyADH	  presents	  a	  more	  
favourable	  hydrophobic	  interaction	  between	  the	  alkyl	  chain	  and	  Trp191.	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Figure	   61	   -­‐	   RasADH	   docking	   with	   PPK.	   Key	   catalytic	   residue	   distances	   are	   shown	   with	   closely	   interacting	  
residues	  as	  calculated	  from	  AutoDockVina.	  Most	  noticeably	  is	  PPK	  bound	  in	  a	  hydrophobic	  pocket	  also	  unable	  
to	  fully	  extend	  the	  alkyl	  chain.	  	  
Superposing	  both	  docking	  results	  upon	  NADPH	  (Figure	  62)	  enables	  comparisons	  
of	  binding	  between	  the	  two	  enzymes.	  Figure	  62	  clearly	  illustrates	  why	  the	  alkyl	  chain	  
is	  unable	  to	  fully	  extend	  in	  RasADH,	  as	  Gln191	  is	  effectively	  pushing	  the	  chain	  away.	  
This	   poses	   as	   structural	   evidence	   for	   RasADH	   being	   unable	   to	   accommodate	   less	  
flexible,	   aromatic,	   ‘bulky-­‐bulky’	   substrates,	   supporting	   substrate	   specificity	   studies	  
by	  Kulig	  and	  co-­‐workers	  in	  2012	  (26).	  The	  larger	  hydrophobic	  tunnel	  of	  SyADH	  may	  
accommodate	   such	   substrates	   favourably	   interacting	  with	   Trp191.	   Despite	   a	  more	  
favourable	   interaction	   between	   the	   alkyl	   chain	   and	   Trp191	   in	   SyADH,	   the	   larger	  
hydrophobic	  tunnel	  may	  hinder	  the	  enantioselectivity	  for	  PPK,	  99%	  and	  97%	  e.e.	  for	  
RasADH	   and	   SyADH	   respectively.	   This	   also	   suggests	   a	   basis	   for	   SyADH’s	   non-­‐
selectivity	  towards	  smaller	  prochiral	  ketones,	  as	  hypothesised	  by	  Lavandera	  and	  co-­‐
workers	  in	  2008	  (30).	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Figure	  62	  –	  RasADH-­‐Gln191	  and	  SyADH-­‐Trp191	  are	  potential	  residues	  for	  differentiating	  substrate	  specificities.	  
Conformational	  differences	  of	  PPK	  result	  from	  residues	  SyADH-­‐Trp191	  and	  RasADH-­‐Gln191.	  PPK	  is	  able	  to	  slot	  
into	  the	  pocket	  due	  to	  Trp191	  in	  SyADH.	  PPK	  is	  forced	  to	  curl-­‐up	  due	  to	  Gln191	  in	  RasADH.	  
	   Both	  models	   (Figure	   60	   and	  Figure	   61)	   propose	   that	  NADPH	  provides	   its	  pro-­‐S	  
hydride	   to	   attack	   the	   re-­‐face	   of	   PPK’s	   prochiral	   carbonyl.	   This	   suggests	   that	   both	  
enzymes	   reactions	   proceed	   by	   the	   ‘E4-­‐pathway’	   (42).	   Previously	   incorrect	  
assignment	   by	   Lerchner	   and	   co-­‐workers	   in	   2013	   (28)	   suggested	   that	   the	   pro-­‐R	  
hydride	  from	  NADPH	  was	  delivered	  to	  the	  re-­‐face	  of	  a	  prochiral	  ketone	  yielding	  the	  
(S)-­‐alcohol,	   suggesting	   for	   reactions	   proceeding	   by	   the	   ‘E3-­‐pathway’.	   Other	   ADHs	  
that	  follow	  the	  selectivity	  from	  the	  ‘E3-­‐pathway’	  are	  yeast	  ADH	  (YADH),	  HLADH	  and	  
TbADH	   (PDB	   entries:	   2HCY,	   6ADH	   and	   1KEV	   respectively)	   from	   the	   MDR	   family,	  
where	   the	   opposite	   face	   of	   the	   nicotinamide	   ring	   is	   presented	   to	   the	   active	   site,	  
through	  rotation	  about	   the	  nicotinamide-­‐ribose	  bond,	   relative	   to	   the	  conformation	  
observed	  with	  the	  SDRs.	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3.4.	  Structure-­‐Guided	  Mutation:	  RasADH	  I187A	  Mutant	  	  
	   The	   elucidation	   of	   the	   crystal	   structure	   of	   RasADH	   has	   allowed	   for	   further	  
structure-­‐guided	   engineering.	   Kulig	   and	   co-­‐workers	   recently	   showed	   that	   RasADH	  
has	  a	  very	  broad	  substrate	  spectrum,	  however	  there	  were	  still	  some	  substrates	  such	  
as	  benzoin	  (Figure	  63)	  and	  its	  derivatives	  that	  had	  negligible	  or	  no	  detected	  activity	  
with	   RasADH	   (26).	   Thus,	   the	   appropriate	   structure-­‐guided	   mutations	   for	   RasADH	  
could	   be	  made	   for	   RasADH	   to	   be	   a	   biocatalytic	   tool	   to	   oxidise	   or	   reduce	   sterically	  
demanding	  substrates	  like	  benzoin.	  
	  
	  	  
Figure	  63	  –	  The	  desired	  reaction	  for	  RasADH.	  The	  reduction	  or	  oxidation	  of	  benzoin	  like	  substrates.	  
	   The	  docking	  with	  PPK	   (Figure	   61)	  presented	   the	  potential	   interactions	  with	   the	  
catalytic	   residues.	   Using	   the	   same	   interactions	   as	   seen	   with	   PPK,	   benzoin	   was	  
manually	   docked	   into	   the	   active	   site	   (Figure	   64),	   such	   that	   the	  pro-­‐S	   nicotinamide	  
hydride	  was	  presented	  to	  the	  re-­‐face.	  
	  
Figure	  64	  	  -­‐	  Manual	  dock	  of	  benzoin	   in	   the	  active	  site	  of	  RasADH	  to	   rationalise	  why	  the	  active	  site	  could	  not	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3.4.1.	  Site-­‐Directed	  Mutagenesis	  
	  
It	  can	  be	  seen	  in	  the	  manual	  dock	  (Figure	  64)	  that	  Ile187	  may	  be	  causing	  a	  steric	  
clash	  with	  the	  substrate.	  As	  such,	  if	  a	  smaller	  residue	  was	  present	  at	  position	  187,	  it	  
may	  allow	  for	  benzoin	  and	  its	  derivatives	  to	  fit	  in	  the	  active	  site.	  Hence,	  the	  mutation	  
proposed,	  I187A	  (Figure	  65),	  would	  potentially	  allow	  the	  active	  site	  to	  accommodate	  
larger	  substrates.	  
	  
Figure	  65	  –	  The	  proposed	  mutation	  for	  RasADH	  at	  residue	  position	  187.	  Mutating	  Ile187	  to	  Ala187.	  
The	  proposed	  mutant	  I187A	  was	  successfully	  performed	  (Section	  2.2.	  and	  2.2.1.)	  and	  
confirmed	  by	  gene	  sequence	  analysis.	  
	  
3.4.2.	  Expression	  Test	   	  
	  
An	  expression	  test	   (Section	  2.3.4.1.)	  was	  performed	  to	  analyse	  the	  solubility	  of	  the	  
mutant	  in	  solution.	  BL21	  (DE3)	  was	  chosen	  as	  the	  expression	  strain.	  Surprisingly	  the	  
mutant	  expresses	  much	  better	  and	  in	  much	  higher	  soluble	  yields	  than	  the	  wild	  type	  
(Figure	  66).	  The	  expression	  test	  samples	  were	  analysed	  by	  SDS-­‐PAGE	  (Section	  2.3.3.	  
and	  2.3.3.1.).	  Expression	  at	  16°C	  overnight	  after	  induction	  yielded	  best	  results.	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Figure	   66	   –	   Expression	   test	   of	   RasADH	   I187A	   in	   BL21	   (DE3)	   expression	   strain.	   The	   mutant	   yielded	   better	  
expression	  as	  well	  as	  more	  soluble	  protein.	  	  
3.4.3.	  Purification	   	  
	  
The	  same	  purification	  protocol	  that	  was	  used	  to	  purify	  RasADH	  wt	  (Section	  3.1.2)	  
was	  used	  to	  successfully	  purify	  RasADH	  I187A	  by	  nickel	   IMAC	  (Section	  2.4.3.).	  After	  
nickel	   purification,	   the	  mutant	  was	   concentrated	   above	   5	  mg/mL	  without	   signs	   of	  
aggregation.	  As	  such,	  the	  mutant	  was	  much	  more	  stable	  in	  solution	  compared	  to	  the	  
wild	  type.	  
	  
Figure	  67	  –	  SDS-­‐PAGE	  analysis	  of	  RasADH	  I187A	  after	  nickel	  purification.	  
Following	   nickel	   purification	   (Figure	   67),	   RasADH	   I187A	   was	   purified	   by	   SEC	  
(Section	   2.4.4.).	   Interestingly,	   the	   second	   peak	   at	   approximately	   100	   mL	   elution	  
volume	  was	  nearly	  undetectable	  (Figure	  68).	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Figure	  68	  –	  Chromatagram	  for	  RasADH	  I187A	  purification	  by	  SEC.	  The	  peak	  between	  40-­‐60	  mL	  represents	  the	  
dimeric	  form	  of	  the	  mutant.	  
	   Protein	  purity	  after	  SEC	  was	  confirmed	  by	  SDS-­‐PAGE	  analysis	  (Section	  2.3.3.	  and	  
2.3.3.1).	   The	   protein	   was	   sufficiently	   pure	   (Figure	   69)	   for	   further	   characterisation	  
experiments	  by	  UV-­‐VIS	  kinetics	  and	  biotransformations.	  
	  
Figure	  69	  –	  SDS-­‐PAGE	  analysis	  of	  RasADH	  I187A	  after	  SEC.	  The	  gel	  suggests	  the	  protein	  is	  sufficiently	  pure	  for	  
further	  characterisation.	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3.4.4.	  Kinetics	  
	   	  
The	  mutant	  I187A	  was	  predicted	  to	  reduce	  the	  carbonyl	  with	  NADPH	  (Figure	  70).	  
Using	  UV-­‐VIS	  spectroscopy,	  the	  reaction	  was	  monitoring	  the	  depletion	  of	  NADPH	  at	  
340	  nm	  by	  an	  absorbance-­‐time	  scan.	  
	  
	  	  
Figure	  70	  –	  Schematic	  of	  the	  predicted	  reaction	  for	  the	  RasADH	  187A	  mutant.	  
	   However,	   due	   to	   the	   very	   limited	   solubility	   of	   benzoin	   in	   buffer,	   the	   reaction	  
could	  not	   be	  monitored	   in	   solution.	   	  Despite	  optimising	   the	  buffer	  with	   additional	  
water	  miscible	  solvents,	  phase	  separation	  would	  occur	  with	  the	  substrate	  forming	  an	  
oil	  drop	  and	  the	  reaction	  cell	  becoming	  turbid.	  
	  
3.4.5.	  GC	  Analysis	  
	  
	   GC	  analysis	  was	  also	  attempted	  to	  monitor	  the	  kinetics	  parameters	   for	  RasADH	  
I87A	   with	   the	   substrate	   benzoin.	   However,	   the	   results	   for	   the	   control	   conditions	  
without	   enzyme	  were	   identical	   to	   the	   reaction	  with	   enzyme.	   Therefore,	   the	   I187A	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3.5.	  TADH	  
	  
TADH	   is	   an	   MDR	   from	   Thermus	   sp.	   Serena	   Gargiulo	   from	   Delft	   University	   of	  
Technology	   in	   Delft	   had	   cloned	   the	   gene	   encoding	   TADH,	   expressed,	   purified	   and	  
crystallised	   the	   protein.	   Purification	  was	   performed	   in	   one	   step	   by	   denaturing	   the	  
lysate	  except	  for	  the	  desired	  protein	  due	  to	  its	  thermophilic	  properties	  and	  purifying	  
with	   SEC.	   TADH	   has	  major	   benefits	   as	   a	   biocatalyst	   in	   that	   it	   utilises	   NADH	   (over	  
NADPH),	   has	   a	   very	  broad	   substrate	   specificity	   producing	   enatiomerically	   pure	   (S)-­‐
alcohols,	   such	  as	   (S)-­‐2-­‐pentaol	   (>99%	  e.e.)	   from	  2-­‐pentanone	  and	   it	   is	   also	   able	   to	  
tolerate	  up	  to	  10%	  v.v	  water-­‐miscible	  solvents.	  	  
	  
The	  data	  collection	  and	  refinement	  statistics	  for	  TADH	  are	  shown	  below	  (Table	  3):	  
	   TADH	  
Beamline	   Diamond	  I04-­‐1	  
Wavelength	  (Å)	   0.91999	  
Resolution	  (Å)	   48.22	  -­‐	  2.74	  (2.91-­‐2.74)	  
Space	  Group	   P3121	  
Unit	  Cell	  (Å)	   a	  =	  b	  =	  87.36;	  c	  =	  337.56;	  α	  =	  β	  =	  90;	  γ	  =	  120	  
No.	  of	  molecules	  in	  
the	  asymmetric	  unit	   4	  
Unique	  reflections	   40559	  (6444)	  
Completeness	  (%)	   99.9	  (99.4)	  
Rmerge	  (%)	   0.09	  (0.50)	  
Rp.i.m.	   0.03	  (0.15)	  
Multiplicity	   12.2	  (11.9)	  
<I/σ(I)>	   22.2	  (4.9)	  
CC1/2	   0.99	  (0.81)	  
Overall	  B	  factor	  from	  
Wilson	  plot	  (Å2)	   54	  
Rcryst/Rfree	  (%)	   19.6/24.6	  
No.	  protein	  atoms	   10147	  
No.	  water	  molecules	   165	  
r.m.s.d.	  1-­‐2	  bonds	  (Å)	   0.01	  
r.m.s.d.	  1-­‐3	  bonds	  (°)	   1.53	  
Avge	  main	  chain	  B	  (Å2)	   56	  
Avge	  side	  chain	  B	  (Å2)	   60	  
Avge	  water	  B	  (Å2)	   44	  
Avge	  ligand	  B	  (Å2)	   65	  
PDB	  entry	   To	  be	  deposited	  
	  
Table	  3	  -­‐	  The	  data	  collection	  and	  refinement	  statistics	  for	  TADH.	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3.5.1.	  Structure	  Building	  
	  
The	   structure	   of	   TADH	   was	   solved	   using	   the	   molecular	   replacement	   program	  
MOLREP.	  A	  monomer	  model	  was	  derived	   from	  Pseudomonas	  putida	   formaldehyde	  
dehydrogenase	  (PDB	  entry:	  1KOL).	  The	  structure	  solution	  contained	  four	  subunits	  in	  
the	   asymmetric	   unit	   assembling	   a	   homotetramer.	   The	   structure	   was	   built	   and	  
refined	  with	   iterative	  cycles	  of	  COOT	  and	  REFMAC5	  with	   local	  NCS	  restraints.	  Once	  
the	   model	   for	   TADH	   was	   built	   and	   refined	   to	   a	   satisfactory	   level,	   the	   omit	   map,	  
revealed	  residual	  electron	  density	  for	  NADH	  to	  be	  rationally	  assigned	  and	  refined	  in	  
three	   of	   the	   four	   active	   sites.	   Additionally,	   two	   zinc	   sites	   per	   subunit	   could	   be	  
assigned	   for	   the	  active	  site	  and	   the	  structural	   site.	  TADH	  was	  built	   (Figure	   71)	  and	  
refined	  to	  Rcryst/Rfree	  values	  of	  20.2%/24.2%.	  
	  
	  
Figure	  71	  -­‐	  The	  asymmetric	  unit	  for	  TADH	  is	  a	  tetramer	  with	  NADH	  bound	  in	  3	  of	  4	  active	  sites.	  Each	  subunit	  for	  
TADH	  is	  denoted	  as	  T.	  The	  electron	  density	  for	  NADH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  
level	  of	  3σ	  which	  was	  obtained	  after	  refinement	  in	  the	  absence	  of	  NADH.	  	   A	  monomer	  of	  TADH,	  represented	  by	  subunit	  T4	  (Figure	  72)	  is	  comprised	  of	  two	  
distinct	   domains,	   a	  metal	   binding	   domain	   and	   a	   nucleotide	   Rossman	   fold	   domain.	  
The	  metal	   binding	   domain	   is	   supported	  by	   an	   array	   of	   β-­‐sheet	   core	   formed	  by	   β1	  
(residues	   2-­‐6),	   β2	   (12-­‐16),	   β3	   (27-­‐36),	   β4	   (55-­‐56),	   β5	   (61-­‐68),	   β6	   (80-­‐82),	   β7	   (125-­‐
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peripheries:	  α1	   (42-­‐45),	  α2	   (93-­‐97),	  α3	   (131-­‐134),	  α4	   (144-­‐147)	  and	  α12	  (326-­‐335).	  
At	  the	  centre	  of	  TADH,	  α11	  (residues	  296-­‐308)	  lies	  at	  the	  base	  of	  the	  cleft	  forming	  an	  
axis	  between	  the	  two	  domains.	  The	  nucleotide	  binding	  domain	  is	  formed	  by	  a	  classic	  
Rossman	   fold	   with	   a	   central	   β-­‐sheet	   formed	   from	   six	   alternating	   helicies	   and	   β-­‐
sheets	  by	  β9	  (residues	  172-­‐175),	  β10	  (196-­‐200),	  β11	  (215-­‐218),	  β12	  (239-­‐242),	  β13	  
(262-­‐266),	   β15	   (286-­‐290)	   along	  with	   β14	   (273-­‐277)	   on	   the	   periphery.	   The	   helicies	  
encompassing	  the	  β-­‐sheet	  is	  formed	  by	  α5	  (153-­‐164),	  α6	  (179-­‐191),	  α7	  (203-­‐212),	  α8	  
(224-­‐231),	  α9	  (247-­‐256)	  and	  α10	  (279-­‐284).	  
	  
Figure	  72	  -­‐	  A	  monomer	  of	  TADH,	  represented	  by	  T4,	  displaying	  the	  Rossman	  fold	  and	  metal	  binding	  domains.	  
Only	  three	  of	   the	   four	  active	  sites	  of	  TADH	  are	  bound	  to	  NADH.	  As	  such,	  when	  
superimposing	   subunits	   T2	   (apo)	   in	   coral	   and	   T4	   (holo)	   in	   ice	   blue	   (Figure	   73),	   it	  
appears	   α11	   is	   the	   axis	   upon	   which	   the	   two	   domains	   may	   close	   in	   for	   cofactor	  
binding.	  It	  is	  apparent	  that	  upon	  cofactor	  binding,	  secondary	  structure	  is	  conserved	  
however	  there	  is	  a	  small	  degree	  of	  displacement	  (RMSD	  of	  0.86	  Å	  over	  346	  residues).	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The	  nicotinamide	  cofactor	  resides	  in	  the	  centre	  of	  the	  cleft	  of	  a	  TADH	  monomer	  
with	   strict	   selectivity	   towards	   NADH	   due	   to	   Asp200	   repelling	   any	   potential	  
phosphate	   groups	   bound	   to	   the	   2’	   position	   of	   the	   ribose-­‐adenine	   ring.	   However	  
Arg201	   is	   near-­‐by	   allowing	   π-­‐stacking	   interaction	   with	   the	   adenine	   ring	   of	   the	  
cofactor.	  
	  
Figure	  73	  -­‐	  Subunits	  T2	  (apo)	  coral	  and	  T4	  (holo)	  ice	  blue	  displaying	  displacement	  in	  cofactor	  binding.	  The	  two	  
domains	  close	  in	  when	  the	  cofactor	  is	  bound.	  
The	  potential	  ligands	  (Asp152,	  His53	  and	  Cys38)	  for	  the	  catalytic	  zinc	  (Figure	  74)	  
are	   similar	   to	   that	   of	   HLADH	   as	   studied	   by	   Eklund	   (31).	   It	   appears	   that	   the	   zinc	  
cofactor	   is	   highly	   conserved	   throughout	  MDRs	   not	   only	  with	   its	   catalytic	   function,	  
but	   also	   its	   structural	   role.	   In	   the	   case	   of	   the	   reduction	   of	   2-­‐pentanone	   to	   (S)-­‐2-­‐
pentanol,	  the	  re-­‐face	  of	  the	  prochiral	  carbonyl	  must	  be	  attacked.	  The	  positioning	  of	  
the	  cofactor	  suggests	  for	  the	  delivery	  of	  the	  pro-­‐R	  hydride	  to	  the	  relevant	  substrate,	  
in	   this	   case	   2-­‐pentanone.	   Therefore	   TADH	   reactions	   should	   proceed	   by	   the	   ‘E3-­‐
pathway’	  similar	  to	  YADH,	  HLADH	  and	  TbADH.	  
The	  active	  site	  for	  TADH	  is	  formed	  in	  the	  cleft	  between	  the	  two	  domains	  giving	  
rise	  to	  a	  hydrophobic	  tunnel	  formed	  by	  residues:	  Ser40	  (the	  potential	  proton	  donor),	  
Val108,	   Leu292,	   Val268,	   Ile49,	   Tyr111	   and	   Phe115.	   However	   due	   to	   the	   inherent	  
steric	  bulk	  exhibited	  by	  the	  active	  site	  residues,	  the	  hydrophobic	  tunnel	  appears	  very	  
narrow.	   Nevertheless,	   it	   is	   possible	   the	   active	   site	   could	   be	   more	   flexible	   than	   it	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seem	  allowing	  for	  the	  accommodation	  of	  larger	  substrates	  due	  to	  the	  axis	  between	  
the	  two	  domains	  and	  the	  substrate	  specificity	  is	  still	  relatively	  broad	  for	  MDRs.	  
	  
	  	  
Figure	   74	   –	   The	   active	   site	   of	   TADH	   in	   subunit	   T4,	   where	   zinc	   is	   coordinated	   to	   three	   protein	   ligands.	   The	  
electron	   density	   for	   NADH	   is	   generated	   from	   the	   omit	   map	   (Fo-­‐Fc)	   contoured	   to	   a	   level	   of	   3σ	   which	   was	  
obtained	  after	  refinement	  in	  the	  absence	  of	  NADH.	  
	   	  
Analysis	  with	  PISA	  shows	  the	  major	  dimer	  interface,	  represented	  by	  subunits	  T4	  
in	  ice	  blue	  and	  T1	  in	  black	  (Figure	  75),	  is	  formed	  from	  32	  hydrogen	  bonds	  and	  14	  salt	  
bridges.	  The	  Gibbs	  free	  energy	  for	  the	  dimer	  formation	  is	  relatively	  low,	  where	  ΔG	  =	  -­‐
13.1	  kcal/M.	  Despite	  many	  hydrogen	  bonds	  and	  salt	  bridges,	  the	  Gibbs	  free	  energy	  
for	  dimerisation	  is	  unusually	  low	  for	  MDRs.	  The	  free	  energy	  may	  suggest	  TADH	  has	  a	  
preference	   towards	   the	  monomeric	   form,	  however	   this	   is	   very	  unlikely	   due	   to	   the	  
favourable	  interactions	  between	  the	  dimer	  interface.	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Figure	  75	  –	  The	  major	  dimer	  interface	  for	  TADH	  represented	  by	  subunits	  T4	  (blue)	  and	  T1	  (black).	  The	  electron	  
density	  for	  NADH	  is	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  a	  level	  of	  3σ	  which	  was	  obtained	  after	  
refinement	  in	  the	  absence	  of	  NADH.	  
	   Aside	   from	   the	  model	   derived	   from	   formaldehyde	   dehydrogenase	   (PDB	   entry:	  
1KOL)	  that	  was	  used	  to	  solve	  the	  structure,	  DALI	  identified	  several	  metal-­‐dependent	  
MDRs.	   Such	   as	   the	   tetrameric	   formaldehyde	   dismutase	   from	  Pseudomonas	   putida	  
(PDB	  entry:	  2DPH)	  with	  a	  sequence	  similarity	  of	  28%	  and	  an	  RMSD	  of	  1.6	  Å	  over	  398	  
residues.	  The	  formaldehyde	  dismutase	  also	  utilises	  zinc	  and	  NADH	  as	  the	  cofactors	  
with	   oxidoreductase	   activity.	   DALI	   also	   identified	   the	   dimeric	   hypoxanthine	  
phosphorisosyltransferase	   from	   Trypanosomea	   cruzi	   (PDB	   entry:	   1P18)	   which	   has	  
sequence	  similarity	  of	  26%	  and	  an	  RMSD	  of	  1.8	  Å	  over	  356	  residues.	  Interestingly	  the	  
transferase	  utilises	  magnesium	  rather	   than	  zinc	   for	   transferase	  activity,	  where	   two	  
magnesium	   atoms	   binds	   the	   diphosphate	   substrate	   in	   an	   octahedral	   geometry,	  
rather	  than	  tetrahedrally	  with	  zinc	  in	  MDRs.	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3.6.	  CPCR2	  
	  
CPCR2	  is	  an	  MDR	  from	  Candida	  parapsilosis.	  Christoph	  Loderer	  from	  Technische	  
Universität	  Dresden	  in	  Dresden	  had	  previously	  cloned	  the	  gene	  encoding	  CPCR2	  into	  
a	   pET-­‐22b	   C-­‐terminus	   Strep-­‐tag	   vector,	   expressed	   and	   purified	   and	   attempted	   to	  
crystallise	  the	  Strep-­‐tag	  construct.	  However,	  there	  were	  no	  successes	  with	  previous	  
crystallisation	  experiments.	  
The	   pET-­‐22b	   vector	   allowed	   protein	   secretion	   in	   the	   periplasm	   due	   to	   a	   PelB	  
leader	   sequence.	   This	   can	   often	   lead	   to	   an	   increase	   in	   protein	   stability,	   which	  
allowed	   for	   chemical	   lysis	   with	   lysozyme	   and	   DNAse	   rather	   than	   mechanical	  
methods.	   However	   the	   protein	   yield	   from	   chemical	   cell	   lysis	   is	   not	   always	   be	  
reproducible.	   Despite	   periplasm	   secretion,	   CPCR2	   degraded	   in	   solution	   within	   48	  
hours	  of	  cell	  lysis	  at	  4°C.	  
CPCR2	  has	   very	   valuable	  properties	   as	   a	  biocatalyst.	   Such	  as,	   exhibiting	   a	  wide	  
substrate	  spectrum,	  nearly	  exclusively	  producing	  enantiomerically	  pure	  ‘bulky-­‐small’	  
(S)-­‐alcohols	  and	   its	  ability	  to	  retain	  all	  activity	   in	  neat	  substrate	  as	   lyophilised	  cells.	  
Mutational	   studies	  have	  been	  performed	  based	  on	  a	  high	  quality	  homology	  model	  
from	  the	  ADH	   from	  the	  archaeon	  Sulfolobus	  solfataricus	   (SsADH).	  However,	  SsADH	  
only	  has	  34%	  homology,	   therefore	  many	  regions	  may	  not	  be	  conserved.	  As	  such,	  a	  




The	  gene	  encoding	  CPCR2	  was	  sub-­‐cloned	  into	  the	  pET-­‐YSBLIC3C	  vector,	  which	  is	  
based	  on	  pET-­‐28a,	  promoting	  cytoplasmic	  expression.	  The	  vector	   fuses	  a	   cleavable	  
N-­‐terminal	  hexa	  His-­‐tag	  allowing	  for	  a	  much	  cheaper	  purification	  by	  IMAC.	  Strep-­‐tag	  
purification	  requires	  elution	  by	  biotin	  on	  a	  streptavidin	  column,	  where	  biotin	  is	  more	  
than	  three	  times	  the	  price	  of	  imidazole.	  	  
The	  template,	  received	  as	  a	  gift	  from	  Prof.	  Ansorge-­‐Schumacher,	  was	  successfully	  
amplified	   (Section	   2.1.1.),	   with	   the	   appropriate	   primers	   (Figure	   76	   -­‐	   left).	   After	  
purification	  and	  T4	  digest,	  the	   insert	  was	  annealed	  to	  the	  pET-­‐YSBLIC3C	  vector	  and	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transformed	  into	  Nova	  Blue	  cells	   for	  plasmid	  extraction	  (Sections	  2.1.4	  -­‐	  2.1.10.).	  A	  
double	  digest	  (Figure	  76	  -­‐	  right),	  with	  Nco1,	  Ndo1	  and	  buffer	  4	  was	  performed	  with	  
the	  plasmid	  after	  plasmid	  extraction	  (Section	  2.1.11.)	  to	  evaluate	  the	  presence	  of	  the	  
insert.	  
	  	  	   	  
Figure	  76	  –	  CPCR2	  1%	  agarose	  gel	  of	  PCR	  products	  (left)	  and	  double	  digest	  (right)	  of	  the	  plasmid	  with	  Nde1	  and	  
Nco1.	   The	   gels	   and	   samples	   were	   prepared	   as	   described	   in	   sections	   2.1.2	   and	   2.1.3.	   The	   1	   kb	   ladder	   was	  




The	  plasmid	  was	  transformed	  into	  BL21	  (DE3)	  and	  Rosetta	  2	  (DE3)	  for	  expression	  
testing	  (Section	  2.3.4.1.),	  as	  seen	  in	  Figure	  77.	  Cells	  were	  lysed	  by	  sonication	  (Section	  
2.3.6.1.).	   The	   observed	   overexpression	   in	   both	   strains	   was	   similar,	   however	   BL21	  
(DE3)	  resulted	  in	  greater	  amount	  of	  soluble	  protein	  at	  16°C.	  	  
	  
Figure	  77	  -­‐	  Expression	  test:	  Rossetta	  2	  (left)	  and	  BL21	  (right)	  performed	  using	  the	  methods	  described	  in	  section	  
2.2.4.1.	  Results	  show	  that	  greater	  soluble	  expression	  is	  achieved	  with	  BL21	  (DE3)	  strain.	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3.6.3.	  Purification	  
	  
CPCR2	  was	   known	   to	   be	   a	   very	   sensitive	   and	   difficult	   to	   handle	   protein	   in	   the	  
pET-­‐22b	  strep-­‐tag	  vector;	  after	  the	  strep-­‐tag	  purification	  protein	  concentration	  was	  
limited	   to	  5	  mg/mL	  and	  after	  SEC	  protein	   concentration	  was	   limited	   to	  10	  mg/mL.	  
Exceeding	  those	  limits	  would	  cause	  protein	  aggregation.	  	  
Cobalt	   was	   chosen	   as	   the	   divalent	   metal	   for	   IMAC.	   Cobalt	   is	   known	   to	   have	  
higher	  selectivity	  for	  histidine,	  however	  the	  binding	  affinity	  is	  lower	  than	  nickel.	  The	  
benefit	  of	  using	  cobalt	  was	  to	  reduce	  non-­‐specific	  binding	  and	  allow	  the	  protein	  to	  
elute	   at	   lower	   concentrations	  of	   imidazole	   (Figure	   78).	   Purification	  by	  nickel	   IMAC	  




Figure	  78	  –	  SDS-­‐PAGE	  analysis	  of	  CPCR2	  purified	  by	  cobalt	  IMAC.	  Lane	  1	  is	  a	  Low	  Molecular	  Weight	  Ladder	  from	  
BioRad.	  Lane	  2	  and	  3	  are	  samples	  from	  20	  mM	  and	  50	  mM	  imidazole	  wash	  steps.	  Lane	  4-­‐15	  are	  samples	  from	  
the	  elution	  gradient.	  Gel	  and	  sample	  preparation	  were	  performed	  as	  described	  in	  Section	  2.3.3.	  and	  2.3.3.1.	  
	  
The	   His-­‐tag	   construct	   was	   noticeably	   more	   soluble;	   after	   cobalt	   purification	   it	  
was	  possible	  to	  concentrate	  the	  protein	  beyond	  100	  mg/mL	  with	  no	  signs	  of	  protein	  
aggregation.	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Figure	  79	  -­‐	  Chromatagram	  of	  the	  SEC	  purification	  of	  CPCR2	  from	  a	  6	  L	  culture	  preparation.	  Elution	  between	  40-­‐
60	  mL	  would	  represent	  the	  dimer	  form	  of	  CPCR2,	  elution	  at	  100	  ml	  would	  be	  the	  monomer.	  
CPCR2	  was	   further	   purified	   by	   SEC	   (Figure	   79).	   Comparing	  with	   the	   calibration	  
curve	  for	  the	  Hiload	  16/60	  Superdex	  75	  Prep	  Grade,	  the	  first	  peak	  between	  40-­‐60	  mL	  
elution	  volume	  is	  believed	  to	  be	  the	  dimeric	  form.	  The	  second	  peak	  at	  100	  ml	  elution	  
volume	  is	  most	  likely	  the	  monomeric	  form.	  This	  suggests	  CPCR2	  primarily	  exists	  as	  a	  




CPCR2	  was	  screen	  with	   INDEX,	  PACT	  and	  CSS	  1	  +	  2	  crystallisation	  screens	  at	  21	  
mg/mL.	  The	  most	  promising	  hits	  were	  found	   in	   INDEX	  after	  24	  hours,	  however	  the	  
crystals	  formed	  had	  very	  thin	  needle	  like	  morphology.	  The	  condition	  was	  successfully	  
optimised	   using	   hanging	   drop	   vapour	   diffusion	   method	   (Section	   2.6.1)	   with	   the	  
addition	   of	   additives	   producing	   much	   larger	   crystals	   (Figure	   80	   –	   left).	   The	   best	  
crystals	  were	  formed	  in	  0.1	  M	  Tris-­‐HCl	  pH	  8.0,	  30%	  (w/v)	  PEG	  3350	  and	  2-­‐methyl-­‐1,4-­‐
pentanediol	   (40%	   v/v)	   at	   69	   mg/mL	   protein	   concentration.	   For	   an	   apo-­‐structure,	  
crystals	  were	  flash	  cooled	  in	  liquid	  nitrogen	  prior	  to	  in-­‐house	  diffraction	  analysis.	  For	  
NADH	  and	  NAD+	  complexes,	  crystals	  were	  soaked	  in	  solutions	  of	  mother	  liquor	  with	  
additional	  20	  mM	  NADH	  and	  NAD+	   respectively	  prior	   to	   flash	  cooling	  and	   in-­‐house	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diffraction	   analysis	   (Figure	   80	   –	   right).	   The	   best	   diffracting	   crystals	   were	   sent	   to	  
Diamond,	  Dicot	  for	  full	  dataset	  collection	  on	  the	  I03	  beamline	  on	  2nd	  May	  2013,	  I02	  
beamline	  on	  22nd	  June	  2013	  and	  I04-­‐1	  beamline	  on	  14th	  July	  for	  the	  apo,	  NADH	  and	  
NAD+	  datasets	  respectively.	  
	   	  
Figure	  80	  –	  Protein	  crystals	  (left)	  of	  CPCR2	  in	  conditions	  containing	  0.1	  M	  Tris-­‐HCl	  pH	  8.0,	  30%	  (w/v)	  PEG	  3350	  
and	   2-­‐methyl-­‐1,4-­‐pentanediol	   (40%	   v/v)	   at	   69	   mg/mL	   protein	   concentration	   with	   its	   in-­‐house	   diffraction	  
pattern	  (right).	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The	  data	  collection	  and	  refinement	  statistics	  for	  CPCR2	  in	  complex	  with	  NADH	  (72)	  is	  
shown	  below	  (Table	  4):	  
	  
	   CPCR2	  (NADH	  complex)	  
Beamline	   Diamond	  I02	  
Wavelength	  (Å)	   0.97949	  
Resolution	  (Å)	   58.13-­‐2.05	  (2.13-­‐2.05)	  
Space	  Group	   P211	  
Unit	  Cell	  (Å)	   a	  =	  66.72;	  b	  =	  88.84;	  c	  =	  118.20;	  α	  =	  γ	  =	  90.0;	  β	  =	  100.4	  
No.	  of	  molecules	  in	  the	  
asymmetric	  unit	   4	  
Unique	  reflections	   85098	  (6264)	  
Completeness	  (%)	   99.9	  (100)	  
Rmerge	  (%)	   0.04	  (0.58)	  
Rp.i.m.	   0.04	  (0.49)	  
Multiplicity	   4.1	  (4.1)	  
<I/σ(I)>	   18.7	  (2.1)	  
CC1/2	   0.99	  (0.67)	  
Overall	  B	  factor	  from	  
Wilson	  plot	  (Å2)	   34	  
Rcryst/Rfree	  (%)	   20.5/24.1	  
No.	  protein	  atoms	   9259	  
No.	  water	  molecules	   243	  
r.m.s.d.	  1-­‐2	  bonds	  (Å)	   0.018	  
r.m.s.d.	  1-­‐3	  bonds	  (°)	   1.99	  
Avge	  main	  chain	  B	  (Å2)	   46	  
Avge	  side	  chain	  B	  (Å2)	   49	  
Avge	  water	  B	  (Å2)	   42	  
Avge	  ligand	  B	  (Å2)	   49	  
PDB	  entry	   4C4O	  
	  
Table	  4	  -­‐	  The	  data	  collection	  and	  refinement	  statistics	  for	  CPCR2	  in	  complex	  with	  NADH.	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3.6.5.	  Structure	  Solution	  and	  Model	  Building	  
	  
	   The	   initial	   crystal	   structure	   for	   the	   2.8	   Å	   apo-­‐dataset,	   was	   solved	   with	   the	  
automated	   molecular	   replacement	   program	   BALBES.	   A	   dimer	   model	   was	   derived	  
from	  the	  tetramer	  structure	  of	  the	  ADH	  from	  Bacillus	  stearothemophilus	  (PDB	  entry:	  
1RJW).	  The	  structure	  solution	  revealed	  four	  subunits	  assembling	  as	  a	  tetramer	  in	  the	  
asymmetric	   unit.	   The	  apo-­‐structure	  was	   built	   and	   refined	  with	   iterative	   rounds	   of	  
building	   and	   refinement	   with	   COOT	   and	   REFMAC5	   to	   Rcryst/Rfree	   values	   of	  
22.0%/26.1%.	  Subsequent	  2.0	  Å	  NADH	  and	  2.3	  Å	  NAD+	  datasets	  were	  solved	  using	  a	  
monomer	   model	   of	   the	   refined	   apo-­‐structure,	   both	   revealing	   a	   tetramer	   in	   the	  
asymmetric	  unit.	  Once	  both	  complex	  models	  had	  been	  built	   to	  a	  satisfactory	   level,	  
the	  omit	  map	  revealed	  density	  for	  the	  nicotinamide	  cofactor	  in	  all	  four	  active	  sites.	  
However,	   higher	   resolution	   (>1.5	   Å)	   is	   required	   to	   differentiate	  whether	   NADH	   or	  
NAD+	   is	   bound,	   as	   the	   nicotinamide	   ring	   is	   bent	   in	   NADH	   due	   to	   the	   loss	   in	  
aromaticity.	  The	  two	  complexes	  were	  identical,	  as	  such,	  only	  the	  NADH	  complex	  was	  
fully	  built	  and	  refined.	  The	  NADH	  complex	  was	  built	  and	  refined	  to	  Rcryst/Rfree	  values	  
of	  20.6%/24.5%	  (Figure	  81).	  	  
	  
Figure	  81	  –	  The	  tetrameric	  model	  of	  NADH-­‐complex	  in	  the	  asymmetric	  unit.	  Each	  subunit	  for	  CPCR2	  is	  denoted	  
as	  C.	  The	  electron	  density	  for	  the	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	  
	   The	   overall	   structural	   fold	   of	   CPCR2	   is	   similar	   to	   many	   other	   MDRs,	   with	   a	  
monomer	  represented	  by	  subunit	  C1	  consisting	  of	  a	  metal	  binding	  catalytic	  domain	  
with	   a	   Rossman	   fold	   nucleotide	   binding	   domain	   (Figure	   82).	   The	   metal	   binding	  
domain	  is	  β-­‐strand	  rich	  featuring	  ten	  strands:	  β1	  (residues	  6-­‐7),	  β2	  (9-­‐13),	  β3	  (17-­‐21),	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β4	   (24-­‐25),	   β5	   (34-­‐42),	   β6	   (60-­‐62),	   β7	   (67-­‐74),	   β8	   (85-­‐89),	   β9	   (128-­‐131),	   β10	   (137-­‐
139)	   and	   a	   helix	   from	   the	   N-­‐terminus	   α1	   (47-­‐52).	   The	   metal	   binding	   domain	   is	  
connected	   by	   helix	   α2	   (142-­‐166)	   leading	   into	   the	   nucleotide	   binding	   domain	  
consisting	  of	  a	  typical	  Rossman	  fold	  of	  a	  central	  β-­‐sheet	  in	  the	  domain	  including	  β11	  
(173-­‐177),	   β12	   (217-­‐219),	   β13	   (233-­‐236),	   β14	   (256-­‐260),	   β15	   (266-­‐270)	   and	   β16	  
(280-­‐282)	  which	  is	  encased	  by	  five	  helices:	  α3	  (181-­‐193),	  α4	  (204-­‐213),	  α5	  (241-­‐251),	  
α6	   (241-­‐251)	   and	   α7	   (271-­‐277).	   The	   helix	   α8	   (289-­‐301)	   in	   the	   cleft	   between	   two	  
domains	  forms	  a	  pivot	  point	  for	  the	  two	  domains	  to	  close	  in	  on	  nucleotide	  binding	  as	  
mentioned	   earlier	   with	   TADH.	   Following	   the	   pivot,	   two	   peripheral	   β-­‐strands	   [β17	  
(308-­‐312)	  and	  β18	  (331-­‐335)]	  are	  accompanied	  by	  helix	  α9	  (316-­‐325)	  completing	  the	  
catalytic	  metal	  binding	  domain.	  
	  
Figure	  82	  -­‐	  A	  monomer	  of	  CPCR2	  represented	  by	  subunit	  C1	  displaying	  the	  catalytic	  metal	  binding	  domain	  and	  
the	  nucleotide	  binding	  domain.	  
NADH	  is	  bound	  between	  the	  cleft	  of	  the	  two	  domains	  with	  Lys202	  providing	  π-­‐
stacking	   interactions	  with	   adenine	   group	   and	   ribose	   hydroxyl	   groups	   anchored	   by	  
interactions	  with	  Asp201.	  The	  acidic	  residue	  dictates	  the	  strict	  specificity	  of	  the	  non-­‐
phosphorylated	   cofactor	   in	   CPCR2.	   Further	   interactions	   are	   made	   with	   His49	   and	  
Ser46,	  the	  potential	  proton	  donor,	  to	  the	  2’-­‐hydroxyl	  on	  the	  ribose	  adjacent	  to	  the	  
nicotinamide	  group.	  The	  cofactor	  lies	  at	  the	  base	  of	  the	  cleft	  in	  a	  very	  hydrophobic	  
	  	   115	  
pocket	  featuring	  residues:	  Leu55,	  Val50,	  Leu119,	  Trp116,	  Pro92,	  Trp286,	  Phe285	  and	  
Leu262.	   Despite	   the	   inherent	   steric	   bulk	   displayed	   by	   the	   residues	   in	   the	   binding	  
pocket,	  the	  active	  site	  is	  exposed	  and	  therefore	  relatively	  large	  compared	  to	  TADH.	  
The	  nicotinamide	   ring	  of	  NADH	   is	  bound	   in	  a	   conformation	   that	  would	  present	  
the	  pro-­‐R	  hydride	  of	  NADH	  to	  the	  active	  site	  (Figure	  83).	  CPCR2	  is	  predominantly	  (S)-­‐
selective,	  where	  the	  nicotinamide	  hydride	  is	  delivered	  to	  the	  re-­‐face	  of	  the	  carbonyl	  
giving	  the	  (S)-­‐alcohol.	  As	  such,	  CPCR	  follows	  the	  ‘E3-­‐pathway’	  like	  many	  other	  MDRs	  
such	  as	  YADH	   (PDB	  entry:	  2HCY)	  and	  HLADH	   (PDB	  entry:	  6ADH).	  However	   in	   cases	  
such	  as	  4-­‐chloro-­‐3-­‐oxobutanoate,	  (R)-­‐selectivity	  is	  observed	  however	  this	  is	  due	  to	  a	  
switch	  in	  CIP	  priority	  rules.	  
	  
Figure	  83	   -­‐	   The	  active	   site	  CPCR2	  as	   in	   subunit	  C1.	  NADH	   is	  bound	   in	   the	  base	  of	   the	   cleft	  with	   surrounding	  
hydrophobic	  residues.	  
Previous	   studies	   on	  MDRs,	   such	   as	  HLADH	   (PDB	  entry:	   6ADH),	   had	   shown	   that	  
the	   catalytic	   zinc	   is	   coordinated	   in	   a	   tetrahedral	   geometry	   with	   three	   amino	   acid	  
side-­‐chain	  ligands	  (Cys46,	  His67	  and	  Cys174	  in	  HLADH,	  PDB	  entry:	  6ADH)	  and	  either	  a	  
water	  molecule	  or	  a	  substrates	  hydroxyl	  or	  carbonyl	  group.	  More	  recently	   in	  2009,	  
Baker	   and	   co-­‐workers	   (33)	   have	   shown	   that	   the	   coordination	   sphere	   around	   the	  
catalytic	   zinc	   is	   dynamic	   and	   changes	   in	   response	   to	   the	   binding	   and	   release	   of	  
substrates.	  This	  particular	  study	  was	  performed	  on	  the	  MDR	  glucose	  dehydrogenase	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from	  Haloferax	  mediterranei	  (HmGDH),	  where	  Glu64	  (equivalent	  to	  Glu68	  in	  HLADH	  
and	   Glu66	   in	   CPCR2)	  was	   observed	   to	   be	   a	   ligand	   for	   the	   catalytic	   zinc	   at	   certain	  
points	  to	  fulfil	  the	  tetrahedral	  coordination.	  	  These	  observations	  with	  HmGDH	  were	  
also	   seen	   and	   supported	   by	   the	   structure	   of	   CPCR2.	   In	   subunits	   C1,	   C3	   and	   C4	   the	  
catalytic	   zinc	   is	   coordinated	  by	  His65,	  Asp154	   and	  Glu66	   (homologous	   to	  Glu68	   in	  
HLADH)	  as	  well	  as	  a	  water	  molecule	  in	  a	  tetrahedral	  coordination	  sphere.	  	  
	  
	  
	   	   	  
Figure	   84	   –	   Split	   conformation	   of	   zinc	   at	   the	   active	   site	   with	   (left)	   and	   without	   density	   (right),	   depicting	  
activation	  and	   inactivation	   represented	  by	   subunit	   C1.	   The	  electron	  density	   for	   the	  active	   site	  was	  obtained	  
from	  2Fo-­‐Fc	  and	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	  	  
	  
In	  subunit	  C3,	  Cys44	  is	  not	  coordinated	  by	  the	  catalytic	  zinc	  (Figure	  85	   -­‐	   left),	   in	  
certain	   cases	   of	   low	   resolution,	   the	   electron	   density	   for	   the	   loop	   region	   may	  
resemble	   this	   residue.	  However	   as	   in	   Baker	   and	   co-­‐workers	   study,	   this	   region	   is	   a	  
flexible	   loop	   that	   is	   thought	   to	   close	   over	   the	   active	   site	   in	  MDRs	   upon	   substrate	  
binding,	  as	  such	  in	  some	  cases	  the	  electron	  density	  is	  mostly	  poor	  or	  absent	  (Figure	  
85	  -­‐	  right).	  In	  subunit	  C1,	  there	  is	  excellent	  density	  for	  this	  loop	  region	  and	  the	  side-­‐
chain	   for	   Cys44	   is	   present	   (Figure	   84).	   Also	   the	   catalytic	   zinc	   in	   subunit	   C1	   has	  
alternate	   conformations	   and	   two	   corresponding	   peaks	   in	   the	   difference	  map	   that	  
can	  be	  modelled	  as	   two	  zinc	  atoms	  at	  0.5	  occupancy	  each.	   In	  one	  conformation	   is	  
the	   tetrahedral	   coordination	   as	   seen	   with	   subunits	   C1,	   C3	   and	   C4	   with	   zinc	  
coordinated	   to	   His65,	   Asp154	   and	   Glu66	   as	   ligands;	   the	   second	   features	   zinc	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displaced	  by	  2.3	  Å	  and	  now	  tetrahedrally	  coordinated	  with	  His65,	  Asp154	  and	  Cys44	  
from	   the	   flexible	   loop.	   As	   such,	   Glu66	   is	   observed	   in	   two	   conformations	   and	  
modelled	  with	   0.5	   occupancy;	   one	  with	   Glu66	   coordinating	  with	   the	   catalytic	   zinc	  
and	  another	  pointing	  away	  from	  the	  metal.	  Hence,	  the	  involvement	  of	  Glu66	  in	  zinc	  
binding	   is	   clear	   and	   the	   observed	   changes	   in	   the	   coordination	   of	   zinc	   overall,	  




Figure	  85	  –	  Accurate	   interpretation	  of	   the	  active	  site	  of	  CPCR2	  at	   the	  higher	   resolution	  NADH	  complex	   (left)	  
represented	   by	   subunit	   C3	   where	   the	   electron	   density	  was	   obtained	   from	   2Fo-­‐Fc	  contoured	   to	   3σ.	   At	   lower	  
resolution,	  the	  active	  site	  of	  the	  apo-­‐CPCR2,	  the	  electron	  density	  was	  obtained	  from	  from	  the	  omit	  map	  (Fo-­‐Fc)	  
contoured	  to	  3σ.	  	  
	  
	   In	   solution,	   CPCR2	   is	   predominately	   a	   dimer	   as	   seen	   with	   subunits	   C2	   and	   C3	  
(Figure	  86),	  however	  very	  small	  quantities	  of	  the	  monomer	  can	  be	  isolated.	  As	  such,	  
PISA	   analysis	   shows	   that	   the	   major	   dimer	   interface	   potentially	   consists	   of	   19	  
hydrogen	  bonds	  and	  8	  salt	  bridges	  with	  a	  ΔG	  value	  of	  -­‐20.6	  kcal/M.	  The	  relatively	  low	  
number	  of	  interactions	  could	  contribute	  to	  its	  overall	   low	  stability.	  Superposing	  the	  
major	   dimer	   interface	   for	   the	   apo-­‐	   and	   NADH	   complex	   shows	   that	   there	   is	   little	  
secondary	  structure	  conformational	  change	  upon	  cofactor	  binding.	  The	  forms	  of	  the	  
dimer	  superpose	  with	  an	  RMSD	  of	  1.06	  Å	  over	  642	  atoms.	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Figure	   86	   -­‐	   The	  major	   dimer	   interface	   for	   CPCR2	   represented	   by	   subunits	   C2	   (yellow)	   and	   C3	   (ice	   blue).	   The	  
electron	  density	  for	  the	  cofactor	  was	  generated	  from	  the	  omit	  map	  (Fo-­‐Fc)	  contoured	  to	  3σ.	  
Comparing	   the	   major	   dimer	   interface	   of	   the	   homology	   model	   of	   CPCR2	   in	  
magenta	   with	   the	   crystal	   structure	   in	   cyan	   (Figure	   87),	   despite	   high	   secondary	  
structure	   conservation	   with	   MDRs,	   much	   of	   the	   models’	   secondary	   structure	   is	  
displaced.	  With	  advanced	  homology	  modelling,	   the	   structure	  of	   some	   loop	   regions	  
can	  be	  predicted.	  However,	  the	  actual	  positions	  of	  many	  atoms	  of	  the	  model	  deviate	  
greatly	  from	  the	  crystal	  structure,	  as	  seen	  when	  superposing	  the	  dimers,	  the	  model	  
has	   an	   RMSD	   of	   2.52	   Å	   over	   590	   atoms.	   Whereas,	   the	   apo-­‐structure	   and	   NADH	  
complex	  superpose	  with	  a	  better	  RMSD	  over	  642	  atoms.	  
	  
Figure	   87	   –	   SSM	   superpose	   of	   the	   homology	   model	   (magenta)	   with	   the	   crystal	   structure	   (cyan).	   Despite	  
conservation	  of	  secondary	  structure,	  there	  is	  still	  a	  lot	  of	  difference	  with	  the	  crystal	  structure.	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   Using	   the	   apo-­‐structure	   of	   CPCR2,	   many	   other	   MDRs	   were	   identified	   by	   DALI	  
including	   the	   tetrameric	   MDR	   from	   Bacillus	   stearothermophilus	   strain	   LLD-­‐R	   (PDB	  
entry:	   1RJW),	   where	   a	   model	   was	   derived	   to	   solve	   the	   structure.	   The	  MDR	   from	  
Bacillus	  stearothermophilus	  has	  a	  sequence	  similarity	  of	  30%	  and	  an	  RMSD	  of	  1.8	  Å	  
over	   339	   residues.	  Using	   the	  NADH-­‐complexed	   structure	   of	   CPCR2,	   again	   different	  
results	   were	   yielded	   from	   DALI.	   Upon	   cofactor	   binding,	   CPCR2	   now	   bears	   closer	  
resemblance	   to	   the	   tetrameric	   MDR	   from	   Pseudomonas	   aeruginosa	   (PDB	   entry:	  
1LLU)	  which	  has	  29%	  sequence	  similarity	  and	  an	  RMSD	  of	  1.7	  Å	  over	  341	  residues.	  
Many	   of	   the	   targets	   identified	   by	   DALI	   are	   MDR	   with	   relatively	   low	   sequence	  
similarity.	  
	   Despite	  CPCR2	  (CCR)	   in	   ice	  blue	  and	  TADH	  (TAD)	   in	  coral	  belonging	  to	  the	  MDR	  
family,	  they	  superimpose	  (Figure	  88)	  relatively	  poorly	  with	  an	  RMSD	  of	  1.66	  Å	  over	  
299	   residues.	   The	   overall	   secondary	   structures	   are	   similar,	   yet	   there	   is	   noticeable	  
difference	   and	   displacement;	   such	   as	   helix	   (α8)	   in	   TADH	   is	   equivalent	   to	   a	   loop	  
region	  in	  CPCR2.	  Aside	  from	  high	  conservation	  with	  the	  potential	  proton	  donor	  Ser46	  
(equivalent	   to	  Ser40	   in	  TADH)	  and	   the	  protein	   ligands	  Cys44	   (Cys38),	  His65	   (His53)	  
and	  Asp154	  (Asp152)	  bound	  to	  catalytic;	  there	  is	  limited	  homology	  shared	  between	  
CPCR2	  and	  TADH.	  Trp286	  and	  its	  equivalent	  in	  TADH-­‐Phe85	  are	  on	  opposite	  sides	  to	  
each	  other,	  however	  it	  is	  suspected	  that	  both	  residues	  provide	  steric	  shielding	  from	  
the	   active	   site	   towards	   the	   rest	   of	   the	   protein.	   The	   remaining	   residues:	   Phe285	  
(Leu292	   in	   TADH),	   Leu119	   (Tyr111)	   and	   Trp116	   (Val108)	   share	   little	   homology	   to	  
their	  TADH	  counterpart.	  This	  is	  mostly	  due	  to	  loops	  being	  heavily	  displaced	  not	  being	  
conserved,	  as	  seen	  with	  TADH-­‐Phe115	  has	  no	  equivalent	   in	  CPCR2.	  However	  Leu55	  
(I49	  in	  TADH)	  share	  some	  homology	  contributing	  towards	  the	  hydrophobicity	  in	  the	  
active	  site.	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Figure	  88	  -­‐	  Active	  site	  comparison	  between	  CPCR2	  (CCR)	  in	  ice	  blue	  and	  TADH	  (TAD)	  in	  coral.	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4.	  Conclusion	  
ADHs	   are	   a	   family	   of	   enzymes	   that	   have	   been	   thoroughly	   investigated	   as	  
biocatalysts	   for	   academic	   and	   industrial	   purposes.	   As	   such,	   there	   are	   ADHs	  
commercially	   available.	   Many	   ADHs	   have	   had	   their	   crystal	   structures	   determined	  
which	  have	  lead	  to	  structure	  guided	  mutants	  with	  vastly	  improved	  activity.	  However	  
the	  downfall	  of	  many	  ADHs	  is	  the	  limited	  substrate	  scope.	  
The	  elucidation	  of	  the	  crystal	  structures	  of	  RasADH	  and	  SyADH	  has	  revealed	  the	  
molecular	   basis	   for	   the	   recognition	   of	   ‘bulky-­‐bulky’	   substrates	   of	   both	   enzymes,	  
which	  could	  potentially	  widen	  up	  the	  substrate	  specificity	  of	  ADHs	  as	  a	  whole.	  Due	  to	  
the	   low	   solubility	   of	   certain	   substrates,	   it	   is	   often	   not	   possible	   to	   obtain	   a	   ligand	  
complex	   with	   these	   types	   of	   substrates.	   However,	   using	   the	   crystal	   structures	   of	  
RasADH	  and	  SyADH,	  ligand	  docking	  has	  enabled	  insight	  into	  the	  molecular	  basis	  for	  
the	  recognition	  of	  ‘bulky-­‐bulky’	  ketones.	  These	  dockings	  may	  also	  serve	  as	  a	  basis	  for	  
future	  mutants	  for	  docking	  substrates	  that	  currently	  do	  not	  currently	  fit	  in	  the	  active	  
site.	  
Previous	   mutant	   studies	   with	   CPCR2	   were	   based	   on	   a	   homology	   model	   using	  
SsADH,	  which	  only	  had	  34%	  homology.	  Hence,	  many	  of	   the	  mutations	  made	  were	  
inaccurate.	   Both	   TADH	   and	   CPCR2	   have	   very	   wide	   substrate	   spectrum	   for	   ‘small-­‐
bulky’	   ketones.	   The	   crystal	   structures	   of	   both	   have	   provided	   insight	   into	   the	  
difference	   between	   the	   dimerising	   interface	   of	   thermophilic	   and	  mesophilic	   ADHs.	  
Where	   TADH	  has	   shown	   a	   considerable	   number	   of	   potential	   interactions	   between	  
the	  major	  dimer	  interface	  compared	  to	  that	  of	  CPCR2.	  These	  interactions	  most	  likely	  
contribute	  towards	  TADHs	  thermostability	  and	  could	  be	  used	  as	  a	  basis	  to	  engineer	  
these	  interactions	  into	  CPCR2	  for	  better	  overall	  stability.	  
	   The	  mechanism	  for	  catalysis	  of	  MDRs	   is	  well-­‐known	  and	  yet	   it	   is	  still	  a	  debated	  
over.	   Recent	   investigations	   have	   shown	   that	   the	   catalytic	   zinc	   is	   not	   as	   static	   as	  
previously	  thought.	  As	  such,	  the	  crystal	  structure	  for	  CPCR2	  has	  provided	  supporting	  
evidence	  of	  the	  dynamics	   in	  the	  active	  site.	  These	  dynamics	  captured	   in	  CPCR2	  are	  
not	   easily	   modelled	   by	   computational	   methods	   and	   may	   provide	   insights	   into	  
dynamics	  for	  not	  just	  MDRs	  but	  other	  metalloproteins.	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   The	  basis	  of	  the	  work	  performed	  in	  this	  thesis	  was	  to	  provide	  crystal	  structures	  of	  
each	  enzyme	  to	  allow	  for	  rational	  structure-­‐guided	  mutations	  for	  the	  improvement	  
of	   selectivity,	   substrate	   specificity	   and	   enzyme	   stability.	   As	   such,	   these	   objectives	  
have	  been	  satisfied	  and	  the	  crystal	  structures	  of	  RasADH,	  SyADH,	  TADH	  and	  CPCR2	  
can	  be	  applied	  as	  a	  basis	  for	  future	  mutational	  studies	  for	  the	  benefit	  of	  providing	  a	  
green	  alternative	  to	  abiotic	  asymmetric	  alcohol	  synthesis.	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Abbreviations	  
ADH	   	   	   Alcohol	  Dehydrogenase	  
APS	   	   	   Ammonium	  Persulfate	  
BINAP	   	   	   2,2’-­‐bis(diphenylphosphino)-­‐1,1’binaphthyl	  
CPCR2	   	   	   Candida	  parapsilosis	  Alcohol	  Dehydrogenase	  
DKR	   	   	   Dynamic	  Kinetic	  Resolution	  
DMS	   	   	   Dimethyl	  Sulfide	  
DMSO	   	   	   Dimethyl	  Sulfoxide	  
DYKAT	  	   	   Dynamic	  Kinetic	  Asymmetric	  Transformation	  
e.e	  	   	   	   Enantiomeric	  Excess	  
IMAC	   	   	   Immobilised	  Metal	  Affinity	  Chromatography	  
IPTG	   	   	   Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  	  
LB	   	   	   	   Lysogeny	  Broth	  
LIC	  	   	   	   Ligation	  Independent	  Cloning	  
MDR	   	   	   Medium	  Chain	  Alcohol	  Dehydrogenase/Carbonyl	  Reductase	  
MPD	   	   	   2-­‐Methyl-­‐2,4-­‐Pentanediol	  
PCC	   	   	   Pyridinium	  chlorochromate	  
PCR	   	   	   Polymerase	  Chain	  Reaction	  
PPK	   	   	   Phenyl	  Pentyl	  Ketone	  
RasADH	   	   Ralstonia	  Alcohol	  Dehydrogenase	  
SDM	   	   	   Site	  Directed	  Mutagenesis	  
SDR	   	   	   Short	  Chain	  Alcohol	  Dehydrogenase/Carbonyl	  Reductase	  
SEC	   	   	   Size	  Exclusion	  Chromatography	  
SOC	   	   	   Super	  Optimal	  broth	  with	  Catabolite	  repression	  
SyADH	  	   	   Sphingobium	  Alcohol	  Dehydrogenase	  
TADH	   	   	   Thermus	  Alcohol	  Dehydrogenase	  
TAE	   	   	   Tris-­‐Acetate-­‐EDTA	  
TEMED	  	   	   TetraMethylEthyleneDiamine	  
Tris	  	   	   	   Tris(hydroxmethyl)aminomethane	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